Gene References

 A B C D E F G H I K L M N O P R S T U V W X Z

A (Contd) →

A2M (alpha-2-macroglobulin)

Albert MS, Basu S, Bassett SS et al. Genetic association of Alzheimer’s disease with multiple polymorphisms in alpha-2-macroglobulin. Hum Mol Genet 2003; 12:2765-76.

Blacker D, Laird NM, Wilcox MA et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998; 19:357-60.

Bogard C, Daveau M, Deybach JC et al. Heme and acute inflammation role in vivo of heme in the hepatic expression of positive acute-phase reactants in rats. Eur J Biochem 1999; 261:190-6.

Businaro R, Fabrizi C, Fumagalli L, Lauro GM. Role of alpha-2-macroglobulin in regulating amyloid beta-protein neurotoxicity: protective or detrimental effect? J Neurochem 2001; 78:406-12.

Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann Med 2002; 34:357-79.

Cacabelos R, Fernández-Novoa L, Kubota Y, Lombardi V, Takeda M. Molecular genetics of Alzheimer’s disease and aging. Methods Find Exp Clin Pharmacol 2005; 27:1-573.

Cooper A, Daly E, Foy C et al. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease. J Neurol 2008; 255:1712-20.

Cruts M, Dermaut B, Koster MN et al. The alpha-2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology 2000; 55:678-84.

Darnell JE Jr, Henriksen MA, Lerner L, Zhang X. STAT3-dependent enhanceosome assembly and disassembly: synergy with GR for full transcriptional increase of the alpha 2-macroglobulin gene. Genes Dev 2003; 17:2564-77.

Edwards TL, Gilbert JR, Haines JL, Martin ER, Pericak-Vance M, Ritchie MD. An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3. Am J Med Genet B Neuropsychiatr Genet 2009; 150:721-35.

Ghelani AM, Samanta A, Jones AC, Mastana SS. Association analysis of TNFR2, VDR, A2M, GSTT1, GSTM1, and ACE genes with rheumatoid arthritis in South Asians and Caucasians of East Midlands in the United Kingdom. Rheumatol Int 2011; 31:1355-61.

Gonias SL, Lysiak JJ, Umans L, van Leuven F, Webb DJ, Wen J. Murine alpha-macroglobulins demonstrate divergent activities as neutralizers of transforming growth factor-beta and as inducers of nitric oxide synthesis: a possible mechanism for the endotoxin insensitivity of the alpha-2-macroglobulin gene knock-out mouse. J Biol Chem 1996; 271:24982-88.

Greenberg SM, Liao A, Nitsch RM et al. Genetic association of an alpha-2 macroglobulin (Val1000Ile) polymorphism and Alzheimer’s disease. Hum Mol Genet 1998; 7:1953-6.

Greene S, Kaysen GA, Stevenson FT. Serum alpha 2-macroglobulin and alpha 1-inhibitor 3 concentrations are increased in hypoalbuminemia by post-transcriptional mechanisms. Kidney Int 1998; 53:67-75.

Herring A, Yasin H, Ambrée O, Sachser N, Paulus W, Keyvani K. Environmental enrichment counteracts Alzheimer’s neurovascular dysfunction in TgCRND8 mice. Brain Pathol 2008; 18:32-9.

Hochepied T, Ameloot P, Brouckaert P, van Leuven F, Libert C. Differential response of a(2)-macroglobulin-deficient mice in models of lethal TNF-induced inflammation. Eur Cytokine Netw 2000; 11:597-601.

Hope C, Chu CT, DeKosky ST, Gonias SL, Kamboh MI, Mettenburg J. Functional analysis of plasma α2-macroglobulin from Alzheimer’s disease patients with the A2M intronic deletion. Neurobiology of Disease 2003; 14:504-12.

Hyman BT, Qiu Z, Rebeck GW, Strickland DK. Alpha-2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem 1999; 73:1393-8.

Lorent K, Serneels L, Overbergh L, Umans L, van den Berghe H, van Leuven F. Targeted inactivation of the mouse alpha-2-macroglobulin gene. J Biol Chem 1995; 270:19778-85.

Petrusz P, Jeyaraj DA, Grossman G. Microarray analysis of androgen-regulated gene expression in testis: the use of the androgen-binding protein (ABP)-transgenic mouse as a model. Reprod Biol Endocrinol 2005; 3:70.

Song H, Jia L, Zuo X, Jia J. Association between haplotype -88G/25G in A2M with Alzheimer’s disease. Neurosci Lett 2010; 479:143-5.

Umans L, Serneels L, Overbergh L, Stas L, van Leuven F. alpha2-macroglobulin- and murinoglobulin-1- deficient mice. A mouse model for acute pancreatitis. Am J Pathol 1999; 155:983-93.

ABCA1 (ATP-binding cassette, sub-family A (ABC1), member 1)

Acuña-Alonzo V, Flores-Dorantes T, Kruit JK et al. A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans. Hum Mol Genet 2010; 19:2877-85.

Adorni MP, Favari E, Ronda N et al. Free cholesterol alters macrophage morphology and mobility by an ABCA1 dependent mechanism. Atherosclerosis 2011; 215:70-6.

Aguilar-Salinas CA, Canizales-Quinteros S, Rojas-Martínez R et al. The non-synonymous Arg230Cys variant (R230C) of the ATP-binding cassette transporter A1 is associated with low HDL cholesterol concentrations in Mexican adults: A population based nation wide study. Atherosclerosis 2011; 216:146-50.

Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. Increased expression of RXRα in dementia: an early harbinger for the cholesterol dyshomeostasis? Mol Neurodegener 2010; 5:36.

Albrecht C, McVey JH, Elliott JI et al. A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome. Blood 2005; 106:542-9.

Aron-Wisnewsky J, Julia Z, Poitou C et al. Effect of bariatric surgery-induced weight loss on SR-BI, ABCG1-, and ABCA1-mediated cellular cholesterol efflux in obese women. J Clin Endocrinol Metab 2011; 96:1151-9.

Aulchenko YS, Ripatti S, Lindqvist I et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009; 41:47-55.

Aye IL, Waddell BJ, Mark PJ, Keelan JA. Placental ABCA1 and ABCG1 transporters efflux cholesterol and protect trophoblasts from oxysterol induced toxicity. Biochim Biophys Acta 2010; 1801:1013-24.

Berge KE, Leren TP. Mutations in APOA-I and ABCA1 in Norwegians with low levels of HDL cholesterol. Clin Chim Acta 2010; 411:2019-23.

Brooks-Wilson A, Marcil M, Clee SM et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22:336-45.

Brunham LR, Kruit JK, Iqbal J et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006; 116:1052-62.

Brunham LR, Kruit JK, Pape TD et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007; 13:340-7.

Bryan A, Watters C, Koenig L et al. Human transcriptome analysis reveals a potential role for active transport in the metabolism of Pseudomonas aeruginosa autoinducers. Microbes Infect 2010; 12:1042-50.

Candini C, Schimmel AW, Peter J et al. Identification and characterization of novel loss of function mutations in ATP-binding cassette transporter A1 in patients with low plasma high-density lipoprotein cholesterol. Atherosclerosis 2010; 213:492-8.

Cao XL, Yin RX, Wu DF et al. Genetic variant of V825I in the ATP-binding cassette transporter A1 gene and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis 2011; 10:14.

Cenarro A, Artieda M, Castillo S et al. A common variant in the ABCA1 gene is associated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia. J Med Genet 2003; 40:163-8.

Chen CY, Shyue SK, Ching LC et al. Wogonin promotes cholesterol efflux by increasing protein phosphatase 2B-dependent dephosphorylation at ATP-binding cassette transporter-A1 in macrophages. J Nutr Biochem 2011; 22:1015-21.

Chen DY, Chih HM, Lan JL, Chang HY, Chen WW, Chiang EP. Blood lipid profiles and peripheral blood mononuclear cell cholesterol metabolism gene expression in patients with and without methotrexate treatment. BMC Med 2011; 9:4.

Chen SG, Xiao J, Liu XH et al. Ibrolipim increases ABCA1/G1 expression by the LXRα signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin 2010; 31:1343-9.

Chen X, Zhao Y, Guo Z, Zhou L, Okoro EU, Yang H. Transcriptional regulation of ATP-binding cassette transporter A1 expression by a novel signaling pathway. J Biol Chem 2011; 286:8917-23.

Cheng LC, Su KH, Kou YR et al. α-Lipoic acid ameliorates foam cell formation via liver X receptor α-dependent upregulation of ATP-binding cassette transporters A1 and G1. Free Radic Biol Med 2011; 50:47-54.

Chinetti-Gbaguidi G, Baron M, Bouhlel MA et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways. Circ Res 2011; 108:985-95.

Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305:869-72.

Cui H, Okuhira K, Ohoka N et al. Tributyltin chloride induces ABCA1 expression and apolipoprotein A-I-mediated cellular cholesterol efflux by activating LXRalpha/RXR. Biochem Pharmacol 2011; 81:819-24.

Darabi M, Ani M, Panjehpour M, Rabbani M, Movahedian A, Zarean E. Effect of estrogen receptor β A1730G polymorphism on ABCA1 gene expression response to postmenopausal hormone replacement therapy. Genet Test Mol Biomarkers 2011; 15:11-5.

Darabi M, Rabbani M, Ani M, Zarean E, Panjehpour M, Movahedian A. Increased leukocyte ABCA1 gene expression in post-menopausal women on hormone replacement therapy. Gynecol Endocrinol 2011; 27:701-5.

de Beer MC, Ji A, Jahangiri A et al. ATP binding cassette G1-dependent cholesterol efflux during inflammation. J Lipid Res 2011; 52:345-53.

Decottignies A, Goffeau A. Complete inventory of the yeast ABC proteins. Nat Genet 1997; 15:137-45.

Denk GU, Aslanidis C, Schmitz G, Parhofer KG, Pusl T. Association of HDL deficiency with a novel mutation in the ABCA1 gene. Exp Clin Endocrinol Diabetes 2011; 119:53-5.

Donkin JJ, Stukas S, Hirsch-Reinshagen V et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem 2010; 285:34144-54.

Edmondson AC, Braund PS, Stylianou IM et al. Dense genotyping of candidate gene loci identifies variants associated with high-density lipoprotein cholesterol. Circ Cardiovasc Genet 2011; 4:145-55.

Fernández-Hernando C, Suárez Y, Rayner KJ, Moore KJ. MicroRNAs in lipid metabolism. Curr Opin Lipidol 2011; 22:86-92.

Fitzgerald ML, Morris AL, Rhee JS, Andersson LP, Mendez AJ, Freeman MW. Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J Biol Chem 2002; 277:33178-87.

Flores-Dorantes T, Arellano-Campos O, Posadas-Sánchez R et al. Association of R230C ABCA1 gene variant with low HDL-C levels and abnormal HDL subclass distribution in Mexican school-aged children. Clin Chim Acta 2010; 411:1214-7.

Genvigir FD, Hirata MH, Hirata RD. ABCA1 expression and statins: inhibitory effect in peripheral blood mononuclear cells. Pharmacogenomics 2009; 10:997-1005.

Genvigir FD, Rodrigues AC, Cerda A, Hirata MH, Curi R, Hirata RD. ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells. Drug Metabol Drug Interact 2011; 26:33-6.

Genvigir FD, Soares SA, Hirata MH et al. Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. Clin Chim Acta 2008; 389:79-86.

Getz GS, Wool GD, Reardon CA. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders. Curr Pharm Des 2010; 16:3173-84.

Goldwasser J, Cohen PY, Yang E, Balaguer P, Yarmush ML, Nahmias Y. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha. PLoS One 2010. doi:10. 1371/journal. pone. 0012399.

Grala TM, Kay JK, Walker CG et al. Expression analysis of key somatotropic axis and liporegulatory genes in ghrelin- and obestatin-infused dairy cows. Domest Anim Endocrinol 2010; 39:76-83.

Guan S, Wang B, Li W, Guan J, Fang X. Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. Am J Chin Med 2010; 38:1161-9.

Guevara-Cruz M, Tovar AR, Larrieta E, Canizales-Quinteros S, Torres N. Increase in HDL-C concentration by a dietary portfolio with soy protein and soluble fiber is associated with the presence of the ABCA1R230C variant in hyperlipidemic Mexican subjects. Mol Genet Metab 2010; 101:268-72.

Guo Z, Inazu A, Yu W et al. Double deletions and missense mutations in the first nucleotide-binding fold of the ATP-binding cassette transporter A1 (ABCA1) gene in Japanese patients with Tangier disease. J Hum Genet 2002; 47:325-9.

Higashi N, Matsumura Y, Mizuno F et al. Enhanced expression of ATP-binding cassette transporter A1 in non-rafts decreases the sensitivity of vascular endothelial cells to Shiga toxin. Microb Pathog 2010; 49:141-52.

Hirsch-Reinshagen V, Zhou S, Burgess BL et al. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 2004; 279:41197-207.

Hong C, Walczak R, Dhamko H et al. Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target. J Lipid Res 2011; 52:531-9.

Hong SH, Rhyne J, Zeller K, Miller M. Novel ABCA1 compound variant associated with HDL cholesterol deficiency. Biochim Biophys Acta 2002; 1587:60-4.

Horie T, Ono K, Horiguchi M et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 2010; 107:17321-6.

Hu B, Unwalla RJ, Goljer I et al. Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist. J Med Chem 2010; 53:3296-304.

Huang W, Moriyama K, Koga T et al. Novel mutations in ABCA1 gene in Japanese patients with Tangier disease and familial high density lipoprotein deficiency with coronary heart disease. Biochim Biophys Acta 2001; 1537:71-8.

Iwamoto N, Lu R, Tanaka N, Abe-Dohmae S, Yokoyama S. Calmodulin interacts with ATP binding cassette transporter A1 to protect from calpain-mediated degradation and upregulates high-density lipoprotein generation. Arterioscler Thromb Vasc Biol 2010; 30:1446-52.

Iwamoto N, Yokoyama S. Protein kinase D regulates the adiponectin gene expression through phosphorylation of AP-2: A common pathway to the ABCA1 gene regulation. Atherosclerosis 2011; 216:90-6.

Jia Y, Li ZY, Zhang HG, Li HB, Liu Y, Li XH. Panax notoginseng saponins decrease cholesterol ester via up-regulating ATP-binding cassette transporter A1 in foam cells. J Ethnopharmacol 2010; 132:297-302.

Jiang Z, Zhou R, Xu C, Feng G, Zhou Y. Genetic variation of the ATP-binding cassette transporter A1 and susceptibility to coronary heart disease. Mol Genet Metab 2011; 103:81-8.

Johnson DC, Corthals SL, Walker BA et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 2011; 29:797-804.

Julia Z, Duchene E, Fournier N et al. Postprandial lipemia enhances the capacity of large HDL2 particles to mediate free cholesterol efflux via SR-BI and ABCG1 pathways in type IIB hyperlipidemia. J Lipid Res 2010; 51:3350-8.

Jung CG, Horike H, Cha BY et al. Honokiol increases ABCA1 expression level by activating retinoid X receptor beta. Biol Pharm Bull 2010; 33:1105-11.

Kang J, Cheng B, Jiang L. PPARγ signal transduction pathway in the foam cell formation induced by visfatin. Sheng Li Xue Bao 2010; 62:427-32.

Kang MH, Singaraja R, Hayden MR. Adenosine-triphosphate-binding cassette transporter-1 trafficking and function. Trends Cardiovasc Med 2010; 20:41-9.

Kathiresan S, Melander O, Anevski D et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008; 358:1240-9.

Kathiresan S, Willer CJ, Peloso GM et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009; 41:56-65.

Katzov H, Bennet AM, Hoglund K et al. Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-beta(1-42) and plasma apolipoprotein levels. J Hum Genet 2006; 51:171-9.

Katzov H, Chalmers K, Palmgren J et al. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum Mutat 2004; 23:358-67.

Kim WS, Bhatia S, Elliott DA et al. Increased ATP-binding cassette transporter A1 expression in Alzheimer’s disease hippocampal neurons. J Alzheimers Dis 2010; 21:193-205.

Knoblauch H, Bauerfeind A, Toliat MR et al. Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet 2004; 13:993-1004.

Lapicka-Bodzioch K, Bodzioch M, Krull M et al. Homogeneous assay based on 52 primer sets to scan for mutations of the ABCA1 gene and its application in genetic analysis of a new patient with familial high-density lipoprotein deficiency syndrome. Biochim Biophys Acta 2001; 1537:42-8.

Lee TS, Pan CC, Peng CC et al. Anti-atherogenic effect of berberine on LXRalpha-ABCA1-dependent cholesterol efflux in macrophages. J Cell Biochem 2010; 111:104-10.

Legry V, Bokor S, Beghin L et al. Associations between common genetic polymorphisms in the liver X receptor alpha and its target genes with the serum HDL-cholesterol concentration in adolescents of the HELENA Study. Atherosclerosis 2011; 216:166-9.

Lettre G, Palmer CD, Young T et al. Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: The NHLBI CARe Project. PLoS Genet 2011. doi:10. 1371/journal. pgen. 1001300.

Li J, Wang LF, Li ZQ, Pan W. Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease. Clin Exp Pharmacol Physiol 2009; 36:567-70.

Lin CY, Lee TS, Chen CC et al. Endothelin-1 exacerbates lipid accumulation by increasing the protein degradation of the ATP-binding cassette transporter G1 in macrophages. J Cell Physiol 2011; 226:2198-205.

Liu XH, Xiao J, Mo ZC et al. Contribution of D4-F to ABCA1 expression and cholesterol efflux in THP-1 macrophage-derived foam cells. J Cardiovasc Pharmacol 2010; 56:309-19.

Loane DJ, Washington PM, Vardanian L et al. Modulation of ABCA1 by an LXR agonist reduces beta-amyloid levels and improves outcome after traumatic brain injury. J Neurotrauma 2011; 28:225-36.

Luciani MF, Denizot F, Savary S, Mattei MG, Chimini G. Cloning of two novel ABC transporters mapping on human chromosome 9. Genomics 1994; 21:150-9.

Ma L, Dong F, Denis M, Feng Y, Wang MD, Zha X. Ht31, a protein kinase A anchoring inhibitor, induces robust cholesterol efflux and reverses macrophage foam cell formation through ATP-binding cassette transporter A1. J Biol Chem 2011; 286:3370-8.

Ma XY, Liu JP, Song ZY. Associations of the ATP-binding cassette transporter A1 R219K polymorphism with HDL-C level and coronary artery disease risk: A meta-analysis. Atherosclerosis 2011; 215:428-34.

Mani O, Körner M, Ontsouka CE et al. Identification of ABCA1 and ABCG1 in milk fat globules and mammary cells-Implications for milk cholesterol secretion. J Dairy Sci 2011; 94:1265-76.

Mani O, Körner M, Sorensen MT et al. Expression, localization, and functional model of cholesterol transporters in lactating and nonlactating mammary tissues of murine, bovine, and human origin. Am J Physiol Regul Integr Comp Physiol 2010; 299:642-54.

Marcil M, Yu L, Krimbou L et al. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. Arterioscler Thromb Vasc Biol 1999; 19:159-69.

Marquart TJ, Allen RM, Ory DS, Baldán A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA 2010; 107:12228-32.

Masson CJ, Plat J, Mensink RP et al. Fatty acid- and cholesterol transporter protein expression along the human intestinal tract. PLoS One 2010. doi:10. 1371/journal. pone. 0010380

Mauerer R, Ebert S, Langmann T. High glucose, unsaturated and saturated fatty acids differentially regulate expression of ATP-binding cassette transporters ABCA1 and ABCG1 in human macrophages. Exp Mol Med 2009; 41:126-32.

McNeish J, Aiello RJ, Guyot D et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Nat Acad Sci USA 2009; 7:4245-50.

Mogilenko DA, Shavva VS, Dizhe EB, Orlov SV, Perevozchikov AP. PPARγ activates ABCA1 gene transcription but reduces the level of ABCA1 protein in HepG2 cells. Biochem Biophys Res Commun 2010; 402:477-82.

Morrow MP, Grant A, Mujawar Z et al. Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1. Mol Pharmacol 2010; 78:215-25.

Mujawar Z, Tamehiro N, Grant A, Sviridov D, Bukrinsky M, Fitzgerald ML. Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation. Biochemistry 2010; 49:8338-49.

Najafi-Shoushtari SH, Kristo F, Li Y et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328:1566-9.

Nakaya K, Ayaori M, Uto-Kondo H et al. Cilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo. Atherosclerosis 2010; 213:135-41.

Navab M, Reddy ST, van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011; 8:222-32.

Neufeld EB, Stonik JA, Demosky SJ et al. The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J Biol Chem 2004; 279:15571-8.

Nishiuchi Y, Murao K, Imachi H, Nishiuchi T, Iwama H, Ishida T. Transcriptional factor prolactin regulatory element-binding protein-mediated gene transcription of ABCA1 via 3’,5’-cyclic adenosine-5’-monophosphate. Atherosclerosis 2010; 212:418-25.

Nofer J-R, Herminghaus G, Brodde M et al. Impaired platelet activation in familial high density lipoprotein deficiency (Tangier disease). J Biol Chem 2004; 279:34032-7.

Nonomura K, Arai Y, Mitani H, Abe-Dohmae S, Yokoyama S. Insulin down-regulates specific activity of ATP-binding cassette transporter A1 for high density lipoprotein biogenesis through its specific phosphorylation. Atherosclerosis 2011; 216:334-41.

Okuhira K, Fitzgerald ML, Tamehiro N et al. Binding of PDZ-RhoGEF to ATP-binding cassette transporter A1 (ABCA1) induces cholesterol efflux through RhoA activation and prevention of transporter degradation. J Biol Chem 2010; 285:16369-77.

Orso E, Broccardo C, Kaminski WE et al. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice. Nat Genet 2000; 24:192-6.

Padovani AM, Molina MF, Mann KK. Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol 2010; 30:1228-36.

Pagler TA, Wang M, Mondal M et al. Deletion of ABCA1 and ABCG1 impairs macrophage migration because of increased Rac1 signaling. Circ Res 2011; 108:194-200.

Palozza P, Simone R, Catalano A, Parrone N, Monego G, Ranelletti FO. Lycopene regulation of cholesterol synthesis and efflux in human macrophages. J Nutr Biochem 2011; 22:971-8.

Park SE, Kang ES, Kim Dhet al. Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone. Diabet Med 2009; 26:577-81.

Peloso GM, Demissie S, Collins D et al. Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. J Lipid Res 2010; 51:3524-32.

Peng D, Hiipakka RA, Xie JT et al. A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice. Br J Pharmacol 2011; 162:1792-804.

Pullinger CR, Hakamata H, Duchateau PN et al. Analysis of hABC1 gene 5-prime end: additional peptide sequence, promoter region, and four polymorphisms. Biochem Biophys Res Commun 2000; 271:451-5.

Rayner KJ, Suárez Y, Dávalos A et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328:1570-3.

Rejeb J, Omezzine A, Rebhi L et al. Associations between common polymorphisms of adenosine triphosphate-binding cassette transporter A1 and coronary artery disease in a Tunisian population. Arch Cardiovasc Dis 2010; 103:530-7.

Remaley AT, Rust S, Rosier M et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Nat Acad Sci USA 1999; 96:12685-90.

Repa JJ, Turley SD, Lobaccaro JMA et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289:1524-9.

Rodríguez-Rodríguez E, Vázquez-Higuera JL, Sánchez-Juan P et al. Epistasis between intracellular cholesterol trafficking-related genes (NPC1 and ABCA1) and Alzheimer’s disease risk. J Alzheimers Dis 2010; 21:619-25.

Rust S, Rosier M, Funke H et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22:352-5.

Sabeva NS, McPhaul CM, Li X, Cory TJ, Feola DJ, Graf GA. Phytosterols differentially influence ABC transporter expression, cholesterol efflux and inflammatory cytokine secretion in macrophage foam cells. J Nutr Biochem 2011; 22:777-83.

Sanchez V, Dong JJ. Alteration of lipid metabolism in cells infected with human cytomegalovirus. Virology 2010; 404:71-7.

Santamarina-Fojo S, Peterson K, Knapper C et al. Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter. Proc Nat Acad Sci USA 2000; 97:7987-92.

Sarzynski MA, Jacobson P, Rankinen T et al. Association of GWAS-based candidate genes with HDL-Cholesterol levels before and after bariatric surgery in the Swedish obese subjects study. J Clin Endocrinol Metab 2011; 96:953-7.

Sealls W, Penque BA, Elmendorf JS. Evidence that chromium modulates cellular cholesterol homeostasis and ABCA1 functionality impaired by hyperinsulinemia. Arterioscler Thromb Vasc Biol 2011; 31:1139-40.

Sekine Y, Demosky SJ, Stonik JA et al. High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. Mol Cancer Res 2010; 8:1284-94.

Seo Y, Yang SR, Jee MK et al. Human umbilical cord blood-derived mesenchymal stem cells protect against neuronal cell death and ameliorate motor deficits in Niemann Pick Type C1 mice. Cell Transplant 2011; 20:1033-47.

Sevov M, Elfineh L, Cavelier LB. Resveratrol regulates the expression of LXR-alpha in human macrophages. Biochem Biophys Res Commun 2006; 348:1047-54.

Shridas P, Bailey WM, Gizard F et al. Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages. Arterioscler Thromb Vasc Biol 2010; 30:2014-21.

Singaraja RR, Bocher V, James ER et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem 2001; 276:33969-79.

Sjöblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-74.

Song G, Liu J, Zhao Z et al. Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet. Lipids Health Dis 2011; 10:8.

Srinivasan SR, Li S, Chen W, Boerwinkle E, Berenson GS. R219K polymorphism of the ABCA1 gene and its modulation of the variations in serum high-density lipoprotein cholesterol and triglycerides related to age and adiposity in white versus black young adults. The Bogalusa heart study. Metabolism 2003; 52:930-4.

Stankovic S, Majkic-Singh N. Genetic aspects of ischemic stroke: coagulation, homocysteine, and lipoprotein metabolism as potential risk factors. Crit Rev Clin Lab Sci 2010; 47:72-123.

Stein S, Matter CM. Protective roles of SIRT1 in atherosclerosis. Cell Cycle 2011; 10:640-7.

Sticozzi C, Pecorelli A, Belmonte G, Valacchi G. Cigarette smoke affects ABCAl expression via liver X receptor nuclear translocation in human keratinocytes. Int J Mol Sci 2010; 11:3375-86.

Tanaka AR, Abe-Dohmae S, Ohnishi T et al. Effects of mutations of ABCA1 in the first extracellular domain on subcellular trafficking and ATP binding/hydrolysis. J Biol Chem 2003; 278:8815-9.

Tanaka N, Abe-Dohmae S, Iwamoto N, Fitzgerald ML, Yokoyama S. Helical apolipoproteins of high-density lipoprotein enhance phagocytosis by stabilizing ATP-binding cassette transporter A7. J Lipid Res 2010; 51:2591-9.

Tanaka N, Abe-Dohmae S, Iwamoto N, Yokoyama S. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J Atheroscler Thromb 2011; 18:274-81.

Tandy S, Chung RW, Kamili A et al. Hydrogenated phosphatidylcholine supplementation reduces hepatic lipid levels in mice fed a high-fat diet. Atherosclerosis 2010; 213:142-7.

Tängemo C, Weber D, Theiss S, Mengel E, Runz H. Niemann-Pick Type C disease: characterizing lipid levels in patients with variant lysosomal cholesterol storage. J Lipid Res 2011; 52:813-25.

Tsai JY, Su KH, Shyue SK et al. EGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1. Cardiovasc Res 2010; 88:415-23.

Tsai MY, Ordovas JM, Li N et al. Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. Mol Genet Metab 2010; 100:118-22.

Turley SD, Valasek MA, Repa JJ, Dietschy JM. Multiple mechanisms limit the accumulation of unesterified cholesterol in the small intestine of mice deficient in both ACAT2 and ABCA1. Am J Physiol Gastrointest Liver Physiol 2010; 299:1012-22.

Ueda K. ABC Proteins protect the human body and maintain optimal health. Biosci Biotechnol Biochem 2011; 75:401-9.

van Aalst-Cohen ES, Jansen AC, Boekholdt SM et al. Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. Eur J Hum Genet 2005; 13:1137-42.

Versmissen J, Oosterveer DM, Yazdanpanah M et al. A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients. Eur Heart J 2011; 32:469-75.

von Eckardstein A, Sibler RA. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011; 22:26-32.

Voora D, Shah SH, Reed CR et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet 2008; 1:100-6.

Wahrle SE, Jiang H, Parsadanian M et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 2004; 279:40987-93.

Wang JH, Tuohimaa P. Calcitriol and TO-901317 interact in human prostate cancer LNCaP Cells. Gene Regul Syst Bio 2008; 2:97-105.

Wang N, Chen W, Linsel-Nitschke P et al. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest 2003; 111:99-107.

Wang YH, Chen YF, Chen SR et al. Aspirin increases apolipoprotein-A-I-mediated cholesterol efflux via enhancing expression of ATP-binding cassette transporter A1. Pharmacology 2010; 86:320-6.

Yan W, Zhang T, Cheng J, Zhou X, Qu X, Hu H. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride. Pharmacology 2010; 86:306-12.

Yoshida T, Kato K, Fujimaki T et al. Association of a polymorphism of the apolipoprotein E gene with chronic kidney disease in Japanese individuals with metabolic syndrome. Genomics 2009; 93:221-6.

Zhao L-X, Zhou C-J, Tanaka A et al. Cloning, characterization and tissue distribution of the rat ATP-binding cassette (ABC) transporter ABC2/ABCA2. Biochem J 2000; 350:865-72.

ABCB1 (ATP-binding cassette, sub-family B (MDR/TAP), member 1)

Aarnoudse AJ, Dieleman JP, Visser LE et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics 2008; 18:299-305.

Abate C, Niso M, Contino M et al. 1-Cyclohexyl-4-(4-arylcyclohexyl)piperazines: Mixed σ and human Δ(8)-Δ(7) sterol isomerase ligands with antiproliferative and P-glycoprotein inhibitory activity. ChemMedChem 2011; 6:73-80.

Abbasi M, Lavasanifar A, Berthiaume LG, Weinfeld M, Uludağ H. Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells. Cancer 2010; 116:5544-54.

Abbasi M, Lavasanifar A, Uludaˇ H. Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med Res Rev 2011. doi:10. 1002/med. 20244.

Abdel Halim M, Al-Otaibi T, Gheith O et al. Toxic tacrolimus blood levels with rifampin administration in a renal transplant recipient. Ann Transplant 2010; 15:57-60.

Abraham I, Jain S, Wu CP et al. Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochem Pharmacol 2010; 80:1497-506.

Afsar NA, Haenisch S, Mateen A et al. Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. Basic Clin Pharmacol Toxicol 2010; 107:570-6.

Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 2010; 334:147-55.

Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 2011; 336:223-33.

Ahn HJ, Kim KB, Liu KH et al. In vitro metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223. Xenobiotica 2011; 41:445-55.

Ahn S, Duke CB 3rd, Barrett CM et al. I-387, a novel antimitotic indole, displays a potent in vitro and in vivo antitumor activity with less neurotoxicity. Mol Cancer Ther 2010; 9:2859-68.

Ahn S, Hwang DJ, Barrett CM et al. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. Cancer Chemother Pharmacol 2011; 67:293-304.

Ahn S, Kearbey JD, Li CM, Duke CB 3rd, Miller DD, Dalton JT. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice. Drug Metab Dispos 2011; 39:636-43.

Ahn SJ, Jeon YH, Lee YJ et al. Enhanced anti-tumor effects of combined MDR1 RNA interference and human sodium/iodide symporter (NIS) radioiodine gene therapy using an adenoviral system in a colon cancer model. Cancer Gene Ther 2010; 17:492-500.

Akamine Y, Miura M, Sunagawa S, Kagaya H, Yasui-Furukori N, Uno T. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers. Xenobiotica 2010; 40:782-9.

Akbas SH, Bilgen T, Keser I et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc 2006; 38:1290-2.

Akhtar N, Ahad A, Khar RK et al. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin Ther Pat 2011; 21:561-76.

Al Ahmad A, Taboada CB, Gassmann M, Ogunshola OO. Astrocytes and pericytes differentially modulate blood-brain barrier characteristics during development and hypoxic insult. J Cereb Blood Flow Metab 2011; 31:693-705.

Al-Bataineh MM, van der Merwe D, Schultz BD, Gehring R. Tumor necrosis factor alpha increases P-glycoprotein expression in a BME-UV in vitro model of mammary epithelial cells. Biopharm Drug Dispos 2010; 31:506-15.

Albrecht C, Elliott JI, Sardini A et al. Functional analysis of candidate ABC transporter proteins for sitosterol transport. Biochim Biophys Acta 2002; 1567:133-42.

Al-Deeb ID, Arafat TA, Irshaid YM. The effect of licorice drink on the systemic exposure of verapamil in rabbits. Drug Metab Lett 2010; 4:173-9.

Álvarez-Lorenzo C, Rey-Rico A, Brea J, Loza MI, Concheiro A, Sosnik A. Inhibition of P-glycoprotein pumps by PEO-PPO amphiphiles: branched versus linear derivatives. Nanomedicine 2010; 5:1371-83.

Alves L, Hülsmeyer V, Jaggy A, Fischer A, Leeb T, Drögemüller M. Polymorphisms in the ABCB1 gene in phenobarbital responsive and resistant idiopathic epileptic Border Collies. J Vet Intern Med 2011; 25:484-9.

Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39:361-98.

Ampasavate C, Sotanaphun U, Phattanawasin P, Piyapolrungroj N. Effects of Curcuma spp. on P-glycoprotein function. Phytomedicine 2010; 17:506-12.

An G, Morris ME. Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo. Biopharm Drug Dispos 2010; 31:340-50.

An Y, Yao J, Wei JS et al. Establish a gemcitabine-resistant pancreatic cancer cell line SW1990/GZ and research the relationship between SW1990/GZ and pancreatic cancer stem cell. Zhonghua Wai Ke Za Zhi 2010; 48:999-1003.

Andersen V, Ostergaard M, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer 2009; 9:407.

Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006; 42:441-9.

Angelastro JM, Lamé MW. Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res 2010; 8:1105-15.

Angelini A, di Ilio C, Castellani ML, Conti P, Cuccurullo F. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. J Biol Regul Homeost Agents 2010; 24:197-205.

Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. J Womens Health Gend Based Med 2002; 11:601-15.

Antonić J, Grabnar I, Milčinski L et al. Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. Vet Parasitol 2011; 179:159-66.

Aouali N, El Btaouri H, Dumontet C et al. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells. Oncol Rep 2011; 25:1161-7.

Argov M, Bod T, Batra S, Margalit R. Novel steroid carbamates reverse multidrug-resistance in cancer therapy and show linkage among efficacy, loci of drug action and P-glycoprotein’s cellular localization. Eur J Pharm Sci 2010; 41:53-9.

Arnaud O, Koubeissi A, Ettouati L et al. Potent and fully noncompetitive peptidomimetic inhibitor of multidrug resistance P-glycoprotein. J Med Chem 2010; 53:6720-9.

Asakawa C, Ogawa M, Kumata K et al. [(11)C]Sorafenib: Radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice. Bioorg Med Chem Lett 2011; 21:2220-3.

Asano T, Takahashi KA, Fujioka M et al. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 2003; 13:675-82.

Ashiru-Oredope DA, Patel N, Forbes B, Patel R, Basit AW. The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers. Int J Pharm 2011; 409:164-8.

Aurade RM, Jayalakshmi SK, Sreeramulu K. Modulatory effects of natural curcuminoids on P-glycoprotein ATPase of insecticide-resistant pest Helicoverpa armigera (Lepidopetera: Noctüidae). J Membr Biol 2010; 236:271-8.

Aurade RM, Jayalakshmi SK, Sreeramulu K. P-glycoprotein ATPase from the resistant pest, Helicoverpa armigera: purification, characterization and effect of various insecticides on its transport function. Biochim Biophys Acta 2010; 1798:1135-43.

Aylin Arici M, Kilinc E, Demir O, Ates M, Yesilyurt A, Gelal A. Interactions between verapamil and digoxin in Langendorff-perfused rat hearts: The role of inhibition of P-glycoprotein in the heart. Basic Clin Pharmacol Toxicol 2010. doi:10. 1111/j. 1742-7843. 2010. 00574. x.

Babić Z, Kucisec-Tepes N, Troskot R, Dorosulić Z, Svoboda-Beusan I. The importance of P-glycoprotein multidrug transporter activity measurement in patients with Helicobacter pylori infection. Coll Antropol 2009; 33:1145-50.

Babic Z, Svoboda-Beusan I, Kucisec-Tepes N, Dekaris D, Troskot R. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. World J Gastroenterol 2005; 11:2720-5.

Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, Mullan MJ, Levin GM. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos 2011; 32:233-44.

Baghdasaryan A, Claudel T, Kosters A et al. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010; 59:521-30.

Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010; 46:308-16.

Bajaj G, Rodriguez-Proteau R, Venkataraman A, Fan Y, Kioussi C, Ishmael JE. MDR1 function is sensitive to the phosphorylation state of myosin regulatory light chain. Biochem Biophys Res Commun 2010; 398:7-12.

Baker EK, El-Osta A. Epigenetic regulation of multidrug resistance 1 gene expression: profiling CpG methylation status using bisulphite sequencing. Methods Mol Biol 2010; 596:183-98.

Balcerczak E, Panczyk M, Piaskowski S, Pasz-Walczak G, Sałagacka A, Mirowski M. ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. Int J Colorectal Dis 2010; 25:1167-76.

Ballent M, Lifschitz A, Virkel G, Mate L, Lanusse C. Pretreatment with the inducers rifampicin and phenobarbital alters ivermectin gastrointestinal disposition. J Vet Pharmacol Ther 2010; 33:252-9.

Ballent M, Lifschitz A, Virkel G, Sallovitz J, Maté L, Lanusse C. Gender-related differences on P-glycoprotein-mediated drug intestinal transport in rats. J Pharm Pharmacol 2011; 63:619-26.

Bamburowicz-Klimkowska M, Zywiec K, Potentas A, Szutowski M. Impact of the changes in P-glycoprotein activity on domperidone pharmacokinetics in rat plasma. Pharmacol Rep 2007; 59:752-6.

Bao L, Haque A, Jackson K et al. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol 2011; 178:838-52.

Barash H, R Gross E, Edrei Y et al. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci USA 2010; 107:2207-12.

Barattin R, Perrotton T, Trompier D et al. Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1. Bioorg Med Chem 2010; 18:6265-74.

Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 2010; 11:369-90.

Bartels AL, de Klerk OL, Kortekaas R, de Vries JJ, Leenders KL. 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease. Curr Top Med Chem 2010; 10:1775-84.

Bartmann H, Fuest C, la Fougere C et al. Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia 2010; 51:1780-90.

Basic S, Hajnsek S, Bozina N et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 2008; 17:524-30.

Bassiouny AR, Zaky A, Neenaa HM. Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients. Ann Hepatol 2010; 9:410-8.

Bates SE, Zhan Z, Steadman K et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010; 148:256-67.

Bauer F, Kuntner C, Bankstahl JP et al. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem 2010; 18:5489-97.

Bauer M, Karch R, Neumann F et al. Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab 2010; 30:510-5.

Bebawy M, Rasmussen C, Sambasivam S, Bao S. Dietary nucleotide supplements in infant formula modify the expression of P-glycoprotein in the intestinal epithelium in vitro. Int J Vitam Nutr Res 2009; 79:381-7.

Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Pharmacogenomics 2009; 10:1743-51.

Beghin D, Forestier F, Noël-Hudson MS et al. Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir. Eur J Obstet Gynecol Reprod Biol 2010; 152:55-9.

Bellusci CP, Rocco CA, Aulicino PC et al. MDR1 3435T and 1236T alleles delay disease progression to pediatric AIDS but have no effect on HIV-1 vertical transmission. AIDS 2010; 24:833-40.

Bendel SD, Bona R, Baker WL. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. Adv Ther 2011; 28:460-72.

Berginc K, Trdan T, Trontelj J, Kristl A. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy. Biopharm Drug Dispos 2010; 31:495-505.

Berginc K, Trontelj J, Kristl A. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Drug Metab Pharmacokinet 2010; 25:307-13.

Berginc K, Žakelj S, Kristl A. In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Eur J Nutr 2010; 49:373-84.

Bergmann TK, Brasch-Andersen C, Gréen H et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011; 11:113-20.

Bergmann TK, Gréen H, Brasch-Andersen C et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 2011; 67:693-700.

Bessadok A, Garcia E, Jacquet H et al. Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins. J Biol Chem 2011; 286:3552-69.

Bierman WF, Scheffer GL, Schoonderwoerd A et al. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother 2010; 65:1672-80.

Binkhathlan Z, Hamdy DA, Brocks DR, Lavasanifar A. Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat. Xenobiotica 2010; 40:55-61.

Blaas L, Kornfeld JW, Schramek D et al. Disruption of the growth hormone-signal transducer and activator of transcription 5-insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology 2010; 51:1319-26.

Bliek BJ, van Schaik RH, van der Heiden IP et al. Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate. Am J Med Genet A 2009; 149:2088-92.

Blonk MI, van der Velde N, van den Bemt PM, van Schaik RH, van der Cammen TJ. CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls in elderly people. Pharm World Sci 2010; 32:26-9.

Bochud M, Eap CB, Maillard M et al. Association of ABCB1 genetic variants with renal function in Africans and in Caucasians. BMC Med Genomics 2008; 1:21.

Boeckmann L, Nickel AC, Kuschal C et al. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution. Melanoma Res 2011; 21:206-16.

Bogush TA, Dudko EA, Bogush EA, Kirsanov VIu, Antonov VG. Glutoxime-an inhibitor of multiple drug resistance phenotype associated with Pgp expression. Antibiot Khimioter 2010; 55:18-23.

Borrelli F, Izzo AA. Herb-drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J 2009; 11:710-27.

Borska S, Sopel M, Chmielewska M, Zabel M, Dziegiel P. Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules 2010; 15:857-70.

Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92:1295-302.

Bottke D, Koychev D, Busse A et al. Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines. Radiat Res 2008; 170:41-8.

Bottova I, Sauder U, Olivieri V, Hehl AB, Sonda S. The P-glycoprotein inhibitor GF120918 modulates Ca2+-dependent processes and lipid metabolism in Toxoplasma gondii. PLoS One 2010. doi:10. 1371/journal. pone. 0010062.

Bouamar R, Hesselink DA, van Schaik RH et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Ther Drug Monit 2011; 33:178-84.

Bouchet BP, Galmarini CM. Cabazitaxel, a new taxane with favorable properties. Drugs Today 2010; 46:735-42.

Boulton DW, deVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71:163-9.

Bouquié R, Deslandes G, Renaud C, Dailly E, Haloun A, Jolliet P. Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin. J Clin Rheumatol 2011; 17:28-30.

Bourguinat C, Kamgno J, Boussinesq M, Mackenzie CD, Prichard RK, Geary TG. Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event. Am J Trop Med Hyg 2010; 83:28-32.

Bourguinat C, Keller K, Blagburn B, Schenker R, Geary TG, Prichard RK. Correlation between loss of efficacy of macrocyclic lactone heartworm anthelmintics and P-glycoprotein genotype. Vet Parasitol 2011; 176:374-81.

Bourguinat C, Keller K, Prichard RK, Geary TG. Genetic polymorphism in Dirofilaria immitis. Vet Parasitol 2011; 176:368-73.

Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 2009; 50:898-903.

Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 2008; 42:89-97.

Bozzuto G, Colone M, Toccacieli L, Stringaro A, Molinari A. Tea tree oil might combat melanoma. Planta Med 2011; 77:54-6.

Bracht K, Liebeke M, Ritter CA, Grünert R, Bednarski PJ. Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data. Anticancer Drugs 2007; 18:389-404.

Brant SR, Panhuysen CIM, Nicolae D et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 2003; 73:282-92.

Braun MS, Richman SD, Quirke P et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26:2690-8.

Braun MS, Richman SD, Thompson L et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 2009; 27:5519-28.

Bray J, Sludden J, Griffin MJ et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010; 102:1003-9.

Broccatelli F, Carosati E, Neri A et al. A Novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem 2011; 54:1740-51.

Brunden KR, Yao Y, Potuzak JS et al. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer’s disease and related tauopathies. Pharmacol Res 2011; 63:341-51.

Bruyère A, Declèves X, Bouzom F et al. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm 2010; 7:1596-607.

Bruyne SD, Wyffels L, Moerman L et al. Radiosynthesis and in vivo evaluation of [(11)C]MC80 for P-glycoprotein imaging. Bioorg Med Chem 2010; 18:6489-95.

Buchard A, Linnet K, Johansen SS, Munkholm J, Fregerslev M, Morling N. Postmortem blood concentrations of R-and S-enantiomers of methadone and EDDP in drug users: influence of co-medication and P-glycoprotein genotype. J Forensic Sci 2010; 55:457-63.

Buda G, Ricci D, Huang CC et al. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2010; 89:1133-40.

Burckart GJ, Amur S. Update on the clinical pharmacogenomics of organ transplantation. Pharmacogenomics 2010; 11:227-36.

Burhenne J, Matthée AK, Pasáková I et al. No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother 2010; 54:4185-91.

Burk O, Brenner SS, Hofmann U et al. The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin. Clin Pharmacol Ther 2010; 88:685-94.

Cain JW, Hauptschein RS, Stewart JK, Bagci T, Sahagian GG, Jay DG. Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology. Mol Cancer Res 2011; 9; 637-47.

Callegari E, Malhotra B, Bungay PJ et al. A comprehensive nonclinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 2011; 72:235-46.

Camenzind RS, Chip S, Gutmann H, Kapfhammer JP, Nitsch C, Bendfeldt K. Preservation of transendothelial glucose transporter 1 and P-glycoprotein transporters in a cortical slice culture model of the blood-brain barrier. Neuroscience 2010; 170:361-71.

Candela P, Gosselet F, Saint-Pol J et al. Apical-to-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis 2010; 22:849-59.

Cantarini L, Volpi N, Galeazzi M et al. Colchicine myopathy and neuromyopathy: two cases with different characteristics. J Clin Rheumatol 2010; 16:229-32.

Cao J, Zhang L, Ye Q et al. YQ36: a novel bisindolylmaleimide analogue induces KB/VCR cell death. J Biomed Biotechnol 2009. doi:10. 1155/2009/535072.

Capron A, Mourad M, de Meyer M et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics 2010; 11:703-14.

Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: Focus on selective serotonin reuptake inhibitors and Hypericum extract. Curr Drug Metab 2011; 12:570-7.

Carcaboso AM, Elmeliegy MA, Shen J et al. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res 2010; 70:4499-508.

Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 2011:261-83.

Castro J, Ribó M, Puig T, Colomer R, Vilanova M, Benito A. A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines. Invest New Drugs 2011. doi:10. 1007/s10637-011-9636-2.

Catapano AL. Pitavastatin-pharmacological profile from early phase studies. Atheroscler Suppl 2010; 11:3-7.

Cen J, Qi Y, Tao YF et al. HZ08, a great regulator to reverse multidrug resistance via cycle arrest and apoptosis sensitization in MCF-7/ADM. Eur J Pharmacol 2010; 647:21-30.

Cetinkalp S, Karadeniz M, Erdoğan M et al. Human multidrug resistance-1 gene expression levels in graves-basedow disease. Exp Clin Endocrinol Diabetes 2010; 118:158-60.

Chai L, McLaren RP, Byrne A et al. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function. Int J Oncol 2011; 38:701-11.

Chakraborty PK, Scharner B, Jurasovic J, Messner B, Bernhard D, Thévenod F. Chronic cadmium exposure induces transcriptional activation of the Wnt pathway and upregulation of epithelial-to-mesenchymal transition markers in mouse kidney. Toxicol Lett 2010; 198:69-76.

Chan GN, Bendayan R. Molecular and functional characterization of P-glycoprotein in vitro. Methods Mol Biol 2011; 686:313-36.

Chan GN, Tozammel Hoque M, Cummins CL, Bendayan R. Regulation of P-glycoprotein by orphan nuclear receptors in human brain microvessel endothelial cells. J Neurochem 2011; 118:163-75.

Chang H, Rha SY, Jeung HC et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 2009; 20:272-7.

Chang H, Rha SY, Jeung HC et al. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol Rep 2010; 23:271-8.

Chang JH, Kochansky CJ, Shou M. The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab Dispos 2006; 34:2073-8.

Chang WL, Chang CS, Chiang PC et al. 2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase. Br J Pharmacol 2010; 160:1677-89.

Chanmahasathien W, Ampasavate C, Greger H, Limtrakul P. Stemona alkaloids, from traditional Thai medicine, increase chemosensitivity via P-glycoprotein-mediated multidrug resistance. Phytomedicine 2011; 18:199-204.

Chapman JV, Gouazé-Andersson V, Cabot MC. Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity. Int J Oncol 2010; 37:1591-7.

Chapman JV, Gouazé-Andersson V, Karimi R, Messner MC, Cabot MC. P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells. Exp Cell Res 2011; 317:1736-45.

Chen B, Yin L, Cheng J et al. Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells. Hematology 2011; 16:24-30.

Chen B, Zhang W, Fang J et al. Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. Xenobiotica 2009; 39:931-8.

Chen BA, Mao PP, Cheng J et al. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells. Int J Nanomedicine 2010; 5:437-44.

Chen BA, Shan XY, Chen J, Xia GH, Xu WL, Schmit M. Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line. Chin J Cancer 2010; 29:591-5.

Chen BA, Wang F, Cheng J et al. Effect of hypoxia inducible factor1-α inhibitor on reversal of multidrug resistance of K562/A02 cell line. Zhonghua Xue Ye Xue Za Zhi 2010; 31:389-93.

Chen C, Han YH, Yang Z, Rodrigues AD. Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes. Xenobiotica 2011; 41:476-85.

Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003; 31:312-8.

Chen C, Shen HL, Yang J, Chen QY, Xu WL. Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. J Cancer Res Clin Oncol 2011; 137:9-17.

Chen H, Bi W, Cao B et al. A novel podophyllotoxin derivative (YB-1EPN) induces apoptosis and down-regulates express of P-glycoprotein in multidrug resistance cell line KBV200. Eur J Pharmacol 2010; 627:69-74.

Chen H, Wang L, Beretov J, Hao J, Xiao W, Li Y. Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin Exp Metastasis 2010; 27:557-69.

Chen J, Lu L, Feng Y et al. PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. Cancer Lett 2011; 300:48-56.

Chen J, Sun J, Ma Q et al. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther Drug Monit 2010; 32:573-8.

Chen KX, Vibulbhan B, Liu T et al. The role of P-glycoprotein in the pharmacokinetics and tissue distribution of a hepatitis C virus protease inhibitor. Drug Metab Lett 2009; 3:290-5.

Chen L, Li Y, Zhao Q, Peng H, Hou T. ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques. Mol Pharm 2011; 8:889-900.

Chen LM, Liang YJ, Zhang X et al. Reversal of P-gp-mediated multidrug resistance by bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue. Anticancer Res 2009; 29:4597-604.

Chen Q, Zhou J, Jiang C, Chen J. Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARgamma activation by troglitazone. J Huazhong Univ Sci Technolog Med Sci 2010; 30:326-31.

Chen S, Huo X, Lin Y et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 2010; 213:140-5.

Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011; 71:11-41.

Chen XC, Huang SP, Wang XY. Effect of astrocytes with different degrees of proliferation on multidrug resistance gene expression in rats with epilepsy. Zhongguo Dang Dai Er Ke Za Zhi 2010; 12:908-11.

Chen YW, Lin GJ, Chuang YP et al. Triptolide circumvents drug-resistant effect and enhances 5-fluorouracil antitumor effect on KB cells. Anticancer Drugs 2010; 21:502-13.

Cheng J, Meziani MJ, Sun YP, Cheng SH. Poly(ethylene glycol)-conjugated multi-walled carbon nanotubes as an efficient drug carrier for overcoming multidrug resistance. Toxicol Appl Pharmacol 2011; 250:184-93.

Cheng J, Wang JQ, Chen BA et al. MDR reversal activity of bromotetrandrine in vitro and in vivo. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009; 17:1183-91.

Cheng J, Wang T, Chen BA et al. Effect of desferioxamine on K562/A02 cell line and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011; 19:337-41.

Cheng Z, Zhang J, Liu H, Li Y, Zhao Y, Yang E. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer’s disease-related animal models despite reported blood-brain barrier disruption. Drug Metab Dispos 2010; 38:1355-61.

Cheung ST, Cheung PF, Cheng CK, Wong NC, Fan ST. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology 2011; 140:344-55.

Chew SC, Singh O, Chen X et al. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 2011; 67:1471-8.

Chiba K, Morimoto K. Genetic marker of statin-induced rhabdomyolysis. Yakugaku Zasshi 2011; 131:247-53.

Chieli E, Romiti N, Rodeiro I, Garrido G. In vitro modulation of ABCB1/P-glycoprotein expression by polyphenols from Mangifera indica. Chem Biol Interact 2010; 186:287-94.

Chikazawa N, Tanaka H, Tasaka T et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 2010; 30:2041-8.

Chiu LY, Ko JL, Lee YJ, Yang TY, Tee YT, Sheu GT. L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett 2010; 192:408-18.

Cho HY, Yoo HD, Lee YB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects. Neuroscience 2010; 169:378-87.

Cho HY, Yoon H, Park GK, Lee YB. Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. Clin Ther 2009; 31:2712-21.

Choi BS, Alberti DB, Schelman WR et al. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol 2010; 66:973-80.

Choi DH, Chung JH, Choi JS. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. Eur J Clin Pharmacol 2010; 66:285-90.

Choi DH, Li C, Choi JS. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet 2009; 34:163-8.

Choi DH, Li C, Choi JS. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. J Pharm Pharmacol 2010; 62:908-14.

Choi EM, Lee MG, Lee SH, Choi KW, Choi SH. Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting. Anaesthesia 2010; 65:996-1000.

Choi JS, Burm JP. Effects of oral epigallocatechin gallate on the pharmacokinetics of nicardipine in rats. Arch Pharm Res 2009; 32:1721-5.

Choi JS, Kang NS, Min YK, Kim SH. Euphorbiasteroid reverses P-glycoprotein-mediated multi-drug resistance in human sarcoma cell line MES-SA/Dx5. Phytother Res 2010; 24:1042-6.

Choi KH, Chen C-J, Kriegler M, Roninson IB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1988; 53:519-29.

Choi SJ, Shin SC, Choi JS. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: Possible role of CYP3A4 and P-glycoprotein inhibition by myricetin. Arch Pharm Res 2011; 34:309-15.

Choi YH, Suh JH, Lee JH, Cho IH, Lee MG. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol 2010; 62:1084-8.

Chou M, Bertrand J, Segeral O et al. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother 2010; 54:4432-9.

Chow EC, Sondervan M, Jin C, Groothuis GM, Pang KS. Comparative effects of doxercalciferol (1α-hydroxyvitamin D(2)) versus calcitriol (1α,25-dihydroxyvitamin D(3)) on the expression of transporters and enzymes in the rat in vivo. J Pharm Sci 2010; 100:1594-604.

Chung JW, Yang SH, Choi JS. Effects of lovastatin on the pharmacokinetics of nicardipine in rats. Biopharm Drug Dispos 2010; 31:436-41.

Cianfriglia M, Mallano A, Ascione A, Dupuis ML. Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line. Int J Oncol 2010; 36:1513-20.

Ciccacci C, Borgiani P, Ceffa S et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 2010; 11:23-31.

Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Effects of azithromycin on the expression of ATP binding cassette transporters in epithelial cells from the airways of cystic fibrosis patients. J Chemother 2007; 19:643-9.

Cindric M, Cipak A, Serly J et al. Reversal of multidrug resistance in murine lymphoma cells by amphiphilic dihydropyridine antioxidant derivative. Anticancer Res 2010; 30:4063-9.

Cizmarikova M, Wagnerova M, Schonova L et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 2010; 10:62-9.

Coburger C, Lage H, Molnár J, Langner A, Hilgeroth A. Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors. J Pharm Pharmacol 2010; 62:1704-10.

Coburger C, Wollmann J, Krug M et al. Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators. Bioorg Med Chem 2010; 18:4983-90.

Cocco G, Chu DC, Pandolfi S. Colchicine in clinical medicine. A guide for internists. Eur J Intern Med 2010; 21:503-8.

Cohen JS, Benton AS, Nwachukwu F, Ozedirne T, Teach SJ, Freishtat RJ. P-glycoprotein transporter expression on a549 respiratory epithelial cells is positively correlated with intracellular dexamethasone levels. J Investig Med 2010; 58:991-4.

Colabufo NA, Berardi F, Perrone MG et al. Substrates, inhibitors and activators of P-glycoprotein: candidates for radiolabeling and imaging perspectives. Curr Top Med Chem 2010; 10:1703-14.

Colabufo NA, Contino M, Berardi F et al. A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents. Toxicol In Vitro 2011; 25:222-30.

Colabufo NA, Contino M, Niso M, Berardi F, Leopoldo M, Perrone R. EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives. Front Biosci 2011; 16:1811-23.

Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 2010; 596:341-58.

Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006; 80:682-90.

Collnot EM, Baldes C, Schaefer UF, Edgar KJ, Wempe MF, Lehr CM. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm 2010; 7:642-51.

Contardo-Jara V, Lorenz C, Pflugmacher S, Nützmann G, Kloas W, Wiegand C. Molecular effects and bioaccumulation of levonorgestrel in the non-target organism Dreissena polymorpha. Environ Pollut 2011; 159:38-44.

Contardo-Jara V, Pflugmacher S, Nützmann G, Kloas W, Wiegand C. The beta-receptor blocker metoprolol alters detoxification processes in the non-target organism Dreissena polymorpha. Environ Pollut 2010; 158:2059-66.

Corboz MR, Rivelli MA, McCormick KD et al. Pharmacological characterization of a novel {alpha}2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N’-methylurea (Compound A). J Pharmacol Exp Ther 2011; 337:256-66.

Cornelissen JJ, Sonneveld P, Schoester M et al. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol 1994; 12:115-9.

Correia CT, Almeida JP, Santos PE et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 2010; 10:418-30.

Cotte S, von Ahsen N, Kruse N et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 2009; 132:2517-30.

Cox CD, Garbaccio RM. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs. Anticancer Agents Med Chem 2010; 10:697-712.

Coy DJ, Wooton-Kee CR, Yan B et al. ABCG5/ABCG8-independent biliary cholesterol excretion in lactating rats. Am J Physiol Gastrointest Liver Physiol 2010; 299:228-35.

Crettol S, Déglon JJ, Besson J et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80:668-81.

Cripe LD, Uno H, Paietta EM et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010; 116:4077-85.

Crouthamel MH, Wu D, Yang Z, Ho RJ. A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci 2006; 95:2767-77.

Crouthamel MH, Wu D, Yang Z, Ho RJ. A novel MDR1 GT1292-3TG (Cys431Leu) genetic variation and its effect on P-glycoprotein biologic functions. AAPS J 2010; 12:548-55.

Crowley E, McDevitt CA, Callaghan R. Generating inhibitors of P-glycoprotein: where to, now? Methods Mol Biol 2010; 596:405-32.

Csáki KF. Synthetic surfactant food additives can cause intestinal barrier dysfunction. Med Hypotheses 2011; 76:676-81.

Cui XR, Saito R, Kubo T, Kon D, Hirano Y, Saito S. Preparations of anthraquinone and naphthoquinone derivatives and their cytotoxic effects. Chem Pharm Bull 2011; 59:302-14.

Cutler MJ, Urquhart BL, Velenosi TJ et al. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol 2011. doi:10. 1177/0091270011400414.

Dai Z, Papp AC, Wang D, Hampel H, Sadee W. Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics 2008; 1:24.

Damiani D, Tiribelli M, Michelutti A et al. Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. Leuk Res 2010; 34:942-5.

Daniel F, Loriot MA, Seksik P et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis 2007; 13:19-23.

Darby RA, Callaghan R, McMahon RM. P-glycoprotein inhibition; the past, the present and the future. Curr Drug Metab 2011; 12:722-31.

Darnell M, Karlsson JE, Owen A et al. Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells. Drug Metab Dispos 2010; 38:491-7.

Davies GF, Juurlink BH, Harkness TA. Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Des Devel Ther 2009; 3:79-88.

Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 2010; 30:134-46.

de Bruyne S, Wyffels L, Boos TL et al. In vivo evaluation of [123I]-4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine, an iodinated SPECT tracer for imaging the P-gp transporter. Nucl Med Biol 2010; 37:469-77.

de Denus S, Zakrzewski M, Barhdadi A et al. Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. J Heart Lung Transplant 2011; 30:326-31.

de Iudicibus S, de Pellegrin A, Stocco G, Bartoli F, Bussani R, Decorti G. ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer. Anticancer Res 2008; 28:3921-8.

de Klerk OL, Willemsen AT, Bosker FJ et al. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry Res 2010; 183:151-6.

de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010; 51:80-8.

de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 2010. doi:10. 1007/s10637-010-9569-1.

Dejeux E, Rønneberg JA, Solvang H et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer 2010; 9:68.

Deng Q, Li ZP, Huang CM et al. Effect and mechanism of DNMT inhibitor on the reversal of multidrug resistance in human colon cancer cell line sw620/L-OHP. Sichuan Da Xue Xue Bao Yi Xue Ban 2010; 41:975-9.

Desai PB, Duan J, Sridhar R, Damle BD. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole. Methods Find Exp Clin Pharmacol 1997; 19:231-9.

di Bartolomeo S, Luly P, Spinedi A. P-glycoprotein is not a key target for the chemosensitizing effect of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol in HepG2 cells exposed to doxorubicin. Drug Metab Lett 2010; 4:39-44.

Diamanti AP, Rosado M, Germano V et al. Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A: modulation of P-glycoprotein function. Clin Immunol 2011; 138:9-13.

Digoxin: serious drug interactions. Prescrire Int 2010; 19:68-70.

Dilger K, Cascorbi I, Grünhage F, Hohenester S, Sauerbruch T, Beuers U. Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. Liver Int 2006; 26:285-90.

Dilger K, Schwab M, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 2004; 10:578-83.

Dočolomanský P, Boháčová V, Barančík M, Breier A. Why the xanthine derivatives are used to study of P-glycoprotein-mediated multidrug resistance in L1210/VCR line cells. Gen Physiol Biophys 2010; 29:215-21.

Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010; 30:842-54.

Dohse M, Scharenberg C, Shukla S et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010; 38:1371-80.

Doligalska M, Jóźwicka K, Kiersnowska M, Mroczek A, Pączkowski C, Janiszowska W. Triterpenoid saponins affect the function of P-glycoprotein and reduce the survival of the free-living stages of Heligmosomoides bakeri. Vet Parasitol 2011; 179:144-51.

Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009; 14:1105-18.

Dong HJ, Miao KR, Qiao C et al. Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population. Leuk Lymphoma 2011; 52:1003-9.

Dong L, Luo R, Tong Y, Cai X, Mao M, Yu D. Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: an analysis in a western Chinese pediatric population. Brain Res 2011; 1391:114-24.

Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine 2010; 5:597-615.

Dönmez Y, Gündüz U. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed Pharmacother 2011; 65:85-9.

Dorian P. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther 2010; 15(4 Suppl):15-8.

Dörner B, Kuntner C, Bankstahl JP et al. Radiosynthesis and in vivo evaluation of 1-[(18)F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorg Med Chem 2011; 19:2190-8.

Draheim V, Reichel A, Weitschies W, Moenning U. N-glycosylation of ABC transporters is associated with functional activity in sandwich-cultured rat hepatocytes. Eur J Pharm Sci 2010; 41:201-9.

Dreiseitel A, Oosterhuis B, Vukman KV et al. Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br J Pharmacol 2009; 158:1942-50.

Drigo I, Piscianz E, Valencic E et al. Selective resistance to different glucocorticoids in severe autoimmune disorders. Clin Immunol 2010; 134:313-9.

Droździk M, Białecka M, Myśliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease. Pharmacogenetics 2003; 13:259-63.

du Plooy M, Viljoen M, Rheeders M. Evidence for time-dependent interactions between ritonavir and lopinavir/ritonavir plasma levels following P-glycoprotein inhibition in Sprague-Dawley rats. Biol Pharm Bull 2011; 34:66-70.

Duarte N, Ramalhete C, Varga A, Molnár J, Ferreira MJ. Multidrug resistance modulation and apoptosis induction of cancer cells by terpenic compounds isolated from Euphorbia species. Anticancer Res 2009; 29:4467-72.

Duca RC, Mabondzo A, Bravin F, Delaforge M. In vivo effects of zearalenone on the expression of proteins involved in the detoxification of rat xenobiotics. Environ Toxicol 2010. doi:10. 1002/tox. 20617.

Dumond JB, Vourvahis M, Rezk NL et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 2010; 87:735-42.

Dumontet C, Landi S, Reiman T et al. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplant 2010; 45:1316-24.

Dunn S, Hedges L, Sampson K et al. Pharmacokinetic interaction of the antiparasitic agents ivermectin and spinosad in dogs. Drug Metab Dispos 2011; 39:789-95.

Dunne G, Breen L, Collins DM, Roche S, Clynes M, O’Connor R. Modulation of P-gp expression by lapatinib. Invest New Drugs 2011; 29:1284-93.

Dupuy J, Alvinerie M, Ménez C, Lespine A. Interaction of anthelmintic drugs with P-glycoprotein in recombinant LLC-PK1-mdr1a cells. Chem Biol Interact 2010; 186:280-6.

Dusseaux M, Martin E, Serriari N et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 2011; 117:1250-9.

Dutheil F, Beaune P, Tzourio C, Loriot MA, Elbaz A. Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. Arch Neurol 2010; 67:739-45.

Ebrahimi A, Houshmand M, Tonekaboni SH, Fallah Mahboob Passand MS, Zainali S, Moghadasi M. Two novel mutations in SCN1A gene in Iranian patients with epilepsy. Arch Med Res 2010; 41:207-14.

Eckermann G, Lahu G, Nassr N, Bethke TD. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults. J Clin Pharmacol 2011. doi:10. 1177/0091270010389467.

Eechoute K, Sparreboom A, Burger H et al. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 2011; 17:406-15.

Effendi K, Mori T, Komuta M, Masugi Y, Du W, Sakamoto M. Bmi-1 gene is upregulated in early-stage hepatocellular carcinoma and correlates with ATP-binding cassette transporter B1 expression. Cancer Sci 2010; 101:666-72.

Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S. Development of a drug resistance model for hepatoblastoma. Int J Oncol 2011; 38:447-54.

Ek CJ, Wong A, Liddelow SA, Johansson PA, Dziegielewska KM, Saunders NR. Efflux mechanisms at the developing brain barriers: ABC-transporters in the fetal and postnatal rat. Toxicol Lett 2010; 197:51-9.

El Ela AA, Härtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 2004; 56:967-75.

ElAli A, Hermann DM. Apolipoprotein E controls ATP-binding cassette transporters in the ischemic brain. Sci Signal 2010; 3:ra72.

el-Ashmawy IM, el-Nahas AF, Bayad AE. Teratogenic and cytogenetic effects of ivermectin and its interaction with P-glycoprotein inhibitor. Res Vet Sci 2011; 90:116-23.

Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 2010; 11:1223-34.

Elens L, Yombi JC, Lison D, Wallemacq P, Vandercam B, Haufroid V. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics 2009; 10:1589-97.

Elliott SL, Crawford C, Mulligan E et al. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia. Br J Haematol 2011; 152:61-71.

Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 2011; 17:89-99.

Elsby R, Gillen M, Butters C et al. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos 2011; 39:275-82.

Emmink BL, van Houdt WJ, Vries RG et al. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology 2011; 141:269-78.

Eng KT, Berdis AJ. A novel non-natural nucleoside that influences P-glycoprotein activity and mediates drug resistance. Biochemistry 2010; 49:1640-8.

Enomoto R, Koshiba C, Suzuki C, Lee E. Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects. Cancer Chemother Pharmacol 2011; 67:1063-72.

Ernst IM, Wagner AE, Lipinski S et al. Cellular uptake, stability, visualization by ‘Naturstoff reagent A’, and multidrug resistance protein 1 gene-regulatory activity of cyanidin in human keratinocytes. Pharmacol Res 2010; 61:253-8.

Eshkoli T, Sheiner E, Ben-Zvi Z, Holcberg G. Drug transport across the placenta. Curr Pharm Biotechnol 2011; 12:707-14.

Espelt MV, Croci DO, Bacigalupo ML et al. Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization and in vivo tumor growth. Hepatology 2011; 53:2097-106.

Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolžan V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011; 67:993-1006.

Fajac A, Gligorov J, Rezai K et al. Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer 2010; 103:560-6.

Fan J, Maeng HJ, Du Y, Kwan D, Pang KS. Transport of 5,5-diphenylbarbituric acid and its precursors and their effect on P-gp, MRP2 and CYP3A4 in Caco-2 and LS180 cells. Eur J Pharm Sci 2011; 42:19-29.

Fang D, Bao Y, Li X et al. Effects of iron deprivation on multidrug resistance of leukemic K562 cells. Chemotherapy 2010; 56:9-16.

Fang W, Geng X, Deng Y et al. Platelet activating factor induces blood brain barrier permeability alteration in vitro. J Neuroimmunol 2011; 230:42-7.

Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 2010; 17:356-62.

Feinshtein V, Holcberg G, Amash A et al. Nitrofurantoin transport by placental choriocarcinoma JAr cells: involvement of BCRP, OATP2B1 and other MDR transporters. Arch Gynecol Obstet 2010; 281:1037-44.

Feng DD, Zhang H, Zhang P et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukemia. J Cell Mol Med 2011; 15:2164-75.

Ferrándiz-Huertas C, Fernández-Carvajal A, Ferrer-Montiel A. Rab4 interacts with the human P-glycoprotein and modulates its surface expression in multidrug resistant K562 cells. Int J Cancer 2011; 128:192-205.

Ferreira PE, Veiga MI, Cavaco I et al. Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit 2008; 30:10-5.

Fetisova EK, Avetisyan AV, Izyumov DS, Korotetskaya MV, Chernyak BV, Skulachev VP. Mitochondria-targeted antioxidant SkQR1 selectively protects MDR (Pgp 170)-negative cells against oxidative stress. FEBS Lett 2010; 584:562-6.

Field JJ, Singh AJ, Kanakkanthara A, Halafihi T, Northcote PT, Miller JH. Microtubule-stabilizing activity of zampanolide, a potent macrolide isolated from the Tongan marine sponge Cacospongia mycofijiensis. J Med Chem 2009; 52:7328-32.

Finkelstein Y, Aks SE, Hutson JR et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol 2010; 48:407-14.

Fischer S, Loncar J, Zaja R et al. Constitutive mRNA expression and protein activity levels of nine ABC efflux transporters in seven permanent cell lines derived from different tissues of rainbow trout (Oncorhynchus mykiss). Aquat Toxicol 2011; 101:438-46.

Fojo A, Lebo R, Shimizu N et al. Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Molec Genet 1986; 12:415-20.

Frankfort SV, Doodeman VD, Bakker R et al. ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients. Mol Neurodegener 2006; 1:13.

Fransson MN, Gréen H, Litton JE, Friberg LE. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab Dispos 2011; 39:247-55.

Franzellitti S, Buratti S, Valbonesi P, Capuzzo A, Fabbri E. The β-blocker propranolol affects cAMP-dependent signaling and induces the stress response in Mediterranean mussels, Mytilus galloprovincialis. Aquat Toxicol 2011; 101:299-308.

Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther 2007; 81:828-32.

Friedrich C, Ring A, Brand T, Sennewald R, Graefe-Mody EU, Woerle HJ. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet 2011; 36:17-24.

Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54:1295-310.

Fromm MF. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology 2002; 181-2:299-303.

Fruttero R, Crosetti M, Chegaev K et al. Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein. J Med Chem 2010; 53:5467-75.

Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 2010; 394:1098-104.

Fukui N, Suzuki Y, Sawamura K et al. Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit 2007; 29:185-9.

Fukunaga-Kalabis M, Martinez G, Nguyen TK et al. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene 2010; 29:6115-24.

Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009; 1794:860-71.

Fyrberg A, Peterson C, Kågedal B, Lotfi K. Induction of fetal hemoglobin and ABCB1 gene expression in 9-β-D-arabinofuranosylguanine-resistant MOLT-4 cells. Cancer Chemother Pharmacol 2011; 68:583-91.

Gadeyne C, van der Heyden S, Gasthuys F, Croubels S, Schauvliege S, Polis I. The influence of modulation of P-glycoprotein and/or Cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered in dogs. J Vet Pharmacol Ther 2011; 34:417-23.

Gadhe CG, Madhavan T, Kothandan G, Cho SJ. In silico quantitative structure-activity relationship studies on P-gp modulators of tetrahydroisoquinoline-ethyl-phenylamine series. BMC Struct Biol 2011; 11:5.

Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a odel for assessing population-related pharmacogenomics. J Clin Oncol 2009; 27:3540-6.

Ganguly A, Basu S, Banerjee K et al. Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis. Mol Biosyst 2011; 7:1701-12.

Ganguly A, Basu S, Chakraborty P et al. Targeting mitochondrial cell death pathway to overcome drug resistance with a newly developed iron chelate. PLoS One 2010. doi:10. 1371/journal. pone. 0011253.

Ganta S, Devalapally H, Amiji M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci 2010; 99:4630-41.

Gao A, Liang H, Wang X et al. Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro. Eur J Pharmacol 2011; 659:108-13.

Gao A, Wang X, Xiang W, Liang H, Gao J, Yan Y. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by doramectin and nemadectin. J Pharm Pharmacol 2010; 62:393-9.

Gao P, Wei JM, Li PY et al. Screening of deoxyribozyme with high reversal efficiency against multidrug resistance in breast carcinoma cells. J Cell Mol Med 2011; 15:2130-8.

Gardner ER, Kelly M, Springman E et al. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. Invest New Drugs 2010. doi:10. 1007/s10637-010-9520-5.

Gassó P, Mas S, Álvarez S et al. Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders. Pharmacogenomics 2010; 11:1725-31.

Gawrońska-Szklarz B, Siuda A, Kurzawski M, Bielicki D, Marlicz W, Droździk M. Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol 2010; 66:681-7.

Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T et al. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol 2005; 61:375-9.

Gazzin S, Berengeno AL, Strazielle N et al. Modulation of Mrp1 (ABCc1) and Pgp (ABCb1) by bilirubin at the blood-CSF and blood-brain barriers in the Gunn rat. PLoS One 2011. doi:10. 1371/journal. pone. 0016165.

Genovese S, Epifano F, Curini M, Menger D, Zembruski NC, Weiss J. In vitro effects of natural prenyloxycinnamic acids on human cytochrome P450 isozyme activity and expression. Phytomedicine 2011; 18:586-91.

George J, Dharanipragada K, Krishnamachari S, Chandrasekaran A, Sam SS, Sunder E. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer 2009; 9:161-5.

Gervasini G, Vizcaino S, Carrillo JA, Caballero MJ, Benitez J. The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study. Br J Clin Pharmacol 2006; 62:177-86.

Ghaemmaghami S, Ahn M, Lessard P et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 2009. doi:10. 1371/journal. ppat. 1000673.

Ghanem CI, Arias A, Novak A et al. Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line. Biochem Pharmacol 2011; 81:244-50.

Ghotbi R, Mannheimer B, Aklillu E et al. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 2010; 66:465-74.

Ginguené C, Champier J, Maallem S et al. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas. Brain Pathol 2010; 20:926-35.

Glaeser H, Bailey DG, Dresser GK et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007; 81:362-70.

Glimelius B, Garmo H, Berglund A et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 2011; 11:61-71.

Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011; 338:372-80.

Gnoth MJ, Sandmann S, Engel K, Radtke M. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab Dispos 2010; 38:1341-6.

Goard CA, Mather RG, Vinepal B et al. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. Int J Cancer 2010; 127:2936-48.

Goda K, Bacsó Z, Szabó G. Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets 2009; 9:281-97.

Goler-Baron V, Assaraf YG. Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance. PLoS One 2011. doi:10. 1371/journal. pone. 0016007.

Gontero P, Sargent JM, Hopster DJ et al. Ex vivo chemosensitivity to mitomycin C in bladder cancer and its relationship with P-glycoprotein and apoptotic factors. Anticancer Res 2002; 22:4073-80.

Gonzalez-Haba E, García MI, Cortejoso L et al. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics 2010; 11:1715-23.

Goto H, Takikawa H. Effect of genipin on cholestasis induced by estradiol-17beta-glucuronide and lithocholate-3-O-glucuornide in rats. Hepatol Res 2010; 40:524-9.

Gottschalk S, Cummins CL, Leibfritz D, Christians U, Benet LZ, Serkova NJ. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology 2011; 32:50-7.

Gra OA, Kozhekbaeva ZhM, Litvinov VI. Analysis of genetic predisposition to pulmonary tuberculosis in native Russians. Genetika 2010; 46:262-71.

Graber-Maier A, Büter KB, Aeschlimann J et al. Effects of Curcuma extracts and curcuminoids on expression of P-glycoprotein and cytochrome P450 3A4 in the intestinal cell culture model LS180. Planta Med 2010; 76:1866-70.

Grauer MT, Uhr M. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J Psychopharmacol 2004; 18:66-74.

Gréen H, Falk IJ, Lotfi K et al. Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics J 2010, doi:10. 1038/tpj. 2010. 79.

Greene LM, Nathwani SM, Bright SA et al. The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance. J Pharmacol Exp Ther 2010; 335:302-13.

Greer JP, Mosse CA. Natural killer-cell neoplasms. Curr Hematol Malig Rep 2009; 4:245-52.

Grimm C, Polterauer S, Zeillinger R et al. Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer. Anticancer Res 2010; 30:3487-91.

Grinyó J, Vanrenterghem Y, Nashan B et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 2008; 21:879-91.

Grodzovski I, Lichtenstein M, Galski H, Lorberboum-Galski H. IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathway. Int J Cancer 2011; 128:1966-80.

Grover S, Gourie-Devi M, Baghel R et al. Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics 2010; 11:927-41.

Gruber BM, Bubko I, Krzyszton-Russjan J, Anuszewska EL. Synergistic action of doxorubicin and sulindac in human cervix carcinoma cells-studies on possible mechanisms. Med Sci Monit 2010; 16:45-51.

Guenova ML, Balatzenko GN, Nikolova VR, Spassov BV, Konstantinov SM. An anti-apoptotic pattern correlates with multidrug resistance in acute myeloid leukemia patients: a comparative study of active caspase-3, cleaved PARPs, Bcl-2, Survivin and MDR1 gene. Hematology 2010; 15:135-43.

Guilhaumou R, Simon N, Quaranta S et al. Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases. Cancer Chemother Pharmacol 2010. doi:10. 1007/s00280-010-1541-4.

Gümüş-Akay G, Rüstemoğlu A, Karadağ A, Sunguroğlu A. Haplotype-based analysis of MDR1/ABCB1 gene polymorphisms in a Turkish population. DNA Cell Biol 2010; 29:83-90.

Guo Z, Zhu J, Zhao L, Luo Q, Jin X. Expression and clinical significance of multidrug resistance proteins in brain tumors. J Exp Clin Cancer Res 2010; 29:122.

Gupta SV, Sass EJ, Davis ME et al. Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J 2011; 13:357-64.

Gustafson DL, Thamm DH. Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters. J Vet Intern Med 2010; 24:579-86.

Gyémánt N, Engi H, Schelz Z et al. In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin. Br J Cancer 2010; 103:178-85.

Haas DW, Bartlett JA, Andersen JW et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43:783-6.

Habibollahi P, Ghahremani MH, Azizi E, Ostad SN. Multi drug resistance-1 (MDR1) expression in response to chronic diazinon exposure: an in vitro study on Caco-2 cells. Bull Environ Contam Toxicol 2011; 86:105-9.

Haerian BS, Lim KS, Mohamed EH et al. Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy. Seizure 2011; 20:387-94.

Haerian BS, Lim KS, Mohamed EH et al. Lack of association of ABCB1 haplotypes on five loci with response to treatment in epilepsy. Seizure 2011; 20:546-53.

Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z. Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics 2011; 12:713-25.

Haerian BS, Lim KS, Tan HJ et al. Association between ABCB1 polymorphism and response to sodium valproate treatment in Malaysian epilepsy patients. Epileptic Disord 2011; 13:65-75.

Haerian BS, Roslan H, Raymond AA et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. Seizure 2010; 19:339-46.

Hajda J, Rentsch KM, Gubler C, Steinert H, Stieger B, Fattinger K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci 2010; 41:729-35.

Hamid KA, Lin Y, Gao Y, Katsumi H, Sakane T, Yamamoto A. The effect of wellsolve, a novel solubilizing agent, on the intestinal barrier function and intestinal absorption of griseofulvin in rats. Biol Pharm Bull 2009; 32:1898-905.

Hamidovic A, Hahn K, Kolesar J. Clinical significance of ABCB1 genotyping in oncology. J Oncol Pharm Pract 2010; 16:39-44.

Hampras SS, Sucheston L, Weiss J et al. Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia. Int J Mol Epidemiol Genet 2010; 1:201-7.

Han JI, Son HW, Park SC, Na KJ. Novel insertion mutation of ABCB1 gene in an ivermectin-sensitive Border Collie. J Vet Sci 2010; 11:341-4.

Han N, Yan Z, Guo CA et al. Effects of p-glycoprotein on steroid-induced osteonecrosis of the femoral head. Calcif Tissue Int 2010; 87:246-53.

Han YH, Busler D, Hong Y, Tian Y, Chen C, Rodrigues AD. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters. Drug Metab Dispos 2010; 38:1072-82.

Hanafi-Bojd MY, Iranshahi M, Mosaffa F, Tehrani SO, Kalalinia F, Behravan J. Farnesiferol A from Ferula persica and Galbanic Acid from Ferula szowitsiana inhibit P-glycoprotein-mediated Rhodamine efflux in breast cancer cell lines. Planta Med 2011; 77:1590-3.

Hanke U, May K, Rozehnal V, Nagel S, Siegmund W, Weitschies W. Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2). Eur J Pharm Biopharm 2010; 76:260-8.

Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 2011; 7:267-86.

Hao J, Chen H, Madigan MC et al. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 2010; 103:1008-18.

Hao Q, Wenfang C, Xia A et al. Effects of a moderate-intensity static magnetic field and adriamycin on K562 cells. Bioelectromagnetics 2011; 32:191-9.

Haouala A, Rumpold H, Untergasser G et al. siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors. Drug Metab Lett 2010; 4:114-9.

Haraguchi S, Ho SK, Morrow M, Goodenow MM, Sleasman JW. Developmental regulation of P-glycoprotein activity within thymocytes results in increased protease inhibitor activity. J Leukoc Biol 2011; 90:653-60.

Harisa Gel-D, Ibrahim MF, Alanazi FK. Characterization of human erythrocytes as potential carrier for pravastatin: an in vitro study. Int J Med Sci 2011; 8:222-30.

Harmsze AM, Robijns K, van Werkum JW et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010; 103:920-5.

Harmsze AM, van Werkum JW, Ten Berg JM et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 2010; 31:3046-53.

Harpstrite SE, Prior JL, Sivapackiam J, Collins SD, Rath NP, Sharma V. Synthesis, characterization, and molecular structure of a novel zinc (II) complex: assessment of impact of MDR1Pgp expression on its cytotoxic activity. Med Chem 2010; 6:191-9.

Hartman JC, Brouwer K, Mandagere A, Melvin L, Gorczynski R. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol 2010; 88:682-91.

Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer‘s disease. Mol Pharmacol 2010; 77:715-23.

Hatori A, Yui J, Yanamoto K et al. Determination of radioactivity in infant, juvenile and adult rat brains after injection of anti-influenza drug [(11)C]oseltamivir using PET and autoradiography. Neurosci Lett 2011; 495:187-91.

Haufroid V. Genetic polymorphisms of ATP-Binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targets 2011; 12:631-46.

Hawkins BT, Sykes DB, Miller DS. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 2010; 30:1417-25.

Hawwa AF, McElnay JC. Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. Expert Opin Drug Saf 2011; 10:9-22.

Hayashi Y, Ushijima K, Ando H et al. Influence of a time-restricted feeding schedule on the daily rhythm of abcb1a gene expression and its function in rat intestine. J Pharmacol Exp Ther 2010; 335:418-23.

He L, Yang J, Hu L. Transmembrane transport activity of paclitaxel regulated by fangchinoline in MDR1-mDCK II cells. Zhongguo Zhong Yao Za Zhi 2010; 35:1478-81.

He Q, Zhang G, Hou D et al. Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep 2011; 25:237-43.

He S, Liu F, Xie Z, Zu X, Xu W, Jiang Y. P-glycoprotein/MDR1 regulates pokemon gene transcription through p53 expression in human breast cancer cells. Int J Mol Sci 2010; 11:3309-51.

He SM, Li CG, Liu JP, Chan E, Duan W, Zhou SF. Disposition pathways and pharmacokinetics of herbal medicines in humans. Curr Med Chem 2010; 17:4072-113.

He SM, Li R, Kanwar JR, Zhou SF. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem 2011; 18:439-81.

He XJ, Zhao LM, Qiu F, Sun YX, Li-Ling J. Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. Pharmacol Rep 2009; 61:843-50.

Hedman M, Antikainen M, Holmberg C et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 2006; 61:706-15.

Heidbuchel H, Verhamme P. Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice. Acta Cardiol 2010; 65:491-7.

Hellinger E, Bakk ML, Pócza P, Tihanyi K, Vastag M. Drug penetration model of vinblastine-treated Caco-2 cultures. Eur J Pharm Sci 2010; 41:96-106.

Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GD, Ahmed MS. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol 2010; 202:383-7.

Hemauer SJ, Patrikeeva SL, Wang X et al. Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol 2010; 80:1080-6.

Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 2006; 39:121-7.

Henríquez-Hernández LA, Murias-Rosales A, González-Hernández A, de Leon AC, Díaz-Chico N, Fernández-Pérez L. Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer Epidemiol 2010; 34:634-8.

Henríquez-Hernández LA, Pérez LF, Hernández AG, de León AC, Díaz-Chico B, Rosales AM. TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy. Cancer Epidemiol 2010; 34:490-3.

Herrero MJ, Almenar L, Jordán C, Sánchez I, Poveda JL, Aliño SF. Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation. Transplant Proc 2010; 42:3181-2.

Herrero MJ, Sánchez-Plumed J, Galiana M, Bea S, Marqués MR, Aliño SF. Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation. Transplant Proc 2010; 42:3134-6.

Herrlinger KR, Koc H, Winter S et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther 2011; 89:422-8.

Hien TT, Kim HG, Han EH, Kang KW, Jeong HG. Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res 2010; 54:918-28.

Hippalgaonkar K, Srirangam R, Avula B, Khan IA, Majumdar S. Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. Drug Metab Dispos 2010; 38:1790-7.

Hoenig MR, Walker PJ, Gurnsey C, Beadle K, Johnson L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol 2011; 5:91-6.

Hoffmann AC, Wild P, Leicht C et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010; 12:628-36.

Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-8.

Holmstock N, Mols R, Annaert P, Augustijns P. In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption. Drug Metab Dispos 2010; 38:1407-10.

Holtman L, van Vliet EA, Edelbroek PM, Aronica E, Gorter JA. Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy. Epilepsy Res 2010; 91:49-56.

Honda M, Ogura Y, Toyoda W et al. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. Biol Pharm Bull 2006; 29:772-8.

Hong L, Han Y, Zhang H et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010; 251:1056-63.

Hong SP, Yang JS, Han JY et al. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. J Pharm Pharmacol 2011; 63:129-35.

Honorat M, Falson P, Terreux R, di Pietro A, Dumontet C, Payen L. Multidrug resistance ABC transporter structure predictions by homology modeling approaches. Curr Drug Metab 2011; 12:268-77.

Hooijberg JH, de Vries NA, Kaspers GJ, Pieters R, Jansen G, Peters GJ. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 2006; 58:1-12.

Hopkins S, Scorneaux B, Huang Z et al. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother 2010; 54:660-72.

Horibe S, Nagai J, Yumoto R, Tawa R, Takano M. Accumulation and photodynamic activity of chlorin e6 in cisplatin-resistant human lung cancer cells. J Pharm Sci 2011; 100:3010-7.

Horwedel C, Tsogoeva SB, Wei S, Efferth T. Cytotoxicity of artesunic acid homo-and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells. J Med Chem 2010; 53:4842-8.

Hosten B, Abbara C, Cibert M et al. Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice. Anticancer Drugs 2010; 21:193-201.

Hu C, Xu D, Du W et al. Novel 4 beta-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents. Mol Biosyst 2010; 6:410-20.

Hu Y, Sampson KE, Xing L et al. Two branched polar groups and polar linker moieties of thiophene amide derivatives are essential for MRP2/ABCC2 recognition. Drug Metab Lett 2010; 4:254-61.

Hu YP, Robert J. Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. Biochem Pharmacol 1995; 50:169-75.

Huang IP, Sun SP, Cheng SH et al. Enhanced chemotherapy of cancer using pH-sensitive Mesoporous Silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Mol Cancer Ther 2011; 10:761-9.

Huang LM, Zhao JH, Wang GC, Zhou JP. Recent advance in the mechanism study of polymeric inhibitors of P-glycoprotein. Yao Xue Xue Bao 2010; 45:1224-31.

Huang R, Vider J, Serganova I, Blasberg RG. ATP-Binding cassette transporters modulate both coelenterazine- and d-luciferin-based bioluminescence imaging. Mol Imaging 2011; 10:215-26.

Huang Y, Dong G, Hong X, Chai H, Yuan X. Studies on reversing MDR of K562/A02 by ramification of curcumin hydrolyzed. Zhongguo Zhong Yao Za Zhi 2010; 35:2460-3.

Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci 2010; 113:315-24.

Hung CC, Chen CC, Lin CJ, Liou HH. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics 2008; 18:390-402.

Hung CC, Liou HH. YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. Invest New Drugs 2011; 29:1337-46.

Huo H, Magro PG, Pietsch EC, Patel BB, Scotto KW. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res 2010; 70:8726-35.

Hutson JR, Koren G, Matthews SG. Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology. Placenta 2010; 31:351-7.

Ichihara S, Yamada Y, Kato K et al. Association of a polymorphism of ABCB1 with obesity in Japanese individuals. Genomics 2008; 91:512-6.

Iijima M, Momose I, Ikeda D. Increased ABCB1 expression in TP-110-resistant RPMI-8226 cells. Biosci Biotechnol Biochem 2010; 74:1913-9.

Illmer T, Schuler US, Thiede C et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62:4955-62.

Im YB, Ha I, Kang KW, Lee MY, Han HK. Macelignan: a new modulator of P-glycoprotein in multidrug-resistant cancer cells. Nutr Cancer 2009; 61:538-43.

Iqbal J, Hombach J, Matuszczak B, Bernkop-Schnürch A. Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. J Control Release 2010; 147:62-9.

Iqbal M, Gibb W, Matthews SG. Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier. Endocrinology 2011; 152:1067-79.

Ishii K, Tanaka S, Kagami K et al. Effects of naturally occurring polymethyoxyflavonoids on cell growth, p-glycoprotein function, cell cycle, and apoptosis of daunorubicin-resistant T lymphoblastoid leukemia cells. Cancer Invest 2010; 28:220-9.

Ishikawa Y, Nagai J, Okada Y, Sato K, Yumoto R, Takano M. Function and expression of ATP-binding cassette transporters in cultured human Y79 retinoblastoma cells. Biol Pharm Bull 2010; 33:504-11.

Issaeva N, Thomas HD, Djureinovic T et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res 2010; 70:6268-76.

Ito K, Uchida Y, Ohtsuki S et al. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 2011; 100:3939-50.

Iudicibus SD, Franca R, Martelossi S, Ventura A, Decorti G. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol 2011; 17:1095-108.

Iusuf D, Teunissen SF, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen, and restricts their brain penetration. J Pharmacol Exp Ther 2011; 337:710-7.

Iwaki K, Sakaeda T, Kakumoto M et al. Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein. J Pharm Pharmacol 2006; 58:1617-22.

Iwanaga K, Hayashi M, Hamahata Y et al. Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein. Drug Metab Dispos 2010; 38:1286-94.

Iwata H, Sato H, Suzuki R et al. A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma. Int J Oncol 2011; 38:1653-61.

Izawa A, Schatton T, Frank NY et al. A novel in vivo regulatory role of P-glycoprotein in alloimmunity. Biochem Biophys Res Commun 2010; 394:646-52.

Jafar T, Prasad N, Agarwal V et al. MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2011. doi:10. 1093/ndt/gfr150.

Jaganathan SK. Can flavonoids from honey alter multidrug resistance? Med Hypotheses 2011; 76:535-7.

Jagoda EM, Lang L, McCullough K et al. [(76) Br]BMK-152, a nonpeptide analogue, with high affinity and low nonspecific binding for the corticotropin-releasing factor type 1 receptor. Synapse 2011; 65:910-8.

Jain L, Abraham S, Shord SS. The interactions of anti-cancer drugs approved in the last decade in the United States with membrane transporters. Anticancer Agents Med Chem 2010; 10:601-16.

Jaisue S, Gerber JP, Davey AK. Pharmacokinetics of fexofenadine following LPS administration to rats. Xenobiotica 2010; 40:743-50.

Jambroszyk M, Tipold A, Potschka H. Add-on treatment with verapamil in pharmacoresistant canine epilepsy. Epilepsia 2011; 52:284-91.

Jani M, Makai I, Kis E et al. Ivermectin interacts with human ABCG2. J Pharm Sci 2011; 100:94-7.

Janneh O, Owen A, Bray PG, Back DJ, Pirmohamed M. The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. Br J Pharmacol 2010; 159:484-93.

Jansen G, van der Heijden J, Oerlemans R et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004; 50:2130-9.

Jaszewska E, Kosmider A, Kiss AK, Naruszewicz M. Oenothera paradoxa defatted seeds extract containing pentagalloylglucose and procyanidins potentiates the cytotoxicity of vincristine. J Physiol Pharmacol 2010; 61:637-43.

Jedlitschky G, Vogelgesang S, Kroemer HK. MDR1-P-glycoprotein (ABCB1)-mediated disposition of amyloid-β peptides: implications for the pathogenesis and therapy of Alzheimer’s disease. Clin Pharmacol Ther 2010; 88:441-3.

Jeganathan S, Sanderson L, Dogruel M, Rodgers J, Croft S, Thomas SA. The distribution of nifurtimox across the healthy and trypanosome-infected murine blood-brain and blood-cerebrospinal fluid barriers. J Pharmacol Exp Ther 2011; 336:506-15.

Jeon YH, Bae SA, Lee YJ et al. Evaluation of the reversal of multidrug resistance by MDR1 ribonucleic acid interference in a human colon cancer model using a renilla luciferase reporter gene and coelenterazine. Mol Imaging 2010; 9:343-50.

Jeong YH, Kim IS, Park Y et al. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc Interv 2010; 3:731-41.

Jetter A, Fätkenheuer G, Frank D et al. Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir Ther 2010; 15:975-83.

Jeynes B, Provias J. An investigation into the role of P-glycoprotein in Alzheimer’s disease lesion pathogenesis. Neurosci Lett 2011; 487:389-93.

Ji BS, Li M, He L. Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Pharmazie 2010; 65:515-9.

Ji Z, Long H, Hu Y et al. Expression of MDR1, HIF-1α and MRP1 in sacral chordoma and chordoma cell line CM-319. J Exp Clin Cancer Res 2010; 29:158.

Jiang J, Yang SJ, Wang JC et al. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm 2010; 76:170-8.

Jiang S, Zu Y, Zhang Y, Fu Y, Wang Z, Wang J. Transport of a hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel, by human intestinal epithelial Caco-2 cells. Planta Med 2010; 76:1592-5.

Jiko M, Yano I, Sato E et al. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol 2007; 12:284-90.

Jin J, Bi H, Hu J et al. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats. Biopharm Drug Dispos 2010; 31:264-8.

Jin L, Li J, Nation RL, Nicolazzo JA. Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. Antimicrob Agents Chemother 2011; 55:502-7.

Jin MJ, Han HK. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction. J Food Sci 2010; 75:93-6.

Jin W, Liu Y, Xu SG et al. UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs. Breast Cancer Res Treat 2010; 124:39-48.

Jing X, Liu X, Wen T et al. Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats. Br J Pharmacol 2010; 159:1511-22.

Jones SR, Cyr DG. Regulation and characterization of the ATP-binding cassette transporter-B1 in the epididymis and epididymal spermatozoa of the rat. Toxicol Sci 2011; 119:369-79.

Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, Peleš AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 2010; 66:1109-17.

Joy MS, Boyette T, Hu Y et al. Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. Eur J Clin Pharmacol 2010; 66:1119-30.

Juan ME, González-Pons E, Planas JM. Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats. J Nutr 2010; 140:489-95.

Jung HJ, Chung SY, Nam JW et al. Inhibition of P-glycoprotein-induced multidrug resistance by a clerodane-type diterpenoid from Sindora sumatrana. Chem Biodivers 2010; 7:2095-101.

Kaan HY, Weiss J, Menger D et al. Structure-activity relationship and multidrug resistance study of new S-trityl-l-Cysteine derivatives as inhibitors of Eg5. J Med Chem 2011; 54:1576-86.

Kagan L, Dreifinger T, Mager DE, Hoffman A. Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. Drug Metab Dispos 2010; 38:1560-6.

Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir Ther 2010; 15:817-29.

Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet 2011; 50:25-39.

Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci 2010; 86:52-8.

Kaneda M, Schuetz M, Lin BS et al. ABC transporters coordinately expressed during lignification of Arabidopsis stems include a set of ABCBs associated with auxin transport. J Exp Bot 2011; 62:2063-77.

Kanekura T, Chen X. CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 2010; 57:149-54.

Kang BH, Siegelin MD, Plescia J et al. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res 2010; 16:4779-88.

Kang HA, Cho HY, Lee YB. The effect of MDR1 G2677T/A polymorphism on pharmacokinetics of gabapentin in healthy Korean subjects. Arch Pharm Res 2007; 30:96-101.

Kang MR, Lee K, Kang JS et al. KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein. Oncol Rep 2010; 23:801-9.

Kanintronkul Y, Worayuthakarn R, Thasana N et al. Overcoming multidrug resistance in human lung cancer with novel Benzo[a]quinolizin-4-ones. Anticancer Res 2011; 31:921-7.

Kannan P, Brimacombe KR, Zoghbi SS et al. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos 2010; 38:917-22.

Karlsson L, Hiemke C, Carlsson B et al. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology 2011; 215:367-77.

Karlsson L, Schmitt U, Josefsson M et al. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol 2010; 20:632-40.

Karttunen V, Myllynen P, Prochazka G, Pelkonen O, Segerbäck D, Vähäkangas K. Placental transfer and DNA binding of benzo(a)pyrene in human placental perfusion. Toxicol Lett 2010; 197:75-81.

Kasinathan RS, Morgan WM, Greenberg RM. Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel. Mol Biochem Parasitol 2010; 173:25-31.

Kastelic M, Koprivsek J, Plesnicar BK et al. MDR1 gene polymorphisms and response to acute risperidone treatment. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:387-92.

Kater B, Hunold A, Schmalz HG et al. Iron containing anti-tumoral agents: unexpected apoptosis-inducing activity of a ferrocene amino acid derivative. J Cancer Res Clin Oncol 2011; 137:639-49.

Kato M, Fukuda T, Serretti A et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:398-404.

Kato R, Moriguchi J, Irie T et al. Effects of lipopolysaccharide on P-glycoprotein expression and activity in the liver and kidneys. Eur J Pharmacol 2010; 636:155-8.

Kavallaris M, Madafiglio J, Norris MD, Haber M. Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells. Biochem Biophys Res Commun 1993; 190:79-85.

Kawahara H, Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene. Cancer Sci 2010; 101:1493-500.

Kawami M, Yumoto R, Nagai J et al. Effect of Thai plant extracts on P-glycoprotein function and viability in paclitaxel-resistant HepG2 cells. Drug Metab Pharmacokinet 2010; 25:155-62.

Kawamura K, Konno F, Yui J et al. Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET. Ann Nucl Med 2010; 24:403-12.

Kawamura K, Yamasaki T, Konno F et al. Synthesis and in vivo evaluation of 18F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters. Bioorg Med Chem 2011; 19:861-70.

Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011; 71:443-54.

Kelly RJ, Draper D, Chen CC et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 2011; 17:569-80.

Kerboeuf D, Guégnard F. Anthelmintics are substrates and activators of nematode P-glycoprotein. Antimicrob Agents Chemother 2011; 55:2224-32.

Keskitalo J, Kurkinen K, Neuvonen P, Niemi M. ABCB1 Haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008; 84:457–61.

Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009; 68:207-13.

Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 c. 421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 2009; 10:1617-24.

Khan S, Elshaer A, Rahman AS, Hanson P, Perrie Y, Mohammed AR. Genomic evaluation during permeability of indomethacin and its solid dispersion. J Drug Target 2011; 19:615-23.

Khedri A, Nejat-Shokouhi A, Salek R et al. Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population. Mol Biol Rep 2011; 38:2939-43.

Kiani J, Imam SZ. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J 2007; 6:33.

Kiki-Mvouaka S, Ménez C, Borin C et al. Role of P-glycoprotein in the disposition of macrocyclic lactones: A comparison between ivermectin, eprinomectin, and moxidectin in mice. Drug Metab Dispos 2010; 38:573-80.

Kim DH, Park JY, Sohn SK et al. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 2006; 118:2195-201.

Kim DY, Kim MJ, Kim HB et al. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc. Biochim Biophys Acta 2011; 1812:796-805.

Kim HG, Hien TT, Han EH et al. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 2011; 162:1096-108.

Kim HS, Kim MK, Chung HH et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 2009; 113:264-9.

Kim KA, Park JY. Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. Eur J Clin Pharmacol 2010; 66:721-5.

Kim KA, Park PW, Park JY. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol 2007; 63:53-8.

Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-99.

Kim SG, Lee AJ, Lee SJ, Suh HS, Shin IH. Inhibition of P-glycoprotein facilitated glycosaminoglycan accumulation during chondrogenesis of human bone marrow mesenchymal stem cells. Int J Rheum Dis 2011; 14:199-205.

Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 2002; 62:1-6.

Kimchi-Sarfaty C, Oh JM, Kim IW et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-8.

Kirschbaum KM, Uhr M, Holthoewer D et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 2010; 59:474-9.

Kishi S, Cheng C, French D et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007; 109:4151-7.

Kiyotani K, Mushiroda T, Imamura CK et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010; 28:1287-93.

Klepstad P, Fladvad T, Skorpen F et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 2011; 152:1139-45.

Knöller AS, Blakeslee JJ, Richards EL, Peer WA, Murphy AS. Brachytic2/ZmABCB1 functions in IAA export from intercalary meristems. J Exp Bot 2010; 61:3689-96.

Kobayashi Y, Seino K, Hosonuma S et al. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin. Gynecol Oncol 2011; 121:390-4.

Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther 2010; 333:788-96.

Kofla G, Turner V, Schulz B et al. Doxorubicin induces drug efflux pumps in Candida albicans. Med Mycol 2011; 49:132-42.

Kohen R, Shofer JB, Korvatska O et al. ABCB1 genotype and CSF {beta}-Amyloid in Alzheimer disease. J Geriatr Psychiatry Neurol 2011; 24:63-6.

Kolesar J, Brundage RC, Pomplun M et al. Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients. Cancer Chemother Pharmacol 2011; 67:393-400.

Kolitz JE, George SL, Marcucci G et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010; 116:1413-21.

Komina O, Nosske E, Maurer M, Wesierska-Gadek J. Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells. J Exp Ther Oncol 2011; 9:27-35.

König SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 2010; 65:2319-28.

Kooij G, Backer R, Koning JJ et al. P-glycoprotein acts as an immunomodulator during neuroinflammation. PLoS One 2009. doi:10. 1371/journal. pone. 0008212.

Kooij G, Mizee MR, van Horssen J et al. Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. Brain 2011; 134:555-70.

Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol 2010; 69:465-74.

Koolen SL, van Waterschoot RA, van Tellingen O et al. From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies. J Clin Pharmacol 2011. doi:10. 1177/0091270010397051.

Kooloos WM, Wessels JA, van der Straaten T, Allaart CF, Huizinga TW, Guchelaar HJ. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 2010; 11:163-75.

Kopecka J, Campia I, Brusa D et al. Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med 2011; 15:1492-504.

Kota BP, Abdul MI, Allen JD, Kalagara M, Roufogalis BD. Effect of vitamin D3 supplementation on the pharmacokinetics of digoxin- a pilot study. Fundam Clin Pharmacol 2011. doi:10. 1111/j. 1472-8206. 2011. 00944. x.

Kota BP, Allen JD, Roufogalis BD. The effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance. Basic Clin Pharmacol Toxicol 2011; 109:97-102.

Kota BP, Tran VH, Allen J, Bebawy M, Roufogalis BD. Characterization of PXR mediated P-glycoprotein regulation in intestinal LS174T cells. Pharmacol Res 2010; 62:426-31.

Kovtun YV, Audette CA, Mayo MF et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010; 70:2528-37.

Kozłowska-Rup D, Czekaj P. Barrier role of ABC family of proteins in human placenta. Ginekol Pol 2011; 82:56-63.

Krasznai ZT, Tóth A, Mikecz P et al. Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG. Eur J Pharm Sci 2010; 41:665-9.

Kreisl WC, Liow JS, Kimura N et al. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med 2010; 51:559-66.

Kretschmer M, Leroch M, Mosbach A et al. Fungicide-driven evolution and molecular basis of multidrug resistance in field populations of the grey mould fungus Botrytis cinerea. PLoS Pathog 2009. doi:10. 1371/journal. ppat. 1000696.

Kroetz DL, Pauli-Magnus C, Hodges LM et al. Pharmacogenetics of membrane transporters investigators. sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13:481-94.

Król M, Pawłowski KM, Skierski J et al. Transcriptomic “portraits” of canine mammary cancer cell lines with various phenotypes. J Appl Genet 2010; 51:169-83.

Krug M, Voigt B, Baumert C, Lüpken R, Molnár J, Hilgeroth A. First biological evaluation of developed 3-benzyloxyfluorenes as novel class of MDR modulators. Eur J Med Chem 2010; 45:2683-8.

Kruglova IS, Meshchaninova MI, Venyaminova AG, Zenkova MA, Vlasov VV, Chernolovskaia EL. Cholesterol-modified anti-MDR1 small interfering RNA: Uptake and biological activity. Mol Biol 2010; 44:284-93.

Krupoves A, Mack D, Seidman E, Deslandres C, Amre D. Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with crohn’s disease. Inflamm Bowel Dis 2011; 17:2308-17.

Krupoves A, Seidman EG, Mack D et al. Associations between ABCB1/MDR1 gene polymorphisms and Crohn’s disease: a gene-wide study in a pediatric population. Inflamm Bowel Dis 2009; 15:900-8.

Ku TK, Crowe DL. Genomic profiling of decreased DNA damage response in human squamous carcinoma cells. Mol Med Report 2008; 1:105-17.

Kudzi W, Dodoo AN, Mills JJ. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 2010; 11:111.

KuKanich B, Hubin M. The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. J Vet Pharmacol Ther 2010; 33:42-9.

Kuntner C, Bankstahl JP, Bankstahl M et al. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging 2010; 37:942-53.

Kuo TC, Chiang PC, Yu CC et al. A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways. Biochem Pharmacol 2011; 81:1136-44.

Kuroda J, Yamamoto M, Nagoshi H et al. Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res 2010; 8:994-1001.

Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008; 18:861-8.

Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther 2010; 32:2012-23.

Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit 2010; 32:394-404.

Kwak JO, Lee SH, Lee GS et al. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol 2010; 627:92-8.

Kwan P, Baum L, Wong V et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav 2007; 11:112-7.

Kwan P, Li HM, Al-Jufairi E et al. Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol Dis 2010; 39:192-7.

Kwan P, Wong V, Ng PW et al. Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics 2009; 10:723-32.

Kwatra D, Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. Int J Pharm 2010; 395:114-21.

Labbé R, Caveney S, Donly C. Genetic analysis of the xenobiotic resistance-associated ABC gene subfamilies of the Lepidoptera. Insect Mol Biol 2011; 20:243-56.

Lagas JS, Fan L, Wagenaar E et al. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res 2010; 16:130-40.

Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 2010; 9:319-26.

Lage H, Krühn A. Bacterial delivery of RNAi effectors: transkingdom RNAi. J Vis Exp 2010. doi:10. 3791/2099.

Lai Y, Sampson KE, Balogh LM et al. Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther 2010; 334:936-44.

Laika B, Leucht S, Steimer W. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem 2006; 52:893-5.

Lakhan R, Misra UK, Kalita J et al. No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy Behav 2009; 14:78-82.

Lal S, Wong ZW, Sandanaraj E et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008; 99:816-23.

Langaee TY, Gong Y, Yarandi HN et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther 2007; 81:386-91.

Lange JH, van der Neut MA, Borst AJ et al. Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern. Bioorg Med Chem Lett 2010; 20:2770-5.

Langer R, Ott K, Feith M et al. High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol 2010; 102:503-8.

Lanzani C, Citterio L, Glorioso N et al. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies. Sci Transl Med 2010; 2:59ra87.

Läpple F, von Richter O, Fromm MF et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003; 13:565-75.

Lautier D, Lahmy S, Canitrot Y, Vigo J, Viallet P, Salmon JM. Detection of human leukemia cells with multidrug-resistance phenotype using multilabeling with fluorescent dyes. Anticancer Res 1993; 13:1557-63.

Lazo JS, Reese CE, Vogt A et al. Identifying a resistance determinant for the antimitotic natural products disorazole C1 and A1. J Pharmacol Exp Ther 2010; 332:906-11.

Leabman MK, Huang CC, DeYoung J et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA 2003; 100:5896-901.

Lee CH. Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol 2010; 596:325-40.

Lee CK, Choi JS. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Pharmacology 2010; 85:350-6.

Lee CK, Ki SH, Choi JS. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin. Biopharm Drug Dispos 2011; 32:245-51.

Lee CY, Lai TY, Wu YM et al. Gene expression of P-glycoprotein and cytochrome P450 3A4 in peripheral blood mononuclear cells and correlation with expression in liver. Transplant Proc 2010; 42:834-6.

Lee JH, Shin YJ, Kim HJ, Oh JH, Jang YP, Lee YJ. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein-and cytochrome P4503A-mediated herb-drug interactions. Int J Pharm 2011; 410:68-74.

Lee L, Robb LM, Lee M et al. Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4. J Med Chem 2010; 53:325-34.

Lee SY, Luk SK, Chuang CP, Yip SP, To SS, Yung YM. TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy. Br J Cancer 2010; 103:362-9.

Lee SY, Peckermann I, Abinet E, Okuda J, Henze G, Prokop A. The rare-earth yttrium complex [YR(mtbmp)(thf)] triggers apoptosis via the extrinsic pathway and overcomes multiple drug resistance in leukemic cells. Med Oncol 2010. doi:10. 1007/s12032-010-9787-6.

Lee SY, Rhee YH, Jeong SJ et al. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ Toxicol 2011; 26:424-31.

Lee WK, Torchalski B, Kohistani N, Thévenod F. ABCB1 protects kidney proximal tubule cells against cadmium-induced apoptosis: Roles of cadmium and ceramide transport. Toxicol Sci 2011; 121:343-56.

Lee WY, Cheung CC, Liu KW et al. Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells. J Nat Prod 2010; 73:854-9.

Lee YJ, Lee MG, Lim LA, Jang SB, Chung JY. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010; 48:36-45.

Leggas M, Panetta JC, Zhuang Y et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006; 66:4802-7.

Leitner I, Nemeth J, Feurstein T et al. The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. J Antimicrob Chemother 2011; 66:834-9.

Lenhart JA, Ling X, Gandhi R et al. “Clicked” bivalent ligands containing curcumin and cholesterol as multifunctional abeta oligomerization inhibitors: design, synthesis, and biological characterization. J Med Chem 2010; 53:6198-209.

Lerchner A, Machauer R, Betschart C et al. Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett 2010; 20:603-7.

Leskelä S, Jara C, Leandro-García LJ et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 2011; 11:121-9.

Leslie BJ, Holaday CR, Nguyen T, Hergenrother PJ. Phenylcinnamides as novel antimitotic agents. J Med Chem 2010; 53:3964-72.

Leung K. [O-methyl-11C]2-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione. MICAD 2007; 20641432.

Levran O, O’Hara K, Peles E et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008; 17:2219-27.

Li C, Kim M, Choi JS. Effects of prednisolone on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats. Arch Pharm Res 2010; 33:1395-400.

Li C, Lee MY, Choi JS. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats. Pharmazie 2010; 65:510-4.

Li C, Lim SC, Kim J, Choi JS. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Eur J Drug Metab Pharmacokinet 2011; 36:175-82.

Li CM, Narayanan R, Lu Y et al. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5’-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways. Int J Oncol 2010; 37:1023-30.

Li CM, Wang Z, Lu Y et al. Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor. Cancer Res 2011; 71:216-24.

Li D, Abudula A, Abulahake M, Zhu AP, Lou YQ, Zhang GL. Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 beta-hydroxycortisol/cortisol ratio after grapefruit juice intake in healthy Chinese. J Clin Pharmacol 2010; 50:775-84.

Li DW, Gao S, Shen B, Dong P. Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma. Med Oncol 2010. doi:10. 1007/s12032-010-9686-x.

Li GY, Liu JZ, Chen SG, Zhang B, Wang CB, Wang LX. Tegillarca granosa extract Haishengsu inhibits the expression of P-glycoprotein and induces apoptosis in drug-resistant K562/ADM cells. Pharm Biol 2010; 48:529-33.

Li H, Huo M, Zhou J et al. Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. J Pharm Sci 2010; 99:4543-53.

Li J, Cusatis G, Brahmer J et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 2007; 6:432-8.

Li J, Volpe DA, Wang Y et al. Use of transporter knockdown caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 2011; 39:1196-202.

Li L, Shukla S, Lee A et al. The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res 2010; 70:4509-19.

Li L, Wei XH, Pan YP et al. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 2010; 29:5785-95.

Li L, Zhang ZH, Zhao WD. Apoptosis of MR2 cells induced by Tanshinone II A combined with arsenic trioxide. Sichuan Da Xue Xue Bao Yi Xue Ban 2009; 40:812-6.

Li M, Si L, Pan H et al. Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: assessed in vitro by everted gut sac and in situ by improved intestinal perfusion. Int J Pharm 2011; 403:37-45.

Li PY, Lai PS, Hung WC, Syu WJ. Poly(L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells. Biomacromolecules 2010; 11:2576-82.

Li RJ, Zhang GS, Chen YH et al. Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance. Ann Oncol 2010; 21:1506-14.

Li X, Delzer J, Voorman R, de Morais SM, Lao Y. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-Ribose) polymerase. Drug Metab Dispos 2011; 39:1161-9.

Li Y, Wang Q, Yao X, Li Y. Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor-and pregnane X receptor-mediated pathways. Eur J Pharmacol 2010; 640:46-54.

Li Y, Yue H, Xing Y, Sun H, Pan Z, Xie G. Oxymatrine inhibits development of morphine-induced tolerance associated with decreased expression of P-glycoprotein in rats. Integr Cancer Ther 2010; 9:213-8.

Li Z, Hu S, Wang J et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 2010; 119:125-30.

Li ZM, Hu S, Xiao L et al. Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells. Zhonghua Fu Chan Ke Za Zhi 2010; 45:372-5.

Liang G, Tang A, Lin X et al. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int J Oncol 2010; 37:111-23.

Liang R, Xiong H, Wang Z, Chen XQ. Effect of rapamycin on proliferation of acute myeloid leukemia cell lines HL-60 and HL-60/VCR. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010; 18:1464-8.

Liang X, Hao L, Chen X et al. Effects of bone marrow stromal cells and umbilical cord blood-derived stromal cells on daunorubicin-resistant residual Jurkat cells. Transplant Proc 2010; 42:3767-72.

Liao F, Liu M, Lv L, Dong W. Hepatoma-derived growth factor promotes the resistance to anti-tumor effects of nordihydroguaiaretic acid in colorectal cancer cells. Eur J Pharmacol 2010; 645:55-62.

Lifschitz A, Suarez VH, Sallovitz J et al. Cattle nematodes resistant to macrocyclic lactones: comparative effects of P-glycoprotein modulation on the efficacy and disposition kinetics of ivermectin and moxidectin. Exp Parasitol 2010; 125:172-8.

Lim AY, Segarra I, Chakravarthi S, Akram S, Judson JP. Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice. BMC Pharmacol 2010; 10:14.

Lin KM, Chiu YF, Tsai IJ et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 2011; 21:163-70.

Lin SP, Wu PP, Hou YC et al. Different influences on tacrolimus pharmacokinetics by coadministrations of zhi ke and zhi shi in rats. Evid Based Complement Alternat Med 2011. doi:10. 1155/2011/751671.

Ling G, Zhang P, Zhang W et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release 2010; 148:241-8.

Ling X, Zhou Y, Li SW, Yan B, Wen L. Modulation of mitochondrial permeability transition pore affects multidrug resistance in human hepatocellular carcinoma cells. Int J Biol Sci 2010; 6:773-83.

Liu F, Liu S, He S, Xie Z, Zu X, Jiang Y. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells. Oncol Rep 2010; 23:1469-75.

Liu L, Fan L, Peng X, Hu D, Zhou H. MDR1 C2005T polymorphism changes substrate specificity. Cancer Chemother Pharmacol 2010; 66:617-23.

Liu R, Zhang Y, Chen Y et al. A novel calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine overcomes multidrug resistance in drug-resistant MCF-7/ADR breast carcinoma cells. J Pharm Sci 2010; 99:3266-75.

Liu XD, Sun H, Liu GT. 5-Bromotetrandrine enhances the sensitivity of doxorubicin-induced apoptosis in intrinsic resistant human hepatic cancer Bel7402 cells. Cancer Lett 2010; 292:24-31.

Liu YY, Gupta V, Patwardhan GA et al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer 2010; 9:145.

Liu Z, Qiu M, Tang QL, Liu M, Lang N, Bi F. Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines. Chin J Cancer 2010; 29:661-7.

Liu ZH, He YP, Zhou Y, Zhang P, Qin H. Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. Mol Biol Rep 2011; 38:3075-82.

Liu ZH, Ma YL, He YP, Zhang P, Zhou YK, Qin H. Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics. Mol Biol Rep 2011; 38:1769-75.

Lloret Linares C, Hajj A, Poitou C et al. Pilot study examining the frequency of several gene polymorphisms involved in morphine pharmacodynamics and pharmacokinetics in a morbidly obese population. Obes Surg 2011; 21:1257-64.

Loo TW, Bartlett MC, Clarke DM. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol Pharm 2004; 1:426-33.

Loo TW, Bartlett MC, Clarke DM. The W232R suppressor mutation promotes maturation of a truncation mutant lacking both nucleotide-binding domains and restores interdomain assembly and activity of P-glycoprotein processing mutants. Biochemistry 2011; 50:672-85.

Loo TW, Clarke DM. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst 2000; 92:898-902.

López-López E, Martin-Guerrero I, Ballesteros J et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 57:612-9.

López-Montenegro Soria MA, Kanter Berga J, Beltrán Catalán S, Milara Payá J, Pallardó Mateu LM, Jiménez Torres NV. Genetic polymorphisms and individualized tacrolimus dosing. Transplant Proc 2010; 42:3031-3.

Löscher W, Delanty N. MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. Pharmacogenomics 2009; 10:711-3.

Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50:1-23.

Lu PH, Wei MX, Yang J et al. Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat 2011; 125:537-43.

Lu S, Liow JS, Zoghbi SS, Hong J, Innis RB, Pike VW. Evaluation of [C]S14506 and [F]S14506 in rat and monkey as agonist PET radioligands for brain 5-HT(1A) receptors. Curr Radiopharm 2010; 3:9-18.

Luna-Tortós C, Fedrowitz M, Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008; 55:1364-75.

Luo S, Pal D, Shah SJ, Kwatra D, Paturi KD, Mitra AK. Effect of HEPES buffer on the uptake and transport of P-glycoprotein substrates and large neutral amino acids. Mol Pharm 2010; 7:412-20.

Ma J, Lin JY, Alloo A et al. Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun 2010; 402:711-7.

Ma Q, Brazeau D, Zingman BS et al. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 2007; 8:227-35.

MacLean C, Moenning U, Reichel A, Fricker G. Regional absorption of fexofenadine in rat intestine. Eur J Pharm Sci 2010; 41:670-4.

Maggini V, Buda G, Martino A et al. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics 2008; 18:383-9.

Magliulo L, Dahl ML, Lombardi G et al. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol 2011; 67:47-54.

Mahringer A, Karamustafa S, Klotz D et al. Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional Chinese medicine. Cancer Genomics Proteomics 2010; 7:191-205.

Maia RC, Vasconcelos FC, de Sá Bacelar T et al. LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells. Invest New Drugs 2011; 29:1143-55.

Maier P, Spier I, Laufs S et al. Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K). Gene Ther 2010; 17:389-99.

Mairinger S, Erker T, Müller M, Langer O. PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr Drug Metab 2011. doi:10. 2174/1389211214348592002.

Mairinger S, Langer O, Kuntner C et al. Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. Nucl Med Biol 2010; 37:637-44.

Maleki M, Sayyah M, Kamgarpour F et al. Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients. Iran Biomed J 2010; 14:89-96.

Manceau S, Giraud C, Declèves X et al. Lack of P-glycoprotein induction by rifampicin and phenobarbital in human lymphocytes. Int J Pharm 2010; 395:98-103.

Manda VK, Mittapalli RK, Bohn KA, Adkins CE, Lockman PR. Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem 2010; 115:1495-507.

Marathe P, Tang Y, Sleczka B et al. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci 2010; 99:3579-93.

Maráz A, Furák J, Pálföldi R et al. Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. Anticancer Res 2011; 31:1431-6.

Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007; 12:927-41.

Marcin LR, Higgins MA, Zusi FC et al. Synthesis and SAR of indole-and 7-azaindole-1,3-dicarboxamide hydroxyethylamine inhibitors of BACE-1. Bioorg Med Chem Lett 2011; 21:537-41.

Marie JP, Legrand O. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol 1999; 457:1-9.

Marill J, Idres N, Capron CC, Nguyen E, Chabot GG. Retinoic acid metabolism and mechanism of action: a review. Curr Drug Metab 2003; 4:1-10.

Marquez B, van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets 2011; 12:600-20.

Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007; 25:4528-35.

Martelli C, Coronnello M, Dei S et al. Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. J Med Chem 2010; 53:1755-62.

Martelli C, Dei S, Lambert C et al. Inhibition of P-glycoprotein-mediated Multidrug Resistance (MDR) by N,N-bis(cyclohexanol)amine aryl esters: further restriction of molecular flexibility maintains high potency and efficacy. Bioorg Med Chem Lett 2011; 21:106-9.

Martins A, Vasas A, Schelz Z et al. Constituents of Carpobrotus edulis inhibit P-glycoprotein of MDR1-transfected mouse lymphoma cells. Anticancer Res 2010; 30:829-35.

Martirosyan A, Clendening JW, Goard CA, Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 2010; 10:103.

Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.

Mas S, Gassò P, Álvarez S, Parellada E, Bernardo M, Lafuente A. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J 2010. doi:10. 1038/tpj. 2010. 91.

Mason BL, Pariante CM, Jamel S, Thomas SA. Central nervous system (CNS) delivery of glucocorticoids is fine-tuned by saturable transporters at the blood-CNS barriers and nonbarrier regions. Endocrinology 2010; 151:5294-305.

Mason BL, Thomas SA, Lightman SL, Pariante CM. Desipramine treatment has minimal effects on the brain accumulation of glucocorticoids in P-gp-deficient and wild-type mice. Psychoneuroendocrinology 2011; 36:1351-60.

Mason CW, Hassan HE, Kim KP et al. Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl-and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. J Pharmacol Exp Ther 2010; 333:854-64.

Masuda M, Tanaka S, Nakajima K et al. Clinical implications of the type 1/type 2 balance of helper T cells and P-glycoprotein function in peripheral T lymphocytes of myasthenia gravis patients. Eur J Pharmacol 2010; 627:325-31.

Matthes H, Friedel WE, Bock PR, Zänker KS. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med 2010; 10:430-9.

Mayur YC, Zaheeruddin, Peters GJ, Lemos C, Kathmann I, Prasad VV. Synthesis of 2-fluoro N(10)-substituted acridones and their cytotoxicity studies in sensitive and resistant cancer cell lines and their DNA intercalation studies. Arch Pharm 2009; 342:640-50.

McCracken JT, Aman MG, McDougle CJ et al. Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. J Child Adolesc Psychopharmacol 2010; 20:1-5.

Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001; 11:727-33.

Mealey KL, Waiting D, Raunig DL, Schmidt KR, Nelson FR. Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs. J Vet Pharmacol Ther 2010; 33:453-60.

Mega JL, Close SL, Wiviott SD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376:1312-9.

Megaraj V, Iida T, Jungsuwadee P, Hofmann AF, Vore M. Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters. Drug Metab Dispos 2010; 38:1723-30.

Mellor HR, Callaghan R. Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein. Cancer Chemother Pharmacol 2011. doi:10. 1007/s00280-011-1598-8.

Mendoza JL, Urcelay E, Lana R et al. MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn’s disease. Inflamm Bowel Dis 2007; 13:585-90.

Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y. Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav 2011; 21:27-30.

Meng H, Liong M, Xia T et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010; 4:4539-50.

Menu P, Gressier F, Verstuyft C, Hardy P, Becquemont L, Corruble E. Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study. Neuropsychobiology 2010; 62:193-7.

Mercado-Lubo R, McCormick BA. The interaction of gut microbes with host ABC transporters. Gut Microbes 2010; 1:301-6.

Mercer SL, Coop A. Opioid analgesics and P-glycoprotein efflux transporters: A potential systems-level contribution to analgesic tolerance. Curr Top Med Chem 2011; 11:1157-64.

Merk J, Rolff J, Dorn C, Leschber G, Fichtner I. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur J Cardiothorac Surg 2011; 40:29-33.

Mi YJ, Liang YJ, Huang HB et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 2010; 70:7981-91.

Michaud M, Barakat S, Magnard S, Rigal D, Baggetto LG. Leucine-rich protein 130 contributes to apoptosis resistance of human hepatocarcinoma cells. Int J Oncol 2011; 38:169-78.

Michelon H, König J, Durrbach A et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 2010; 11:1703-13.

Milane A, Fernandez C, Dupuis L et al. P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. Neurosci Lett 2010; 472:166-70.

Milanowski B, Lulek J, Lehmler HJ, Kania-Korwel I. Assessment of the disposition of chiral polychlorinated biphenyls in female mdr 1a/b knockout versus wild-type mice using multivariate analyses. Environ Int 2010; 36:884-92.

Min SI, Kim SY, Ahn SH et al. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation 2010; 90:1394-400.

Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther 2010; 9:33-45.

Mitra P, Audus K, Williams G, Yazdanian M, Galinis D. A comprehensive study demonstrating that p-glycoprotein function is directly affected by changes in pH: Implications for intestinal pH and effects on drug absorption. J Pharm Sci 2011. doi:10. 1002/jps. 22596.

Mitsuhashi J, Hosoyama H, Tsukahara S et al. In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med 2010; 12:596-603.

Miura M, Motoyama S, Hinai Y et al. Influence of CYP2C19 and ABCB1 polymorphisms on plasma concentrations of lansoprazole enantiomers after enteral administration. Xenobiotica 2010; 40:630-6.

Miura M, Satoh S, Inoue K et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 2008; 30:46-51.

Miura M, Satoh S, Tada H et al. Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. Int J Clin Pharmacol Ther 2006; 44:605-13.

Miura M, Uno T. Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol 2010; 6:69-74.

Mizutani T. Toxicity of xanthene food dyes by inhibition of human drug-metabolizing enzymes in a noncompetitive manner. J Environ Public Health 2009. doi:10. 1155/2009/953952.

Mlejnek P, Dolezel P, Faber E, Kosztyu P. Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells. Ann Hematol 2011; 90:837-42.

Mlejnek P, Dolezel P. Induction of apoptosis by A3 adenosine receptor agonist N-(3-iodobenzyl)-adenosine-5’-N-methylcarboxamide in human leukaemia cells: a possible involvement of intracellular mechanism. Acta Physiol 2010; 199:171-9.

Mlejnek P, Dolezel P, Kosztyu P. P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N(6)-(3-iodobenzyl)-adenosine-5’-N-methyluronamide in human leukemia cells. J Cell Physiol 2011. doi:10. 1002/jcp. 22775.

Mo R, Jin X, Li N et al. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles. Biomaterials 2011; 32:4609-20.

Mo R, Xiao Y, Sun M, Zhang C, Ping Q. Enhancing effect of N-octyl-O-sulfate chitosan on etoposide absorption. Int J Pharm 2011; 409:38-45.

Mo SM, Oh IJ. Release of adriamycin from poly(lactide-co-glycolide)-polyethylene glycol nanoparticles. J Nanosci Nanotechnol 2011; 11:1795-8.

Moerman L, Wyffels L, Slaets D, Raedt R, Boon P, de Vos F. Antiepileptic drugs modulate P-glycoproteins in the brain: A mice study with (11)C-desmethylloperamide. Epilepsy Res 2011; 94:18-25.

Moitra K, Scally M, McGee K, Lancaster G, Gold B, Dean M. Molecular evolutionary analysis of ABCB5: the ancestral gene is a full transporter with potentially deleterious single nucleotide polymorphisms. PLoS One 2011. doi:10. 1371/journal. pone. 0016318.

Mollazadeh S, Matin MM, Iranshahi M, Bahrami AR, Neshati V, Behnam-Rassouli F. The enhancement of vincristine cytotoxicity by combination with feselol. J Asian Nat Prod Res 2010; 12:569-75.

Molnár J, Engi H, Hohmann J et al. Reversal of multidrug resitance by natural substances from plants. Curr Top Med Chem 2010; 10:1757-68.

Momper JD, Venkataramanan R, Nolin TD. Nonrenal drug clearance in CKD: Searching for the path less traveled. Adv Chronic Kidney Dis 2010; 17:384-91.

Montiel V, Huberlant V, Vincent MF, Bonbled F, Hantson P. Multiple organ failure after an overdose of less than 0. 4 mg/kg of colchicine: role of coingestants and drugs during intensive care management. Clin Toxicol 2010; 48:845-8.

Morais C, Gobe G, Johnson DW, Healy H. Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. Apoptosis 2010; 15:412-25.

Moreau A, Le Vee M, Jouan E, Parmentier Y, Fardel O. Drug transporter expression in human macrophages. Fundam Clin Pharmacol 2011; 25:743-52.

Morita N, Yasumori T, Nakayama K. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 2003; 65:1843-52.

Morjani H, Madoulet C. Immunosuppressors as multidrug resistance reversal agents. Methods Mol Biol 2010; 596:433-46.

Mosaffa F, Kalalinia F, Parhiz BH, Behravan J. Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2-overexpressing resistant breast cancer cells compared with their drug-sensitive parental line. DNA Cell Biol 2011; 30:413-8.

Moss DM, Kwan WS, Liptrott NJ et al. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2011; 55:879-87.

Mosyagin I, Runge U, Schroeder HW et al. Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia 2008; 49:1555-61.

Mounsey KE, Pasay CJ, Arlian LG et al. Increased transcription of Glutathione S-transferases in acaricide exposed scabies mites. Parasit Vectors 2010; 3:43.

Mruk DD, Su L, Cheng CY. Emerging role for drug transporters at the blood-testis barrier. Trends Pharmacol Sci 2011; 32:99-106.

Muggerud AA, Rønneberg JA, Wärnberg F et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res 2010; 12:3.

Mukonzo JK, Röshammar D, Waako P et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 2009; 68:690-9.

Mukonzo JK, Waako P, Ogwal-Okeng J, Gustafsson LL, Aklillu E. Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans. Ther Drug Monit 2010; 32:346-52.

Munić V, Kelnerić Z, Mikac L, Eraković Haber V. Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci 2010; 41:86-95.

Muñoz-Martínez F, Lu P, Cortés-Selva F et al. Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance. Cancer Res 2004; 64:7130-8.

Murakami T, Yokooji T, Mori N. Study on absorption sites of quinidine and methotrexate in rat intestine. Pharmazie 2010; 65:440-7.

Musuamba FT, Mourad M, Haufroid V, Delattre IK, Verbeeck RK, Wallemacq P. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. Ther Drug Monit 2009; 31:734-42.

Myllynen P, Kummu M, Sieppi E. ABCB1 and ABCG2 expression in the placenta and fetus: an interspecies comparison. Expert Opin Drug Metab Toxicol 2010; 6:1385-98.

Nabekura T, Yamaki T, Hiroi T, Ueno K, Kitagawa S. Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals. Pharmacol Res 2010; 61:259-63.

Nabekura T, Yamaki T, Ueno K, Kitagawa S. Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem Biophys Res Commun 2008; 369:363-8.

Nait Chabane M, Al Ahmad A, Peluso J, Muller CD, Ubeaud G. Quercetin and naringenin transport across human intestinal Caco-2 cells. J Pharm Pharmacol 2009; 61:1473-83.

Naito T, Takashina Y, Yamamoto K et al. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. J Clin Pharmacol 2011; 51:1529-38.

Najar IA, Sharma SC, Singh GD, Koul S, Gupta PN, Javed S, Johri RK. Involvement of P-glycoprotein and CYP 3A4 in the enhancement of etoposide bioavailability by a piperine analogue. Chem Biol Interact 2011; 190:84-90.

Nakagawa-Goto K, Chang PC, Lai CY et al. Antitumor agents. 280. Multidrug resistance-selective desmosdumotin B analogues. J Med Chem 2010; 53:6699-705.

Nakagawa-Goto K, Wu PC, Lai CY et al. Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents. J Med Chem 2011; 54:1244-55.

Nakamura T, Okamura N, Yagi M et al. Effects of ABCB1 3435C>T genotype on serum levels of cortisol and aldosterone in women with normal menstrual cycles. Genet Mol Res 2009; 8:397-403.

Nakatsuma A, Fukami T, Suzuki T, Furuishi T, Tomono K, Hidaka S. Effects of kaempferol on the mechanisms of drug resistance in the human glioblastoma cell line T98G. Pharmazie 2010; 65:379-83.

Nannelli A, Rossignolo F, Tolando R et al. Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem 2010; 337:133-43.

Napper JM, Sollars VE. 17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells. Leuk Res 2010; 34:1493-500.

Narayan S, Carlson EM, Cheng H et al. Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility. Bioorg Med Chem Lett 2011; 21:1630-3.

Nare B, Wring S, Bacchi C et al. Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis. Antimicrob Agents Chemother 2010; 54:4379-88.

Narumiya K, Metzger R, Bollschweiler E et al. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics 2011; 12:205-14.

Nathwani SM, Butler S, Fayne D et al. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer Chemother Pharmacol 2010; 66:585-96.

Nawa A, Fujita Hamabe W, Tokuyama S. Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions. Life Sci 2010; 86:402-9.

Nawa A, Fujita-Hamabe W, Nakamoto K, Tokuyama S. Nitric oxide synthase-mediated alteration of intestinal P-glycoprotein under hyperglycemic stress. Yakugaku Zasshi 2011; 131:487-92.

Nawa A, Fujita-Hamabe W, Tokuyama S. Regulatory action of nitric oxide synthase on ileal P-glycoprotein expression under streptozotocin-induced diabetic condition. Biol Pharm Bull 2011; 34:436-8.

Nazari ZE, Iranshahi M. Biologically active sesquiterpene coumarins from Ferula species. Phytother Res 2011; 25:315-23.

Neff MW, Robertson KR, Wong AK et al. Breed distribution and history of canine mdr1-1-delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Nat Acad Sci USA 2004; 101:11725-30.

Neuvonen AM, Palo JU, Sajantila A. Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users. Int J Legal Med 2011; 125:265-9.

Ngaimisi E, Mugusi S, Minzi OM et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010; 88:676-84.

Ni LN, Li JY, Miao KR et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 2011; 28:265-9.

Ni Z, Mao Q. ATP-binding cassette efflux transporters in human placenta. Curr Pharm Biotechnol 2011; 12:674-85.

Nichols AI, Tourian KA, Tse SY, Paul J. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol 2010; 6:1565-74.

Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42:819-50.

Niemi M, Backman JT, Kajosaari LI et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005; 77:468-78.

Nievergelt A, Huonker P, Schoop R, Altmann KH, Gertsch J. Identification of serotonin 5-HT1A receptor partial agonists in ginger. Bioorg Med Chem 2010; 18:3345-51.

Nikisch G, Baumann P, Oneda B et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol 2011; 25:896-907.

Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 2008; 58:344-7.

Nishanth RP, Ramakrishna BS, Jyotsna RG et al. C-Phycocyanin inhibits MDR1 through reactive oxygen species and cyclooxygenase-2 mediated pathways in human hepatocellular carcinoma cell line. Eur J Pharmacol 2010; 649:74-83.

Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci 2009; 100:1701-7.

Nurmohamed L, Garcia-Bournissen F, Buono RJ, Shannon MW, Finkelstein Y. Predisposition to epilepsy-does the ABCB1 gene play a role? Epilepsia 2010; 51:1882-5.

Obermeier M, Yao M, Khanna A et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010; 38:405-14.

O’Brien MM, Lacayo NJ, Lum BL et al. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2010; 54:694-702.

Oh JH, Dong MS, Choi MG et al. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin. J Gastroenterol Hepatol 2009; 24:294-8.

Oh WK, Cho KB, Hien TT et al. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol Pharmacol 2010; 78:855-64.

Ohnuma S, Chufán EE, Nandigama K et al. Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5’-Fluorosulfonylbenzoyl 5’-Adenosine: Evidence for an ATP analog that interacts with both drug-substrate-and nucleotide-binding sites. Biochemistry 2011; 50:3724-35.

Okegawa T, Nutahara K, Higashihara E. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol 2010; 17:466-75.

Okura T, Ibe M, Umegaki K, Shinozuka K, Yamada S. Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull 2010; 33:255-9.

Oselin K, Gerloff T, Mrozikiewicz PM, Pähkla R, Roots I. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol 2003; 17:463-9.

Osswald E, Johne A, Laschinski G et al. Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol 2007; 63:9-16.

Oswald S, Giessmann T, Luetjohann D et al. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther 2006; 80:477-85.

Oswald S, Haenisch S, Fricke C et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 2006; 79:206-17.

Oswald S, May K, Rosin J, Lütjohann D, Siegmund W. Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats. J Pharm Sci 2010; 99:422-9.

Oswald S, Nassif A, Modess C et al. Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther 2010; 87:663-7.

Oswald S, Nassif A, Modess C et al. Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther 2011; 89:524-8.

Oswald S, Terhaag B, Siegmund W. In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans. Handb Exp Pharmacol 2011:403-47.

Otová B, Ojima I, Václavíková R et al. Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes. Invest New Drugs 2011. doi:10. 1007/s10637-011-9654-0.

Ott M, Huls M, Cornelius MG, Fricker G. St. John’s Wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier. Pharm Res 2010; 27:811-22.

Padowski JM, Pollack GM. Examination of the ability of the nasal administration route to confer a brain exposure advantage for three chemical inhibitors of P-glycoprotein. J Pharm Sci 2010; 99:3226-33.

Paik D, Cocco E, Bellone S et al. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecol Oncol 2010; 119:140-5.

Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006; 78:2131-45.

Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 2011; 5:117-24.

Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002; 43:1221-8.

Palner M, McCormick P, Gillings N, Begtrup M, Wilson AA, Knudsen GM. Radiosynthesis and ex vivo evaluation of (R)-(-)-2-chloro-N-[1-11C-propyl]n-propylnorapomorphine. Nucl Med Biol 2010; 37:35-40.

Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 2008; 75:380-5.

Panczyk M, Balcerczak E, Piaskowski S, Jamroziak K, Pasz-Walczak G, Mirowski M. ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. Int J Colorectal Dis 2009; 24:895-905.

Pander J, Guchelaar HJ, Gelderblom H. Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet. Curr Opin Mol Ther 2010; 12:654-61.

Parasrampuria R, Mehvar R. Divergent effects of nitric oxide donors on the biliary efflux transporters in isolated perfused rat livers: nitric oxide-independent inhibition of ABC transporters by sodium nitroprusside. Drug Metab Lett 2011; 5:64-72.

Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 2007; 81:539-46.

Park JR, Kim RJ, Lee YK et al. Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells. J Hepatol 2011; 54:122-31.

Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 2010; 177:1087-94.

Park SJ, Bijangi-Vishehsaraei K, Safa AR. Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells. Int J Biochem Mol Biol 2010; 1:90-100.

Park WB, Choe PG, Song KH et al. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clin Infect Dis 2010; 51:101-6.

Parker RB, Yates CR, Laizure SC, Weber KT. P-glycoprotein modulates aldosterone plasma disposition and tissue uptake. J Cardiovasc Pharmacol 2006; 47:55-9.

Parkman HP, Jacobs MR, Mishra A et al. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci 2011; 56:115-24.

Parveen Z, Stockner T, Bentele C et al. Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein. Mol Pharmacol 2011; 79:443-52.

Pasquier J, Magal P, Boulangé-Lecomte C, Webb G, Le Foll F. Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population dynamics model. Biol Direct 2011; 6:5.

Pathak SM, Musmade P, Dengle S, Karthik A, Bhat K, Udupa N. Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation. Eur J Pharm Sci 2010; 41:440-51.

Pathak SM, Udupa N. Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin. Biopharm Drug Dispos 2010; 31:202-14.

Patutina OA, Mironova NL, Popova NA et al. The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer 2010; 10:204.

Paule B, Castagne V, Picard V et al. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med Oncol 2010; 27:1066-72.

Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004; 21:904-13.

Pekcec A, Schneider EL, Baumgärtner W, Stein VM, Tipold A, Potschka H. Age-dependent decline of blood-brain barrier P-glycoprotein expression in the canine brain. Neurobiol Aging 2011; 32:1477-85.

Penzak SR, Robertson SM, Hunt JD et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010; 30:797-805.

Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 2010; 67:1110-3.

Perroud N, Bondolfi G, Uher R et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 2011; 12:365-77.

Peters BJ, Rodin AS, Klungel OH et al. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics 2010; 11:1065-76.

Peters EJ, Slager SL, Kraft JB et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 2008. doi:10. 1371/journal. pone. 0001872.

Pétriz J, García-López J. Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia 1997; 11:1124-30.

Petropoulos S, Gibb W, Matthews SG. Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation. Brain Res 2010; 1357:9-18.

Petropoulos S, Gibb W, Matthews SG. Effect of glucocorticoids on regulation of placental multidrug resistance phosphoglycoprotein (P-gp) in the mouse. Placenta 2010; 31:803-10.

Petrovic V, Piquette-Miller M. Impact of polyinosinic/polycytidylic acid on placental and hepatobiliary drug transporters in pregnant rats. Drug Metab Dispos 2010; 38:1760-6.

Pichika R, Jewett DM, Sherman PS et al. Synthesis and in vivo brain distribution of carbon-11-labeled Δ-opioid receptor agonists. Nucl Med Biol 2010; 37:989-96.

Pierce DA, Reeves-Daniel AM. Ranolazine-tacrolimus interaction. Ann Pharmacother 2010; 44:1844-9.

Pillot GA, Read WL, Hennenfent KL et al. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol 2006; 1:972-8.

Pitchakarn P, Ohnuma S, Pintha K, Pompimon W, Ambudkar SV, Limtrakul P. Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance. J Nutr Biochem 2011; doi:10. 1016/j. jnutbio. 2010. 11. 005.

Pituch-Noworolska A, Zaremba M, Wieczorek A. Expression of proteins associated with therapy resistance in rhabdomyosarcoma and neuroblastoma tumour cells. Pol J Pathol 2009; 60:168-73.

Plasschaert SL, Groninger E, Boezen M et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 2004; 76:220-9.

Poduri A, Khullar M, Bahl A, Sehrawat BS, Sharma Y, Talwar KK. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol 2010; 29:629-37.

Pokharel YR, Kim ND, Han HK, Oh WK, Kang KW. Increased ubiquitination of multidrug resistance 1 by ginsenoside Rd. Nutr Cancer 2010; 62:252-9.

Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab Dispos 2011; 39:729-35.

Poller B, Wagenaar E, Tang SC, Schinkel AH. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast vancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm 2011; 8:571-82.

Potocnik U, Glavac D, Dean M. Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet Cytogenet 2008; 183:28-34.

Prenkert M, Uggla B, Tidefelt U, Strid H. CRIM1 is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia HL60 cells. Anticancer Res 2010; 30:4157-61.

Prenkert M, Uggla B, Tina E, Tidefelt U, Strid H. Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells. Anticancer Res 2009; 29:4071-6.

Probst GD, Bowers S, Sealy JM et al. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region. Bioorg Med Chem Lett 2010; 20:6034-9.

Qi SN, Song LJ, Chen Y, Jing YX. Reversal of mdr1-mediated multidrug resistance in human leukemia cells by a new spin-labeled derivative of podophyllotoxin. Pharmazie 2010; 65:117-21.

Qian W, Homma M, Itagaki F et al. MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biol Pharm Bull 2006; 29:2446-50.

Qiang F, Lee BJ, Ha I, Kang KW, Woo ER, Han HK. Effect of maceligan on the systemic exposure of paclitaxel: in vitro and in vivo evaluation. Eur J Pharm Sci 2010; 41:226-31.

Qin Q, Chen XP, Yang ZS, Xiao YH, Min H, Li YJ. Neferine increases STI571 chemosensitivity via inhibition of P-gp expression in STI571-resistant K562 cells. Leuk Lymphoma 2011; 52:694-700.

Qin XL, Bi HC, Wang XD et al. Mechanistic understanding of the different effects of Wuzhi tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). Int J Pharm 2010; 389:114-21.

Qiu L, Zhang L, Zheng C, Wang R. Improving physicochemical properties and doxorubicin cytotoxicity of novel polymeric micelles by poly(ε-caprolactone) segments. J Pharm Sci 2011; 100:2430-42.

Queiroz KC, Ruela-de-Sousa RR, Fuhler GM et al. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 2010; 29:6314-22.

Quiney C, Billard C, Faussat AM, Salanoubat C, Kolb JP. Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells. Leuk Lymphoma 2007; 48:1587-99.

Raizer J. Issues in developing drugs for primary brain tumors: barriers and toxicities. Toxicol Pathol 2011; 39:152-7.

Rajnai Z, Méhn D, Beéry E et al. ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos 2010; 38:2000-6.

Raju R, Piggott AM, Huang XC, Capon RJ. Nocardioazines: A novel bridged diketopiperazine scaffold from a marine-derived bacterium inhibits P-glycoprotein. Org Lett 2011; 13:2770-3.

Ranganathan P, Culverhouse R, Marsh S et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008; 35:572-9.

Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010; 31:11-9.

Rao AV, Valk PJ, Metzeler KH et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:5580-6.

Rao DN, Anuradha C, Vishnupriya S et al. Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pac J Cancer Prev 2010; 11:1063-6.

Rebello S, Leon S, Hariry S, Dahlke M, Jarugula V. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants. J Clin Pharmacol 2011; 51:218-28.

Reed K, Hembruff SL, Sprowl JA, Parissenti AM. The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance. Pharmacogenomics J 2010; 10:489-504.

Reichel V, Burghard S, John I, Huber O. P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res 2011; 1370:238-45.

Reitman ML, Chu X, Cai X et al. Rifampin’s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 2011; 89:234-42.

Ren Q, Liang YJ, He H, Fu L, Gu Y. A facile synthesis and biological activity of novel tetrahydrobenzo[4’,5’]thieno[3’,2’:5,6]pyrido[4,3-d]pyrimidin-4(3H)-ones. Bioorg Med Chem Lett 2009; 19:6713-6.

Ribaudo HJ, Liu H, Schwab M et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis 2010; 202:717-22.

Riccioni R, Dupuis ML, Bernabei M et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 2010; 45:86-92.

Rigalli JP, Ruiz ML, Perdomo VG, Villanueva SS, Mottino AD, Catania VA. Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells. Toxicology 2011; 285:18-24.

Riganti C, Voena C, Kopecka J et al. Liposome-encapsulated doxorubicin reverses drug-resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 2011; 8:683-700.

Rijavec M, Silar M, Triller N et al. Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients. Pathol Oncol Res 2011; 17:691-6.

Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985; 316:817-9.

Risinger AL, Westbrook CD, Encinas A et al. ELR510444, a novel microtubule disruptor with multiple mechanisms of action. J Pharmacol Exp Ther 2011; 336:652-60.

Ritchie MD, Haas DW, Motsinger AA et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 2006; 43:779-82.

Rivera E. Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options. Breast J 2010; 16:252-63.

Rizzo R, Spaggiari F, Indelli M et al. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 2010; 124:593-8.

Rizzo S, Hersey JM, Mellor P et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 2011; 10:325-35.

Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2:191-6.

Robey RW, Ierano C, Zhan Z, Bates SE. The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol 2011; 12:595-608.

Rocha GD, Simões M, Oliveira RR, Kaplan MA, Gattass CR. 3beta-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression. Invest New Drugs 2010. doi:10. 1007/s10637-010-9524-1.

Rollema H, Shrikhande A, Ward KM et al. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol 2010; 160:334-45.

Ronaldson PT, Ashraf T, Bendayan R. Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways. Mol Pharmacol 2010; 77:644-59.

Rong G, Jing L, Deng-Qing L, Hong-Shan Z, Shai-Hong Z, Xin-Min N. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Transplant Proc 2010; 42:3455-8.

Ross JR, Riley J, Taegetmeyer AB et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 2008; 112:1390-403.

Rothweiler F, Michaelis M, Brauer P et al. Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia 2010; 12:1023-30.

Roumier C, Cheok MH. Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics 2009; 10:1839-51.

Rowe A, Narlawar R, Groundwater PW, Ramzan I. Kavalactone pharmacophores for major cellular drug targets. Mini Rev Med Chem 2011; 11:79-83.

Roy U, Chakravarty G, Honer Zu Bentrup K, Mondal D. Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. Biol Pharm Bull 2009; 32:2002-9.

Rubis B, Polrolniczak A, Knula H, Potapinska O, Kaczmarek M, Rybczynska M. Phytosterols in physiological concentrations target multidrug resistant cancer cells. Med Chem 2010; 6:184-90.

Rudolph A, Sainz J, Hein R et al. Modification of menopausal hormone therapy associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes. Endocr Relat Cancer 2011; 18:371-84.

Ruike Z, Junhua C, Wenxing P. In vitro and in vivo evaluation of the effects of duloxetine on P-gp function. Hum Psychopharmacol 2010; 25:553-9.

Rzuczek SG, Pilch DS, Liu A, Liu L, LaVoie EJ, Rice JE. Macrocyclic pyridyl polyoxazoles: selective RNA and DNA G-quadruplex ligands as antitumor agents. J Med Chem 2010; 53:3632-44.

Sabahi Z, Salek R, Heravi RE, Mosaffa F, Avanaki ZJ, Behravan J. Association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population. Indian J Cancer 2010; 47:317-21.

Saeki M, Kurose K, Hasegawa R, Tohkin M. Functional analysis of genetic variations in the 5’-flanking region of the human MDR1 gene. Mol Genet Metab 2011; 102:91-8.

Saeki M, Kurose K, Tohkin M, Hasegawa R. Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem Pharmacol 2008; 76:531-42.

Safa AR, Stern RK, Choi K et al. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly185-to-Val185 substitution in P-glycoprotein. Proc Nat Acad Sci USA 1990; 87:7225-9.

Sainz J, Rudolph A, Hein R et al. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer 2011; 18:265-76.

Saito S, Kato J, Hiraoka S et al. DNA methylation of colon mucosa in ulcerative colitis patients: Correlation with inflammatory status. Inflamm Bowel Dis 2011; 17:1955-65.

Saitoh A, Capparelli E, Aweeka F et al. CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 54:285-9.

Sakaeda T, Iwaki K, Kakumoto M et al. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 2005; 57:759-64.

Sakata S, Fujiwara M, Ohtsuka K et al. ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells. Oncol Rep 2011; 25:333-9.

Saksena S, Goyal S, Raheja G et al. Upregulation of P-glycoprotein by probiotics in intestinal epithelial cells and in the dextran sulfate sodium model of colitis in mice. Am J Physiol Gastrointest Liver Physiol 2011; 300:1115-23.

Sakurai A, Onishi Y, Hirano H et al. Quantitative structure-activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry 2007; 46:7678-93.

Sakurai K, Enomoto K, Amano S. The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer. Gan To Kagaku Ryoho 2010; 37:2246-8.

Salomon JJ, Ehrhardt C. Nanoparticles attenuate P-glycoprotein/MDR1 function in A549 human alveolar epithelial cells. Eur J Pharm Biopharm 2011; 77:392-7.

Salphati L, Lee LB, Pang J, Plise EG, Zhang X. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 2010; 38:1422-6.

Salvatore CA, Moore EL, Calamari A et al. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther 2010; 333:152-60.

Sam SS, Thomas V, Reddy KS, Surianarayanan G, Chandrasekaran A. Gene-gene interactions of drug metabolizing enzymes and transporter protein in the risk of upper aerodigestive tract cancers among Indians. Cancer Epidemiol 2010; 34:626-33.

Sánchez MB, Herranz JL, Leno C et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 2010; 19:93-101.

Santos PC, Soares RA, Santos DB et al. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet 2011; 12:13.

Saraeva RB, Paskaleva ID, Doncheva E, Eap CB, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J Clin Pharm Ther 2007; 32:641-9.

Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM Jr. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 2010; 20:467-75.

Saricaoglu H, Yilmaz M, Karkucak M et al. Investigation of ABCB1 gene polymorphism with colchicine response in Behçet’s disease. Genet Mol Res 2011; 10:1-6.

Satoh T, Watanabe Y, Ikarashi N, Ito K, Sugiyama K. Effects of Kampo medicines on P-glycoprotein. Biol Pharm Bull 2009; 32:2018-21.

Sauerborn Klobucar R, Zaja R, Franjević D, Brozović A, Smital T. Presence of ecotoxicologically relevant Pgp and MRP transcripts and proteins in Cyprinid fish. Arh Hig Rada Toksikol 2010; 61:175-82.

Sawant AD, Miller EL, Duignan DB et al. Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools. Xenobiotica 2010; 40:476-84.

Schaefer M, Roots I, Gerloff T. In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet Genomics 2006; 16:855-61.

Schaeffeler E, Eichelbaum M, Brinkmann U et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358:383-4.

Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010; 49:573-88.

Scheidweiler KB, Ladenheim B, Cadet JL, Huestis MA. Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatum. Neurotox Res 2010; 18:200-9.

Schinkel AH, Mayer U, Wagenaar E et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Nat Acad Sci USA 1997; 94:4028-33.

Schipani A, Siccardi M, D’Avolio A et al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 2010; 54:5242-50.

Schlichtiger J, Pekcec A, Bartmann H et al. Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br J Pharmacol 2010; 160:1062-71.

Schmitt U, Lee DE, Herth MM et al. P-glycoprotein influence on the brain uptake of a 5-HT(2A) ligand: [(18)F]MH. MZ. Neuropsychobiology 2011; 63:183-90.

Schnabel C, Sterz K, Müller H, Rehbein J, Wiese M, Hiersemann M. Total synthesis of natural and non-natural Δ(5,6)Δ(12,13)-jatrophane diterpenes and their evaluation as MDR modulators. J Org Chem 2011; 76:512-22.

Scott SA, Martis S, Peter I, Kasai Y, Kornreich R, Desnick RJ. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J 2011. doi:10. 1038/tpj. 2011. 5.

Seden K, Dickinson L, Khoo S, Back D. Grapefruit-drug interactions. Drugs 2010; 70:2373-407.

Seedhouse CH, Grundy M, White P et al. Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin Cancer Res 2007; 13:7059-66.

Seeland S, Treiber A, Hafner M, Huwyler J. On-line identification of P-glycoprotein substrates by monitoring of extracellular acidification and respiration rates in living cells. Biochim Biophys Acta 2011; 1808:1827-31.

Seneca N, Zoghbi SS, Shetty HU et al. Effects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice. Nucl Med Biol 2010; 37:335-45.

Sengupta S, Mantha AK, Mitra S, Bhakat KK. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene 2011; 30:482-93.

Seo SB, Hur JG, Kim MJ et al. TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases. Mol Cancer 2010; 9:199.

Seo T, Ishitsu T, Ueda N et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 2006; 7:551-61.

Sereš M, Ditte P, Breier A, Sulová Z. Effect of thapsigargin on P-glycoprotein-negative and P-glycoprotein-positive L1210 mouse leukaemia cells. Gen Physiol Biophys 2010; 29:396-401.

Serova M, Astorgues-Xerri L, Bieche I et al. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther 2010; 9:1308-17.

Sertel S, Fu Y, Zu Y et al. Molecular docking and pharmacogenomics of Vinca alkaloids and their monomeric precursors, vindoline and catharanthine. Biochem Pharmacol 2011; 81:723-35.

Shao K, Huang R, Li J et al. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release 2010; 147:118-26.

Sharma G, Mirza S, Parshad R et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem 2010; 43:373-9.

Sharma S, Das M, Kumar A et al. Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics 2008; 18:1041-9.

Shchekotikhin AE, Glazunova VA, Dezhenkova LG et al. The first series of 4,11-bis[(2-aminoethyl)amino]anthra[2,3-b]furan-5,10-diones: Synthesis and anti-proliferative characteristics. Eur J Med Chem 2011; 46:423-8.

Shen C, Bai Y, Wang S et al. Expression profile of PIN, AUX/LAX and PGP auxin transporter gene families in Sorghum bicolor under phytohormone and abiotic stress. FEBS J 2010; 277:2954-69.

Shen H, Lee FY, Gan J. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 2011; 337:423-32.

Shen H, Xu W, Chen Q, Wu Z, Tang H, Wang F. Tetrandrine prevents acquired drug resistance of K562 cells through inhibition of mdr1 gene transcription. J Cancer Res Clin Oncol 2010; 136:659-65.

Shen H, Xu W, Luo W et al. Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. Exp Hematol 2011; 39:558-69.

Shen L, Ahmad S, Park S et al. In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos 2010; 38:1471-9.

Sheng L, Tan W, Hu JP, Chen H, Li Y. Effect of CYP3A and P-glycoprotein on the absorption of buagafuran in rat intestinal lumen. Yao Xue Xue Bao 2010; 45:43-8.

Sherman JG, Paul AJ, Firkins LD. Evaluation of the safety of spinosad and milbemycin 5-oxime orally administered to Collies with the MDR1 gene mutation. Am J Vet Res 2010; 71:115-9.

Sheu MT, Liou YB, Kao YH, Lin YK, Ho HO. A quantitative structure-activity relationship for the modulation effects of flavonoids on p-glycoprotein-mediated transport. Chem Pharm Bull 2010; 58:1187-94.

Shi CJ, Wang F, Ren MF et al. Up-regulation of ABCB1/P-glycoprotein by escaping promoter hypermethylation indicates poor prognosis in hematologic malignancy patients with and without bone marrow transplantation. Leuk Res 2011; 35:73-9.

Shi Z, Peng XX, Kim IW et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007; 67:11012-20.

Shi Z, Tiwari AK, Shukla S et al. Sildenafil reverses ABCB1-and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 2011; 71:3029-41.

Shieh MJ, Hsu CY, Huang LY, Chen HY, Huang FH, Lai PS. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J Control Release 2011; 152:418-25.

Shim HJ, Yun JY, Hwang JE et al. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci 2010; 101:1247-54.

Shingaki T, Hidalgo IJ, Furubayashi T et al. Nasal delivery of P-gp substrates to the brain through nose-brain pathway. Drug Metab Pharmacokinet 2011; 26:248-55.

Shirasaka Y, Suzuki K, Nakanishi T, Tamai I. Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. J Pharm Sci 2011; 100:3843-53.

Shirasaka Y, Suzuki K, Shichiri M, Nakanishi T, Tamai I. Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. Drug Metab Pharmacokinet 2010; 26:171-9.

Shitara K, Matsuo K, Ito S et al. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac J Cancer Prev 2010; 11:447-52.

Shoaf SE, Ohzone Y, Ninomiya SI et al. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J Clin Pharmacol 2011; 51:761-9.

Shukla A, Hillegass JM, MacPherson MB et al. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer 2010; 9:314.

Sia AT, Sng BL, Lim EC, Law H, Tan EC. The influence of ATP-binding cassette sub-family B member -1 (ABCB1) genetic polymorphisms on acute and chronic pain after intrathecal morphine for caesarean section: a prospective cohort study. Int J Obstet Anesth 2010; 19:254-60.

Siddiqui A, Kerb R, Weale ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. New Eng J Med 2003; 348:1442-8.

Sigmond J, Bergman AM, Leon LG, Loves WJ, Hoebe EK, Peters GJ. Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase. Anticancer Drugs 2010; 21:591-9.

Silverberg GD, Messier AA, Miller MC et al. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 2010; 69:1034-43.

Sim HM, Loh KY, Yeo WK, Lee CY, Go ML. Aurones as modulators of ABCG2 and ABCB1: Synthesis and structure-activity relationships. ChemMedChem 2011; 6:713-24.

Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-75.

Singh P, Kaur J, Bhardwaj A. Synthesis of highly functionalized barbituric acids and study of their interactions with p-glycoprotein and Mg2+-potential candidates for multi drug resistance modulation. Eur J Med Chem 2010; 45:1256-62.

Singh R, Srivastava A, Kapoor R, Mittal RD. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period? J Clin Pharmacol 2011; 51:603-15.

Singh YP, Singh RA. Insilico studies of organosulfur-functional active compounds in garlic. Biofactors 2010; 36:297-311.

Sipeky C, Csongei V, Jaromi L et al. Genetic variability and haplotype profile of MDR1 (ABCB1) gene in Roma and Hungarian population samples with a review of the literature. Drug Metab Pharmacokinet 2010; 26:206-15.

Sissung TM, Gardner ER, Piekarz RL et al. Impact of ABCB1 allelic variants on QTc interval prolongation. Clin Cancer Res 2011; 17:937-46.

Sissung TM, Mross K, Steinberg SM et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006; 42:2893-6.

Sivakumar PM, Prabhu Seenivasan S, Kumar V, Doble M. Novel 1,3,5-triphenyl-2-pyrazolines as anti-infective agents. Bioorg Med Chem Lett 2010; 20:3169-72.

Sivapackiam J, Harpstrite SE, Prior JL, Gu H, Rath NP, Sharma V. Synthesis, molecular structure, and validation of metalloprobes for assessment of MDR1 P-glycoprotein-mediated functional transport. Dalton Trans 2010; 39:5842-50.

Skazik C, Wenzel J, Marquardt Y et al. P-glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components. Exp Dermatol 2011; 20:450-2.

Skogh E, Sjödin I, Josefsson M, Dahl ML. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 2011; 31:4-9.

Small DS, Farid NA, Payne CD et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 2010; 49:777-98.

Smith NF, Mani S, Schuetz EG et al. Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. Ann Pharmacother 2010; 44:1709-17.

Song IS, Choi MK, Jin QR, Shim WS, Shim CK. Increased affinity to canalicular P-gp via formation of lipophilic ion-pair complexes with endogenous bile salts is associated with mw threshold in hepatobiliary excretion of quaternary ammonium compounds. Pharm Res 2010; 27:823-31.

Soo GW, Law JH, Kan E et al. Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice. Anticancer Drugs 2010; 21:695-703.

Soranzo N, Cavalleri GL, Weale ME et al. Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res 2004; 14:1333-44.

Soubeyrand S, Pope L, Haché RJ. Topoisomerase IIalpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure. Mol Oncol 2010; 4:38-51.

Spagnuolo PA, Hu J, Hurren R et al. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 2010; 115:4824-33.

Sparreboom A, Marsh S, Mathijssen RH, Verweij J, McLeod HL. Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Invest New Drugs 2004; 22:285-9.

Spence R, Mandagere A, Richards DB, Magee MH, Dufton C, Boinpally R. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther 2010; 88:513-20.

Spengler G, Evaristo M, Handzlik J et al. Biological activity of hydantoin derivatives on P-glycoprotein (ABCB1) of mouse lymphoma cells. Anticancer Res 2010; 30:4867-71.

Srirangam P, Vidya SJ. Modulation of the p-glycoproein-mediated intestinal secretion of glibenclamide: in vitro and in vivo assessments. J Young Pharm 2010; 2:379-83.

Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010; 49:141-75.

Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet 2010; 49:207-21.

Steeghs N, Gelderblom H, Wessels J et al. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. Invest New Drugs 2011; 29:137-43.

Steeghs N, Mathijssen RH, Wessels JA et al. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. Invest New Drugs 2011; 29:953-62.

Strack DK, Leckband SG, Meyer JM. Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine. J Psychiatr Pract 2009; 15:442-8.

Strack I, Schulte S, Varnholt H et al. β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis. Lab Invest 2011; 91:252-61.

Su J, Ruan XC, Zhang YH, She SZ, Xu LX. Effects of morphine and pethidine on the expression of P-glycoprotein in mouse brain microvascular endothelial cells. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30:1824-6.

Su L, Mruk DD, Lee WM, Cheng CY. Drug transporters and blood-testis barrier function. J Endocrinol 2011; 209:337-51.

Sudchada P, Oo-puthinan S, Kerdpin O, Saelim N. ABCB1 gene expression in peripheral blood mononuclear cells in healthy Thai males and females. Genet Mol Res 2010; 9:1177-85.

Sui H, Wang Y, Liu X et al. COX-2 Contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis 2011; 32:667-75.

Sulová Z, Ditte P, Kurucová T et al. The presence of P-glycoprotein in L1210 cells directly induces down-regulation of cell surface saccharide targets of concanavalin A. Anticancer Res 2010; 30:3661-8.

Sun BT, Zheng LH, Bao YL et al. Reversal effect of dioscin on multidrug resistance in human hepatoma HepG2/adriamycin cells. Eur J Pharmacol 2011; 654:129-34.

Sun YB, Li GF, Tang ZK, Wu BY. Modulation on the P-glycoprotein in the jejunum by combined use of Glycyrrhiza inflata and Kansui. Yao Xue Xue Bao 2010; 45:510-6.

Sun YJ, Long DX, Li W, Hou WY, Wu YJ, Shen JZ. Effects of avermectins on neurite outgrowth in differentiating mouse neuroblastoma N2a cells. Toxicol Lett 2010; 192:206-11.

Sun Z, Zhao Z, Li G et al. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori 2010; 96:90-6.

Susa M, Choy E, Yang C et al. Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay. J Biomol Screen 2010; 15:287-96.

Susa M, Iyer AK, Ryu K et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010. doi:10. 1371/journal. pone. 0010764.

Suttana W, Mankhetkorn S, Poompimon W et al. Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols. Mol Cancer 2010; 9:99.

Suzuki H, Tanabe H, Mizukami H, Inoue M. Selective regulation of multidrug resistance protein in vascular smooth muscle cells by the isoquinoline alkaloid coptisine. Biol Pharm Bull 2010; 33:677-82.

Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol 2010; 92:697-701.

Sylvester RK, Steen P, Tate JM et al. Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients. Anticancer Drugs 2011; 22:104-10.

Szczuraszek K, Materna V, Halon A et al. Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin’s lymphomas. Oncol Rep 2009; 22:1315-23.

Taegtmeyer AB, Breen JB, Smith J et al. ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation. Transplantation 2010; 89:75-82.

Taegtmeyer AB, Breen JB, Smith J et al. Effect of ABCB1 genotype on pre- and post-cardiac transplantation plasma lipid concentrations. J Cardiovasc Transl Res 2011; 4:304-12.

Tagen M, Zhuang Y, Zhang F et al. P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett 2010; 4:195-201.

Tahara T, Shibata T, Yamashita H, Hirata I, Arisawa T. Influence of MDR1 polymorphism on H. pylori-related chronic gastritis. Dig Dis Sci 2011; 56:103-8.

Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res 2010; 9:34-40.

Takahashi N, Miura M, Scott SA et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 2010; 55:731-7.

Takahashi T, Kaku T, Sato T, Watanabe K, Sato J. Effects of Acanthopanax senticosus HARMS extract on drug transport in human intestinal cell line Caco-2. J Nat Med 2010; 64:55-62.

Takakura Y, Hinoi T, Oue N et al. CDX2 regulates multidrug resistance 1 gene expression in malignant intestinal epithelium. Cancer Res 2010; 70:6767-78.

Takakuwa O, Oguri T, Ozasa H et al. Over-expression of MDR1 in amrubicinol-resistant lung cancer cells. Cancer Chemother Pharmacol 2011; 68:669-76.

Takano Y, Iwata H, Yano Y et al. Up-regulation of connexin 32 gene by 5-aza-2’-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling. Biochem Pharmacol 2010; 80:463-70.

Takara K, Hayashi R, Kokufu M et al. Effects of nonsteroidal anti-inflammatory drugs on the expression and function of P-glycoprotein/MDR1 in Caco-2 cells. Drug Chem Toxicol 2009; 32:332-7.

Takara K, Sakaeda T, Kakumoto M et al. Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res 2009; 17:527-33.

Takatori R, Takahashi KA, Tokunaga D et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 2006; 24:546-54.

Takeba Y, Matsumoto N, Takenoshita-Nakaya S et al. Comparative study of culture conditions for maintaining CYP3A4 and ATP-binding cassette transporters activity in primary cultured human hepatocytes. J Pharmacol Sci 2011; 115:516-24.

Takeuchi Y, Fujino Y, Fukushima K et al. Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses. J Vet Pharmacol Ther 2011. doi:10. 1111/j. 1365-2885. 2011. 01296. x.

Takigawa N, Tanimoto M. Vinca alkaloid and MDR1. Gan To Kagaku Ryoho 2008; 35:1086-9.

Takizawa Y, Kishimoto H, Kitazato T, Tomita M, Hayashi M. Changes in the localization of ileal p-glycoprotein induced by intestinal ischemia/reperfusion. Biol Pharm Bull 2011; 34:408-14.

Tan BB, Li Y, Han J et al. Relationship of cyclooxygenase-2 and multidrug resistance associated factors to chemosensitivities in gastrointestinal carcinomas. Sichuan Da Xue Xue Bao Yi Xue Ban 2010; 41:128-31.

Tan SH, Lee SC, Goh BC, Wong J. Pharmacogenetics in breast cancer therapy. Clin Cancer Res 2008; 14:8027-41.

Tan X, Yim SY, Uppu P, Kleinow KM. Enhanced bioaccumulation of dietary contaminants in catfish with exposure to the waterborne surfactant linear alkylbenzene sulfonate. Aquat Toxicol 2010; 99:300-8.

Tanaka M, Okazaki T, Suzuki H, Abbruzzese JL, Li D. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer 2011; 117:744-51.

Tang K, Ngoi SM, Gwee PC et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12:437-50.

Tang K, Wong LP, Lee EJD, Chong SS, Lee CGL. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Molec Genet 2004; 13:783-97.

Tang SC, Lagas JS, Lankheet NA et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 2011. doi:10. 1002/ijc. 26000.

Tang Y, Lei T, Manchanda R et al. Simultaneous delivery of chemotherapeutic and thermal-optical agents to cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study. Pharm Res 2010; 27:2242-53.

Tang YZ, Li DQ, Sun FJ, Li L, Yu DM. P-glycoprotein regulating biphasic insulin secretion in rat pancreatic beta cells. Chin Med J 2009; 122:2587-92.

Tapaninen T, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol 2011; 51:359-67.

Tapaninen T, Neuvonen PJ, Niemi M. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol 2010; 66:865-70.

Tapaninen T, Neuvonen PJ, Niemi M. Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol 2011; 71:718-26.

Tapaninen T, Neuvonen PJ, Niemi M. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol 2010; 66:497-502.

Tate SK, Sisodiya SM. Multidrug resistance in epilepsy: a pharmacogenomic update. Expert Opin Pharmacother 2007; 8:1441-9.

Taubert D, von Beckerath N, Grimberg G et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80:486-501.

Taur JS, Desjardins CS, Schuck EL, Wong YN. Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells. Xenobiotica 2011; 41:320-6.

Teft WA, Mansell SE, Kim RB. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos 2011; 39:558-62.

Teixeira RA, Odone-Filho V, de Camargo B et al. P-glycoprotein expression, tumor weight, age, and relapse in patients with stage I and II favorable-histology Wilms‘ tumor. Pediatr Hematol Oncol 2011; 28:194-202.

Teodori E, Dei S, Martelli C, Scapecchi S. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR). Curr Top Med Chem 2010; 10:1715-31.

Terpening C. Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol 2010; 4:117-28.

Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 2010; 30:1270-9.

Thews O, Nowak M, Sauvant C, Gekle M. Hypoxia-induced extracellular acidosis increases p-Glycoprotein activity and chemoresistance in tumors in vivo via p38 signaling pathway. Adv Exp Med Biol 2011; 915:115-22.

Thollet A, Vendrell JA, Payen L et al. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. Mol Cancer 2010; 9:291.

Thompson JF, Man M, Johnson KJ et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005; 5:352-8.

Tiroch KA, Sibbing D, Koch W et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010; 160:506-12.

Tomita M, Doi N, Hayashi M. Effects of acylcarnitines on efflux transporting system in Caco-2 cell monolayers. Eur J Drug Metab Pharmacokinet 2010; 35:1-7.

Tomita M, Kanbayashi A, Murata H et al. Effect of lipopolysaccharide on P-glycoprotein-mediated intestinal and biliary excretion of rhodamine123 in rats. Int J Pharm 2010; 392:35-41.

Tomita M, Kishimoto H, Takizawa Y, Hayashi M. Effects of intestinal ischemia/reperfusion on P-glycoprotein mediated biliary and renal excretion of rhodamine123 in rat. Drug Metab Pharmacokinet 2009; 24:428-37.

Tomita M, Watanabe A, Fujinaga I, Yamakawa T, Hayashi M. Nonlinear absorption of methylprednisolone by absorptive and secretory transporters. Int J Pharm 2010; 387:1-6.

Tomiyasu H, Goto-Koshino Y, Takahashi M, Fujino Y, Ohno K, Tsujimoto H. Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. J Vet Med Sci 2010; 72:1165-72.

Tompkins JB, Stitt LE, Morrissette AM, Ardelli BF. The role of Brugia malayi ATP-binding cassette (ABC) transporters in potentiating drug sensitivity. Parasitol Res 2011; 109:1311-22.

Torres-Romero D, Muñoz-Martínez F, Jiménez IA, Castanys S, Gamarro F, Bazzocchi IL. Novel dihydro-beta-agarofuran sesquiterpenes as potent modulators of human P-glycoprotein dependent multidrug resistance. Org Biomol Chem 2009; 7:5166-72.

Tournier N, Valette H, Peyronneau MA et al. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. J Nucl Med 2011; 52:415-23.

Tran VH, Marks D, Duke RK, Bebawy M, Duke CC, Roufogalis BD. Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. Nutr Cancer 2011; 63:435-43.

Tsang TY, Tang WY, Chan JY et al. P-glycoprotein enhances radiation-induced apoptotic cell death through the regulation of miR-16 and Bcl-2 expressions in hepatocellular carcinoma cells. Apoptosis 2011; 16:524-35.

Tsujimura S, Saito K, Nakayamada S, Tanaka Y. Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. Mod Rheumatol 2010; 20:139-46.

Turolo S, Tirelli AS, Ferraresso M et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 2010; 62:1159-69.

Uchida Y, Ohtsuki S, Katsukura Y et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011; 117:333-45.

Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103:572-85.

Ufer M, Dilger K, Leschhorn L et al. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther 2008; 84:43-6.

Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003; 54:840-6.

Uhr M, Grauer MT. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 2003; 37:179-85.

Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22:380-7.

Uhr M, Tontsch A, Namendorf C et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57:203-9.

Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C, Wiemels JL. MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev 2007; 16:1172-7.

Urien S, Doz F, Giraud C et al. Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. Cancer Chemother Pharmacol 2011; 67:597-603.

Vaclavikova R, Nordgard SH, Alnaes GI et al. Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet Genomics 2008; 18:263-73.

Vaidya SS, Walsh SW, Gerk PM. Application of human placental villous tissue explants to study ABC transporter mediated efflux of 2,4-Dinitrophenyl-S-Glutathione. Curr Pharm Biotechnol 2011; 12:814-23.

Vallakati A, Chandra PA, Pednekar M, Frankel R, Shani J. Dronedarone-induced digoxin toxicity: new drug, new interactions. Am J Ther 2011. doi:10. 1097/MJT. 0b013e31821106c9.

Valle JW, Armstrong A, Newman C et al. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs 2011; 29:1029-37.

van der Heyden S, Vercauteren G, Daminet S et al. Expression of P-glycoprotein in the intestinal epithelium of dogs with lymphoplasmacytic enteritis. J Comp Pathol 2011; 145:199-206.

van der Holt B, van den Heuvel-Eibrink MM, van Schaik RH et al. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther 2006; 80:427-39.

van der Veldt AA, Eechoute K, Gelderblom H et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011; 17:620-9.

van Ness B, Ramos C, Haznadar M et al. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med 2008; 6:26.

van Waarde A, Rybczynska AA, Ramakrishnan N, Ishiwata K, Elsinga PH, Dierckx RA. Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr Pharm Des 2010; 16:3519-37.

van Waterschoot RA, Eman RM, Wagenaar E et al. ABCC2, ABCC3, and ABCB1, but not CYP3A, protect against trabectedin-mediated hepatotoxicity. Clin Cancer Res 2009; 15:7616-23.

van Waterschoot RA, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int J Cancer 2010; 127:2959-64.

van Waterschoot RA, Schinkel AH. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from Knockout and transgenic mice. Pharmacol Rev 2011; 63:390-410.

van Waterschoot RA, ter Heine R, Wagenaar E et al. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 2010; 160:1224-33.

Vandenbossche J, Huisman M, Xu Y, Sanderson-Bongiovanni D, Soons P. Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance. J Pharm Pharmacol 2010; 62:401-12.

Vannay A, Sziksz E, Prókai A et al. Increased expression of hypoxia-inducible factor 1alpha in coeliac disease. Pediatr Res 2010; 68:118-22.

Varma MV, Ambler CM, Ullah M et al. Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab 2010; 11:730-42.

Vasconcelos FC, Silva KL, Souza PS et al. Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom 2011; 80:158-66.

Vautier S, Milane A, Fernandez C, Chacun H, Lacomblez L, Farinotti R. Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration. J Pharm Pharm Sci 2009; 12:199-208.

Venner M, Peters J, Höhensteiger N et al. Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals. Naunyn Schmiedebergs Arch Pharmacol 2010; 381:161-9.

Verstuyft C, Strabach S, El-Morabet H et al. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 2003; 73:51-60.

Viale M, Cordazzo C, de Totero D et al. Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis. Invest New Drugs 2011; 29:98-109.

Vogler M, Dickens D, Dyer MJ, Owen A, Pirmohamed M, Cohen GM. The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun 2011; 408:344-9.

Wagner AD, Kolb JM, Ozbal CC et al. Ultrafast mass spectrometry based bioanalytical method for digoxin supporting an in vitro P-glycoprotein (P-gp) inhibition screen. Rapid Commun Mass Spectrom 2011; 25:1231-40.

Wagner CC, Bauer M, Karch R et al. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med 2009; 50:1954-61.

Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010; 64:956-67.

Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376:1320-8.

Walsh N, Kennedy S, Larkin AM et al. Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis. Br J Cancer 2010; 102:1157-62.

Wan CK, Tse AK, Yu ZL, Zhu GY, Wang H, Fong DW. Inhibition of cytochrome P450 3A4 activity by schisandrol A and gomisin A isolated from Fructus Schisandrae chinensis. Phytomedicine 2010; 17:702-5.

Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002; 46:160-5.

Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol 2010; 12:1043-9.

Wang G, Rong J, Zhou Z, Duo J. Novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2 and Bax in osteosarcoma cells. Mol Biol 2010; 44:1010-7.

Wang H, Ding K, Zhang Y, Jin L, Kullo IJ, He F. Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions. Pharmacogenet Genomics 2007; 17:667-78.

Wang H, Jin G, Wang H et al. Genetic susceptibility of lung cancer associated with common variants in the 3’ untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1)and ABCC1 candidate transporter genes for carcinogen export. Cancer 2009; 115:595-607.

Wang J, Qu H, Jin L et al. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. J Pharm Sci 2011; 100:2267-77.

Wang J, Wang B, Bi J. Significant association between ABCB1 gene C3435T polymorphism and breast cancer risk. Breast Cancer Res Treat 2011; 126:815-7.

Wang J, Wang H, Zhao L et al. Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines. Anticancer Res 2010; 30:3593-8.

Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology 2006; 187:415-23.

Wang L, He K, Maxwell B et al. Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos 2011; 39:256-64.

Wang L, Yin F, Du Y et al. Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin. Tumour Biol 2010; 31:225-32.

Wang P, Mao Y, Razo J et al. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics 2010; 11:1389-402.

Wang W, Li JJ, Foster PS, Hansbro PM, Yang M. Potential therapeutic targets for steroid-resistant asthma. Curr Drug Targets 2010; 11:957-70.

Wang X, Chen J, Wang M, Gu Y, Xiao Y. Influence of scorpion alcoholic extraction on mdr1 mRNA and P-gp expression in brain of phenytoin-resistant convulsive rats. Zhongguo Zhong Yao Za Zhi 2009; 34:2223-7.

Wang X, Hawkins BT, Miller DS. Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J 2011; 25:644-52.

Wang X, Hawkins BT, Miller DS. Activating PKC-β1 at the blood-brain barrier reverses induction of P-glycoprotein activity by dioxin and restores drug delivery to the CNS. J Cereb Blood Flow Metab 2011; 31:1371-5.

Wang X, Sykes DB, Miller DS. Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharmacol 2010; 78:376-83.

Wang XB, Wang SS, Zhang QF et al. Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep 2010; 23:211-5.

Wang XD, Zeng S. The transport of gastrodin in Caco-2 cells and uptake in Bcap37 and Bcap37/MDR1 cells. Yao Xue Xue Bao 2010; 45:1497-502.

Wang XK, Fu LW. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins. Curr Drug Metab 2010; 11:618-28.

Wang Y, Niu XL, Qu Y et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010; 295:110-23.

Wang Y, Wu Q, Yang XW, Yang X, Wang K. The membrane transport of flavonoids from Crossostephium chinense across the Caco-2 monolayer. Biopharm Drug Dispos 2011; 32:16-24.

Wang YL, Yan YL, Zhou NJ et al. Mechanism of multidrug resistance of human small cell lung cancer cell line H446/VP. Chin Med J 2010; 123:3299-303.

Wanger-Baumann CA, Mu L, Honer M et al. In vitro and in vivo evaluation of [(18)F]-FDEGPECO as a PET tracer for imaging the metabotropic glutamate receptor subtype 5 (mGluR5). Neuroimage 2011; 56:984-91.

Wartenberg M, Richter M, Datchev A et al. Glycolytic pyruvate regulates P-glycoprotein expression in multicellular tumor spheroids via modulation of the intracellular redox state. J Cell Biochem 2010; 109:434-46.

Wasilewska A, Zalewski G, Chyczewski L, Zoch-Zwierz W. MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol 2007; 22:44-51.

Wassmur B, Gräns J, Kling P, Celander MC. Interactions of pharmaceuticals and other xenobiotics on hepatic pregnane X receptor and cytochrome P450 3A signaling pathway in rainbow trout (Oncorhynchus mykiss). Aquat Toxicol 2010; 100:91-100.

Waterkotte B, Hambruch N, Döring B, Geyer J, Tinneberg HR, Pfarrer C. P-glycoprotein is functionally expressed in the placenta-derived bovine caruncular epithelial cell line 1 (BCEC-1). Placenta 2011; 32:146-52.

Watson KJ, Davis J, Jones HM. The application of physiologically based pharmacokinetic modelling to understanding the clinical pharmacokinetics of UK-369,003. Drug Metab Dispos 2011; 39:1203-13.

Weber SN, Wasmuth HE. Liver fibrosis: from animal models to mapping of human risk variants. Best Pract Res Clin Gastroenterol 2010; 24:635-46.

Wei N, Sun H, Wang F, Liu G. H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein. Cancer Chemother Pharmacol 2011; 67:1017-25.

Weiner M, Peloquin C, Burman W et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 2010; 54:4192-200.

Weiss J, Herzog M, Haefeli WE. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Pharmacol 2011; 660:298-304.

Weiss J, Sauer A, Divac N et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos 2010; 31:150-61.

Weiss J, Sauer A, Frank A, Unger M. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab Dispos 2005; 33:1580-3.

Weiss M, Sermsappasuk P, Siegmund W. Modeling the kinetics of digoxin absorption: enhancement by P-glycoprotein inhibition. J Clin Pharmacol 2011. doi:10. 1177/0091270010396711.

Wenge B, Geyer J, Bönisch H. Oxybutynin and trospium are substrates of the human organic cation transporters. Naunyn Schmiedebergs Arch Pharmacol 2011; 383:203-8.

Weroha SJ, Oberg AL, Ziegler KL et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol 2011; 122:116-20.

Wesołowska O, Molnar J, Ocsovszki I, Michalak K. Differential effect of phenothiazines on MRP1 and P-glycoprotein activity. In Vivo 2009; 23:943-7.

Wesolowska O, Wisniewski J, Bielawska-Pohl A et al. Stilbenes as multidrug resistance modulators and apoptosis inducers in human adenocarcinoma cells. Anticancer Res 2010; 30:4587-93.

Wesołowska O, Wiśniewski J, Sroda K et al. 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. Eur J Pharmacol 2010; 644:32-40.

Whalen KE, Sotka EE, Goldstone JV, Hahn ME. The role of multixenobiotic transporters in predatory marine molluscs as counter-defense mechanisms against dietary allelochemicals. Comp Biochem Physiol C Toxicol Pharmacol 2010; 152:288-300.

Wijesuriya HC, Bullock JY, Faull RL, Hladky SB, Barrand MA. ABC efflux transporters in brain vasculature of Alzheimer’s subjects. Brain Res 2010; 1358:228-38.

Wiltshire C, Singh BL, Stockley J et al. Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition. Mol Cancer Ther 2010; 9:1730-9.

Woillard JB, Rerolle JP, Picard N et al. Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin Pharmacol Ther 2010; 88:95-100.

Woldemichael GM, Turbyville TJ, Linehan WM, McMahon JB. Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells. Cancer Res 2011; 71:134-42.

Wołuń-Cholewa M, Szymanowski K, Andrusiewicz M, Warchoł W. Studies on function of P-glycoprotein in photodynamic therapy of endometriosis. Photomed Laser Surg 2010; 28:735-40.

Wong H, Chen JZ, Chou B et al. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica 2009; 39:850-61.

Woo S, Gardner ER, Chen X et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res 2009; 15:1496-503.

Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 2005; 19:1617-25.

Wu B, Ueno M, Onodera M et al. Age-related changes in P-glycoprotein expression in senescence-accelerated mouse. Curr Aging Sci 2009; 2:187-92.

Wu F, Shao ZY, Zhai BJ, Zhao CL, Shen DM. Ultrasound reverses multidrug resistance in human cancer cells by altering gene expression of ABC transporter proteins and Bax protein. Ultrasound Med Biol 2011; 37:151-9.

Wu YT, Kao YL, Lin LC, Tsai TH. Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. Int J Pharm 2010; 396:127-33.

Wu YT, Lin CW, Lin LC, Chiu AW, Chen KK, Tsai TH. Analysis of biliary excretion of icariin in rats. J Agric Food Chem 2010; 58:9905-11.

Wyska E. Pharmacokinetic interaction between verapamil and methylxanthine derivatives in mice. Drug Metab Lett 2010; 4:15-24.

Xi GM, Sun B, Jiang HH, Kong F, Yuan HQ, Lou HX. Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity. Bioorg Med Chem 2010; 18:6725-33.

Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 2010; 50:659-66.

Xiang QF, Wang F, Su XD et al. Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. Cell Oncol 2011; 34:33-44.

Xiang W, Gao A, Liang H et al. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells. Toxicol In Vitro 2010; 24:1474-81.

Xie SM, Fang WY, Liu TF, Yao KT, Zhong XY. Association of ABCC2 and CDDP-resistance in two sublines resistant to CDDP derived from a human nasopharyngeal carcinoma cell line. J Oncol 2010. doi:10. 1155/2010/915046.

Xie Y, Liu J, Liu Y, Klaassen CD, Waalkes MP. Toxicokinetic and genomic analysis of chronic arsenic exposure in multidrug-resistance mdr1a/1b(-/-) double knockout mice. Mol Cell Biochem 2004; 255:11-8.

Xie Y, Zeng X, Li G, Cai Z, Ding N, Ji G. Assessment of intestinal absorption of total flavones of Hippophae rhamnoides L. in rat using in situ absorption models. Drug Dev Ind Pharm 2010; 36:787-94.

Xing Q, Gao R, Li H et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006; 7:987-93.

Xiong J, Taniguchi M, Kashiwada Y, Sekiya M, Yamagishi T, Takaishi Y. Papyriferic acid derivatives as reversal agents of multidrug resistance in cancer cells. Bioorg Med Chem 2010; 18:2964-75.

Xu B, Song X, Yip NC et al. Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. Hematology 2010; 15:74-80.

Xu D, Chen M, Guo Y et al. Synergistic antifibrotic effect of verapamil and interferon-gamma in rats: partially based on enhanced verapamil oral bioavailability. Eur J Gastroenterol Hepatol 2010; 22:466-73.

Xu HB, Li L, Liu GQ. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Pharmazie 2009; 64:660-5.

Xu HB, Li L, Liu GQ. Reversal of multidrug resistance by guggulsterone in drug-resistant MCF-7 cell lines. Chemotherapy 2011; 57:62-70.

Xu HW, Xu L, Hao JH, Qin CY, Liu H. Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer. J Int Med Res 2010; 38:34-42.

Xu JH, Deng WL, Fan ZZ. Effects of changwelqing on nuclear translocation of Y-box binding protein-1 and expregslon of P-glycoprotein in human colon cancer cell line with drug-resistance induced by vincristine. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010; 30:743-7.

Xu W, Xi B, Wu J et al. Natural product derivative Bis(4-fluorobenzyl)trisulfide inhibits tumor growth by modification of beta-tubulin at Cys 12 and suppression of microtubule dynamics. Mol Cancer Ther 2009; 8:3318-30.

Xu X, Fu J, Wang H, Zhang B, Wang X, Wang Y. Influence of P-glycoprotein on embryotoxicity of the antifouling biocides to sea urchin (Strongylocentrotus intermedius). Ecotoxicology 2011; 20:419-28.

Xue X, Qu XJ, Gao ZH et al. Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II. Invest New Drugs 2010. doi:10. 1007/s10637-010-9554-8.

Yamada O, Ozaki K, Furukawa T et al. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cell Signal 2011; 23:1119-27

Yamada S, Yasui-Furukori N, Akamine Y, Kaneko S, Uno T. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. Ther Drug Monit 2009; 31:764-8.

Yamakawa Y, Hamada A, Nakashima R et al. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit 2011; 33:244-50.

Yamasaki T, Kawamura K, Hatori A et al. PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein. Nucl Med Commun 2010; 31:985-93.

Yamazaki M, Li B, Louie SW et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 2005; 35:737-53.

Yan F, Wang XM, Liu ZC, Pan C, Yuan SB, Ma QM. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int 2010; 9:287-95.

Yan L, Huo P, Debenham JS et al. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity. J Med Chem 2010; 53:4028-37.

Yanagimachi M, Naruto T, Tanoshima R et al. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation. Clin Transplant 2010; 24:855-61.

Yang AK, He SM, Liu L, Liu JP, Wei MQ, Zhou SF. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem 2010; 17:1635-78.

Yang JJ, Milton MN, Yu S et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett 2010; 4:201-12.

Yang JY, Ha SA, Yang YS, Kim JW. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BMC Cancer 2010; 10:388.

Yang M, Zhang R, Yan M, Ye Z, Liang W, Luo Z. Detection and characterization of side population in Ewing’s sarcoma SK-ES-1 cells in vitro. Biochem Biophys Res Commun 2010; 391:1062-6.

Yang MH, Zhao MY, He YL et al. Interaction of WAVE1 and genes involved in multiple drug resistance in children with acute myeloblastic leukemia. Zhonghua Er Ke Za Zhi 2010; 48:175-9.

Yang MH, Zhao MY, Wang Z et al. WAVE1 regulates P-glycoprotein expression via Ezrin in leukemia cells. Leuk Lymphoma 2011; 52:298-309.

Yang T, McBride BF, Leake BF, Kim RB, Roden DM. Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. Br J Pharmacol 2010; 161:1023-33.

Yang X, Morris ME. Pharmacokinetics and biliary excretion of mitoxantrone in rats. J Pharm Sci 2010; 99:2502-10.

Yang XG, Jiang C. Ligustrazine as a salvage agent for patients with relapsed or refractory non-Hodgkin’s lymphoma. Chin Med J 2010; 123:3206-11.

Yang Z, Wu D, Bui T, Ho RJ. A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J Pharmacol Exp Ther 2008; 327:474-81.

Yanni SB, Augustijns PF, Benjamin DK Jr, Brouwer KL, Thakker DR, Annaert PP. In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. Drug Metab Dispos 2010; 38:1848-56.

Yanxiao C, Ruijuan X, Jin Y et al. Organic anion and cation transporters are possibly involved in renal excretion of entecavir in rats. Life Sci 2011; 89:1-6.

Yap KY, See CS, Chan A. Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. Recent Pat Food Nutr Agric 2010; 2:12-55.

Yde CW, Clausen MP, Bennetzen MV, Lykkesfeldt AE, Mouritsen OG, Guerra B. The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells. Anticancer Drugs 2009; 20:723-35.

Ye CG, Wu WK, Yeung JH et al. Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Cancer Lett 2011; 304:90-6.

Ye ZW, Camus S, Augustijns P, Annaert P. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos 2010; 31:178-88.

Yenugonda VM, Deb TB, Grindrod SC et al. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells. Bioorg Med Chem 2011; 19:2714-25.

Yim H, Na K. Polycationic nanodrug covered with hyaluronic acid for treatment of P-glycoprotein overexpressing cancer cells. Biomacromolecules 2010; 11:2387-93.

Yokooji T, Kida M, Mori M et al. Interaction of Rhei Rhizoma extract with cytochrome P450 3A and efflux transporters in rats. Pharmazie 2010; 65:367-74.

Yokota K, Hirano T, Urata N, Yamauchi N, Hattori MA. Upregulation of P-glycoprotein activity in porcine oocytes and granulosa cells during in vitro maturation. J Reprod Dev 2011; 57:322-6.

Yoo BK, Chen D, Su ZZ et al. Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res 2010; 70:3249-58.

Yoo HD, Cho HY, Lee YB. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br J Clin Pharmacol 2010; 69:27-37.

Yoo HD, Lee SN, Kang HA, Cho HY, Lee IK, Lee YB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br J Pharmacol 2011; 164:433-43.

Yoshikado T, Takada T, Yamamoto T et al. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol 2011; 79:241-50.

You HS, Zhang HF, Dong YL et al. Absorption and transportation characteristics of scutellarin and scutellarein across Caco-2 monolayer model. Zhong Xi Yi Jie He Xue Bao 2010; 8:863-9.

Youssef DM, Elbehidy RM, Abdelhalim HS, Amr GE. Soluble interleukine-2 receptor and MDR1 gene expression levels as inflammatory biomarkers for prediction of steroid response in children with nephrotic syndrome. Iran J Kidney Dis 2011; 5:154-61.

Yu CP, Wu PP, Hou YC et al. Quercetin and rutin reduced the bioavailability of cyclosporine from neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J Agric Food Chem 2011; 59:4644-8.

Yu H, Hu YQ, Ip FC, Zuo Z, Han YF, Ip NY. Intestinal transport of bis(12)-hupyridone in Caco-2 cells and its improved permeability by the surfactant Brij-35. Biopharm Drug Dispos 2011; 32:140-50.

Yu M, Zhang W, Qin L, Tian L, Zhou C. Enhancement of P-glycoprotein expression by hepatocyte transplantation in carbon tetrachloride-induced rat liver. Anat Rec 2010; 293:1167-74.

Yu N, Di Q, Liu H et al. Nuclear factor-kappa B activity regulates brain expression of p-glycoprotein in the kainic acid-induced seizure rats. Mediators Inflamm 2011. doi:10. 1155/2011/670613.

Yu PF, Wang WY, Eerdun G et al. The role of P-glycoprotein in transport of Danshensu across the blood-brain barrier. Evid Based Complement Alternat Med 2011. doi:10. 1155/2011/713523.

Yu S, Yu Y, Liu L et al. Increased plasma exposures of five protoberberine alkaloids from Coptidis Rhizoma in streptozotocin-induced diabetic rats: is P-GP involved? Planta Med 2010; 76:876-81.

Yu ST, Chen TM, Tseng SY, Chen YH. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Commun 2007; 358:79-84.

Yu XN, Li H, Chen XL, Li XX, Wang R, Gao F. Study on reversing mechanism of multidrug resistance of K562/A02 cell line by carnosic acid. Zhonghua Xue Ye Xue Za Zhi 2010; 31:381-4.

Yuan H, Lu LJ, Du YZ, Hu FQ. Stearic acid-g-chitosan polymeric micelle for oral drug delivery: in vitro transport and in vivo absorption. Mol Pharm 2011; 8:225-38.

Zaigraykina N, Potasman I. Polymorphism at the MDR1 locus as a cause of mefloquine-induced psychosis. Harefuah 2010; 149:583-4, 620, 619.

Zamboni WC, Combest AJ, Deloia JA et al. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemother Pharmacol 2011. doi:10. 1007/s00280-011-1609-9.

Zander SA, Kersbergen A, van der Burg E et al. Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 2010; 70:1700-10.

Zeinyeh W, Alameh G, Radix S, Grenot C, Dumontet C, Walchshofer N. Design, synthesis and evaluation of progesterone-adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux. Bioorg Med Chem Lett 2010; 20:3165-8.

Zembruski NC, Büchel G, Jödicke L, Herzog M, Haefeli WE, Weiss J. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother 2011; 66:802-12.

Zembruski NC, Haefeli WE, Weiss J. Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother 2011; 55:1282-4.

Zhang C, Kwan P, Zuo Z, Baum L. In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein. Life Sci 2010; 86:899-905.

Zhang C, Zuo Z, Kwan P, Baum L. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 2011; 52:1894-904.

Zhang H, Li M, Han Y et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010; 55:2545-51.

Zhang H, Shu H, Jiang W. Expression of PTEN, p53 and P-glycoprotein in non-small cell lung cancer and their predictive values. Zhongguo Fei Ai Za Zhi 2009; 12:1213-6.

Zhang J, He XH, Xie XY, Hu X, He C. The potential for serum p53 to predict the response to chemotherapy of patients with gastric cancer. J Int Med Res 2010; 38:423-31.

Zhang J, Zhou F, Wu X et al. 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions. Drug Metab Dispos 2010; 38:2179-87.

Zhang JY, Mi YJ, Chen SP et al. Euphorbia factor L1 reverses ABCB1-mediated multidrug resistance involving interaction with ABCB1 independent of ABCB1 downregualtion. J Cell Biochem 2011; 112:1076-83.

Zhang L, Yan Y, Zhu D et al. Nutlin-1 strengthened anti-proliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells. Invest New Drugs 2010. doi:10. 1007/s10637-010-9512-5.

Zhang PY, Wong IL, Yan CS et al. Design and syntheses of permethyl ningalin B analogues: potent multidrug resistance (MDR) reversal agents of cancer cells. J Med Chem 2010; 53:5108-20.

Zhang X, Liu P, Zhang B, Wang A, Yang M. Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet 2010; 197:46-53.

Zhang X, Qiu F, Jiang J, Gao C, Tan Y. Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein. Xenobiotica 2011; 41:290-6.

Zhang X, Wu X, Li J et al. MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells. J Surg Oncol 2011; 104:466-71.

Zhang Y, Li H, Wang H et al. Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action. Cancer Chemother Pharmacol 2010; 66:851-9.

Zhang YY, Xie KM, Yang GQ et al. The effect of glucosylceramide synthase on P-glycoprotein function in K562/AO2 leukemia drug-resistance cell line. Int J Hematol 2011; 93:361-7.

Zhang Z, Deng X, Ren X et al. Expression of mutant p53 and of the multidrug resistant proteins P-glycoprotein and glutathione S-transferase-pi correlated in colorectal adenocarcinoma. Scand J Gastroenterol 2010; 45:925-34.

Zhao H, Yao Y, Wang Z, Lin F, Sun Y, Chen P. Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. J Chemother 2010; 22:119-24.

Zhao L, Jin X, Xu Y et al. Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene 1. J Exp Clin Cancer Res 2010; 29:98.

Zhao Q, Zhang H, Li Y, Liu J, Hu X, Fan L. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J Exp Clin Cancer Res 2010; 29:118.

Zhao W, Fakhoury M, Jacqz-Aigrain E. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther Drug Monit 2010; 32:688-99.

Zhao Y, Liu J, Hong Q et al. Involvement of MyoD and PEA3 in regulation of transcription activity of MDR1 gene. Acta Biochim Biophys Sin 2010; 42:900-7.

Zhao YX, Liang WQ, Wang Y, Liu DX. Cationic submicron emulsions overcome multidrug resistance in SGC7901/VCR cells. Pharmazie 2011; 66:130-5.

Zhe C, Li-Juan W, Ming Hui W, Yu J, Yu Jie S, Jun G. Mechanism governing reversal of multidrug resistance in human breast carcinoma cells by chelerythrine. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2011; 33:45-50.

Zheng H, Webber S, Zeevi A et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 2002; 63:765-70.

Zheng L, Qing YP, Xu N et al. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-dose intravenous administration in healthy Chinese volunteers. J Clin Pharm Ther 2010; 35:113-9.

Zheng Y, Zhou F, Wu X et al. 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo. J Ethnopharmacol 2010; 128:615-22.

Zhou F, Xu H. Effect of emodin on P-gp expression in intrahepatic cholestatic rats. Zhongguo Zhong Yao Za Zhi 2010; 35:908-11.

Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36:57-104.

Zhou T, Shi Q, Bastow KF, Lee KH. Antitumor agents 286. Design, synthesis, and structure-activity relationships of 3’R,4’R-disubstituted-2’,2’-dimethyldihydropyrano[2,3-f]chromone (DSP) analogues as potent chemosensitizers to overcome multidrug resistance. J Med Chem 2010; 53:8700-8.

Zhu F, Wang Y, Zeng S, Fu X, Wang L, Cao J. Involvement of annexin A1 in multidrug resistance of K562/ADR cells identified by the proteomic study. OMICS 2009; 13:467-76.

Zhu M, LE Moyec L, Starzec A, Stierle V, Marbeuf-Gueye C. Caveolin-1 and doxorubicin-induced P-glycoprotein modulate plasma cholesterol membrane accessibility in erythrolymphoblastic cell line. Anticancer Res 2010; 30:3451-8.

Zhu Y, D’Agostino J, Zhang QY. Role of intestinal cytochrome P450 in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse. Drug Metab Dispos 2011; 39:939-43.

Zimmermann C, Gutmann H, Drewe J. Thalidomide does not interact with P-glycoprotein. Cancer Chemother Pharmacol 2006; 57:599-606.

Zolk O, Jacobi J, Pahl A, Fromm MF, Schmieder RE. MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics 2007; 17:137-44.

Zou SS, Xu R, He QY. Mechanism of Chinese herbal compound Zilongjin for antagonizing multi-drug resistance of tumor cells. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010; 30:601-6.

Zunino SJ, Storms DH, Ducore JM. Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4; 11). Cancer Lett 2010; 296:49-54.

Zwisler ST, Enggaard TP, Mikkelsen S et al. Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. J Clin Pharmacol 2011. doi:10. 1177/0091270010397729.

Zwisler ST, Enggaard TP, Noehr-Jensen L et al. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol 2010; 24:517-24.

A (Contd) →

 A B C D E F G H I K L M N O P R S T U V W X Z